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Summary and Guide to the Thesis.
Aim of Study.
The study aim was to identify a population of live
patients in the Lothian area of Scotland, with presenile dementia
of various aetiologies, and to describe the clinical profiles of each,
and the patterns of decline which occur, together with any
genetic characterisation possible.
Method.
Cases were identified using the Lothian Psychiatric
Case Register. For the demographic data, the CAMDEX (The
Cambridge Examination for Mental Disorders of the Elderly)
informant interview was used. The behavioural assessment
comprised of the CAPE- BRS (Clifton Assessment Procedure
for the Elderly, Behavioural Rating Scale), the Cornell
Depression Scale and the MOUSEPAD (Manchester and Oxford
University ScalE for the Psychopathological Assessment of
Dementia), a new behavioural and psychopathological
assessment. The subject was seen, and where possible the
cognitive assessment was completed using the NART (National
Adult Reading Test) and CAMCOG (cognitive assessment of the
CAMDEX). A physical and neurological examination was done
and the Webster scale for Parkinsonian features included. 40
mis of blood was taken at the assessment interview for the
genetic analysis. After an interval of approximately one year,
each case was re-assessed using these instruments.
Results.
Of 290 potential cases, 164 (57%) were excluded.
Reasons: Death 50 (31%). Unsuitable 40 (24%), Refused 40 (24%),
Untraced 23 (14%), Out of area 11 (7%). Of the 126 (43%) seen,
112 (89%) met the Diagnostic and Statistical Manual of Mental
Disorders, Third Edition, Revised(DSM3R) criteria for dementia. 63
(56%) of the 112 were rated as DSM3R severe type. 80 (72%) of
the 112 fulfilled the McKhann criteria for Alzheimer's Disease. A
full description of the group and the results following the second
assessment are given.
The genetic testing included Apolipoprotein E (APOE),
a-1 antichymotrypsin (ACT) and Very Low Density Lipoprotein
Receptor (VLDL-R) allele typing.
Important data concerning the services provided and
used by this group of patients and their carers has been collected
and can be shared with organisations working to find funding for
presenile dementia in the health service.
Conclusions.
This study will provide a thoroughly documented and
clinically detailed sample. The analysis of the work may help to
identify if subgroups exist, according to the patterns of various
clinical features, the rates of decline, and genetic variations. This
will in turn, give a greater chance to plan appropriately for all
those involved in caring for and managing these illnesses.
An overview of the thesis is given below:
Introduction.
I.Historical Perspective.
Background to the study, originating in the interest in
Prion Disease.
II.Epidemiological Issues.
Aspects of the condition (including the definition of the
condition and difficulties of early diagnosis) are discussed in the
context of epidemiological issues. A brief literature review of
epidemiological studies of presenile dementia, is included.
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III.The Genetics of Younger-Onset Forms
of Dementia.
A review of the genetic understanding of dementia. The
major part of this refers to research into Alzheimer's Disease.
Method.
I. Ascertainment of the sample.
Describes the use of the case register to obtain cases and
details the search for cases. The case note survey is also
described.
II. Choosing an Assessment Battery.
The details of choosing an assessment battery are
discussed. The general requirements are described, as well as the
following areas of data collection: demographic; behavioural;
psychopathological; neurocognitive; neurological.
The refinements made for the second assessment are
discussed.
III. Contacting the Sample and data
Organisation.
The organisation of the pilot study is described as a
model for the working of the study as a whole. The process of
contacting the doctors and relatives, and making the first and
second individual visits, is described. The organisation of the data
base and application of the diagnostic criteria are discussed.
IV. Genetic Method.
This describes the process of blood collection and
storage. The protocols for the molecular analyses are also given.
V. Statistical Method.
Describes the statistical analyses used.
Results.
A very large amount of data was collected for the study.
A selection of the results of greatest interest and relevance, are
given.
Discussion.
The results are discussed in the framework of other
studies and research done into related areas. The findings and




For each of the 126 cases seen, an individual clinical
vignette is given, with details of the onset and course of the
illness, together with other features of interest.
Relatives. Carers and the Services.
This chapter looks at some of the issues arsing from the
emotional reactions of the families and carers seen.
Protocol.
The letters used to establish contact with the study
sample are given. The parts of the first and second assessment
procedure, which are not published elsewhere, are given here.
Glossary.
A list of the abbreviations used in the study, and a brief
explanation, where relevant, is given.
References.
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Author's Comments on the Thesis.
The study aims to investigate presenile dementia, which
previously has not been widely researched. No other study to
date, has attempted to take such a sample and investigate it in
this way. The study provides a wealth of data for exploration. Not
all the possible avenues of analysis have been included here, but
consideration is given as to where the study can lead to in the
future.
The study covers a range of dementia types, and also a
variety of clinical features, aswell as genetic associations. There
are therefore hundreds of potential variables to consider, and ask
if associations exist between them. The difficulty is thus to
maintain some specific purpose and direction to the work, rather
than it becoming over-inclusive in an attempt to be complete.
No full clinical description of the presenile dementias, or
detailed discussion of their possible causes is given in this text.
This can be found in superb detail and completeness, in Lishman,
(1990). Also, this thesis does not attempt to cover areas such as:
neuroimaging; investigation; and treatment. These extremely
important areas are not of relevance to the study here.
Because of the consideration of such a large topic, there
is likely to be overlap between the various parts of the thesis.
Where this happens, attention is drawn to the relevant cross-
references within the text.
Much of the literature quoted, describes findings from
the study of senile dementia, which provides a basis for
beginning to describe presenile dementia. Furthermore, the study
has a broader remit than looking at Alzheimer's Disease alone,
but much of the work quoted, is based on the detailed clinical and
genetic studies undertaken in the study of this dementia type.
The relevance of the literature to various sections
throughout the thesis, means that there is not only one section for
a literature review.
The study is not a true epidemiological survey, and so
there are limitations in trying to compare its findings with certain
other work. It does not aim to identify risk factors for the
population.
This thesis is a document to describe the study in full,
from its conception, and to indicate how far it has achieved its
aim, and the future work it could give rise to.
The study was devised by me, and I alone carried out
the clinical assessments. There has been collaboration with Dr. A.
Brookes for the genetic analysis and with Dr. A. Carothers and
Alan Finlayson for the statistical analysis.
I declare that this thesis has been composed by me, and
that the work of the study is my own.
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Introduction:
I. A Historical Perspective To The Study.
In 1992, there were several news headlines bringing
'mad cow disease' to the public's attention, and raising the
question as to whether this posed a threat to the human
population. The human spongiform encephalopathies, Creutzfeldt-
Jakob Disease (CJD) and Gerstmann-Straussler-Sheinker
syndrome (GSS) have classically been defined by their clinical
presentations of neurological signs and dementia. The diagnosis of
a spongiform encephalopathy has been confirmed by the
neuropathological examination of brain tissue, which shows
changes such as cortical atrophy, spongiform degeneration,
neuronal loss, astrocytosis, vacuolation and amyloidosis. Also, an
added criterion for the neuropathological diagnosis of these
diseases, is the detection of Prion Protein (PrP) aggregates in the
brains of patients with these conditions. Mutations of the PrP
gene have been linked with the susceptibility to develop the
disease (Baker and Ridley 1992). Certain other conditions have
been linked to mutations in the prion protein gene, such as Fatal
Familial Insomnia (Medori et al 1992). Work such as that
published by Collinge et al (1989 and 1990) and Medori et al
(1992), indicated that the phenotype of prion disease was
perhaps more varied than was previously believed, and that
causes of dementia due to this, could represent a greater number
than had been thought previously.
Several mutations in the human PrP gene have been
identified (Prusiner 1991). These are summarised in the
Introduction: Genetics. The relationship between the known
mutations and various clinical conditions is given.
The original plan for the study was similar in some
aspects to that actually carried out. However the original plan for
the genetic study, was to see how many of the cases were
associated with PrP gene mutations.
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The emphasis of the study changed during the course of
the next year, because of the increasing evidence that prion
protein mutations, were not likely to be as relevant as had been
thought previously. Work by Schellenberg et al (1991a), implied
that cases of prion protein gene mutations are extremely
uncommon in screening large numbers of cases of dementia.
Brown et al (1993), also concluded that cases of unsuspected
prion dementia are extremely unlikely. The decisions about
which genetic tests were actually done, are discussed later.
There was further major media coverage of the Bovine
Spongiform Encephalopathy (BSE) story during the time of the
study. In December 1995, several cases of BSE were discovered to
have occurred in teenagers and also in farmers. The likelihood of
this having happened by chance was debated. Meanwhile, beef
was taken off the school menu. Will et al (1996), reported on
cases apparently representing a new variant of CJD, again raising
the debate of the possible transmission to humans from cattle.
Some of the headlines which have appeared over the past few
years, are presented at the end of this chapter.
A further development of the study was the decision to
assess each individual at two points in time, in order to provide
data to measure change. A limitation of this approach is that each
case was not at the same point of the illness to start with.
The aim of the study was thus to have identified a
population of live patients with presenile onset of dementia (of
various aetiologies) in the Lothian area, and to characterise the
clinical and genetic profiles of each,with neuropathological
assessment whenever possible. After a period of about a year
each case would then be re-assessed. The study would provide a
carefully worked up clinical sample, which would be a useful
resource, both for the current study and in the future.
Data from the second assessments would allow the
patterns of decline of the group to be analysed. An aim of the
study was to see if different subgroups of dementia could be
described, based on various clinical features including the
different rates of decline. The genetic studies could also help to
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identify such subgroups in the sample, and demonstrate if clinical
differences in presentation are explicable at the molecular level.
Apart from these aspects of the study, the information
gathered would provide a detailed investigation of a large
number of cases of younger-onset dementia, which had never
been described before.
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Presenile, early- or younger-onset dementia, is
arbitrarily defined as beginning before the age of 65. The
arbitrary nature of this age cut-off is discussed by Netten and
Kavanagh (1993). It is a much rarer condition than older-onset
dementia. As yet, there is only a small number of studies which
has aimed to establish figures for the prevalence and study of
this condition. There are various methodological problems
associated with trying to discover the prevalence figures, and
these issues are explored in this chapter.
The basic questions: Why ?,What ?, Who ?, When ?,
Where ? and How ? are useful starting points and headings for
consideration, to introduce the subject. Why ?. being the reasons
why these issues are of importance. What & Who ?. being the
definition of presenile dementia and the description of the people
with the types of illnesses which could be included in the
definition. When ?. being the issues of defining the effect of time
on prevalence figures. Where & How ?. being the issues involved
in the ascertainment of a complete sample of cases.
In a review of the literature by Liston (1979a), he states
that:
"There are in fact relatively few composite or systematic clinical
studies ofpresenile dementia of even modest sample size; and
many of these, it will be seen, present, with the general exception
ofdemographic information, conflicting pictures Reported
epidemiological data, symptoms and signs, and results ofancillary-
tests often vary widely from study to study, especially as regards
findings ofhistory and ofmental status and neurological
examinations Indeed on the basis of the literature, one might
even question whether there exists a syndrome called presenile
dementia, which can be characterised on the clinical grounds with
reasonable reliability in the absence ofdefinitive pathological
study."
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Liston himself published a report of 50 cases of the
clinical findings in presenile dementia (Liston 1979b). Rosenstock
(1970), studied eleven cases of Alzheimer's presenile dementia,
and Sjogren et al (1952), published their findings from 34
families, of the genetic, clinical and patho-anatomical study of
Alzheimer and Pick's disease. Many of their cases were of
younger onset. Nine presenile dementia cases were described in
great detail by Stengel (1943).
Why?
Epidemiological research enhances the understanding of
a particular disease in several ways. By accurately determining
the prevalence and incidence of a condition, risk factors can be
more accurately identified. Questions as to whether a condition is
becoming commoner can only be answered if the figures at the
first point in time are known. In terms of presenile dementia,
where at present no prevention or treatment cure is possible, the
epidemiological figures can help the policy makers and service
providers to make decisions based on real needs. Juva et al
(1994), comment on the need for epidemiological figures and
ability to predict prognosis, to effectively plan services for people
with Alzheimer's Disease.
The relevance of this is in terms of the people involved.
That is to say, not only the people who suffer from the illness, but
also their relatives and carers. If, by examining the statistics, it is
possible to say with certainty how many people there are who
suffer from this condition in a given area, it is then the next step
to provide comprehensive and adequate services for them. The
extrapolation of the findings of an appropriate survey of the
frequency elsewhere, to the demographic characteristics of a
particular area in question, would allow planning, even where no
such surveys have been carried out.
In regions where the identified target population then
fell short of the expected total, concerns would be raised as to the
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adequate detection of the cases in the area. Plans to identify them
could then be initiated.
Service planning is not a particular matter for this
chapter, but two key issues which arise and are of immediate
relevance to the discussion of the prevalence of the disease are:
1. The small numbers and geographical spread of the group
within one area mean that a centralised service would necessitate
the provision of adequate transport facilities to and from it. Other
models of an outreach variety may well be more suitable.
2. There are also the considerations as to what other patient
groups would be suitable to share in any organised service
provision for this group of people. (This issue is discussed in
greater depth in the 'What & Who ?' section below. )
What & Who ?
An important starting point is to look at the definition of
dementia and so decide who should be included when a
population is studied.
Defining Presenile Dementia.
Dementia is used in two contexts which must be clearly
distinguished. First, it is used to describe a group of specific
disease entities; and second, to refer to a clinical syndrome
which can have many other causes.
When denoting a syndrome, the term is best defined as
an acquired global impairment of intellect, memory and
personality, but without impairment of consciousness. (As such it
is almost always of long duration, usually progressive, and often
irreversible.)
Certain intrinsic degenerative diseases of the brain
occurring in middle or late life have attained the title of dementia
as signifying specific disease entities. These are the so-called
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primary dementias, and need to be distinguished from secondary
degenerative brain processes. These latter are dementias
secondary to the pathological processes underlying them, such as
the cerebrovascular disease underlying Multi-infarct dementia.
The next question is, taking the broad definition of
dementia, what are the most commonly found causes for the
condition ? Among the presenile dementias it is probable that
Alzheimer's Disease is more frequent than the other varieties.
This group may in fact be made up of a number of different sub -
types of dementia. With the present clinical differentiations
possible, such placing into different sub-groups tends to become,
in part, an issue of the current research interests and prevailing
fashions. The position of Lewy Body dementia in the frequency
table of dementias, needs to be clarified. Some believe that for
dementia as a whole, it may represent the second most common
form, see McKeith et al (1994). Shergill et al (1994), investigated
the reports of the clinical prevalence of Lewy Body dementia, and
found it to vary from 12 - 20% in post mortem series. They
concluded that because of the variation in the frequency of the
diagnosis using different criteria, the criteria needed revising.
Another type, which could be the next most frequent, is
arteriosclerotic or Multi-infarct dementia (MID). Pick's Disease,
Huntington's Chorea and Creutzfeldt-Jakob Disease constitute the
best known of the remaining primary dementias and are all very
much less common.
An exhaustive list of all the rarer forms of dementia
would have to include neurological and medical conditions.
Neurological conditions would include multiple sclerosis and
motor neuron disease, and medical conditions would include
epilepsy and diabetes. In these conditions, cognitive decline is
only a mild feature of the overall clinical picture. Another
example would be Acquired Immune Deficiency Syndrome
(AIDS)-associated dementia, but here the overall clinical picture
trumps the additional presentation of a dementing illness, in a
patient whose survival time is in general, severely shortened by
that stage. There are consequently a number of specialties which
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would need to be included if a comprehensive survey of cases
were to be made. It is beyond the range of this chapter to
attempt to define them all.
This illustrates the broad approach required in a wide-
ranging search of what the condition includes, and who it affects,
but also highlights problems in defining dementia when it occurs
as part of another condition. This is also seen when the overlap
between Multi-infarct dementia, vascular dementia and
cerebrovascular disease is examined. This is reviewed by Amar
and Wilcock (1996). Breteler et al (1994), suggest that the total
impact of atheroscerosis on the amount of cognitive impairment
in the population at large, may be much greater than that
contributable to severe atherosclerosis resulting in clinically
overt disease.
A stroke may contribute to dementia but will not
necessarily cause this pathology. The assessment of cognitive
deficiency in stroke-affected patients, is notoriously difficult. It is
the presenting symptomatology which decides to which speciality
a stroke case is referred. Predominant physical impairments
would be the province of general physicians and neurologists,
whereas cognitive effects would be cared for by the old age
psychiatrists and counted as cases of dementia. The overall
pattern of impairment would influence whether the patient is
specifically diagnosed with a dementia, and entered on a register
as such.
In the section on the 'Why?' of epidemiological research,
it was mentioned that a wide range of patient groups could be
considered as suitable to share the services for presenile
dementia. For example, the age group is obviously younger than
the older-onset cases of dementia, for whom various services
exist. But difficulties arise in the sharing of facilities, especially in
the early and more insightful stages of the illness, when a person
may be unhappy at attending a group which they perceive to be
of a much older age. Furthermore, the activity levels of the
younger group would be correspondingly much greater, and their
additional physical problems likely to be less.
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Apart from senile dementia there are other forms of
adult illness which could be grouped with the presenile dementia
sufferers. These fall into the progressive and non-progressive
forms.
First, taking the progressive forms of dementia, there
are many distinct dementias to include: Alzheimer's; Multi-
infarct; Pick's; Lewy Body and Parkinson's Disease with associated
cognitive decline; the extremely rare spongiform
encephalopathies such as Creutzfeldt-Jakob Disease; and
Huntington's Chorea. There is also a significant problem of
Alzheimer's occurring in the population of Down's Syndrome
adults. Consideration of this diversity raises the obvious difficulty
for health providers in catering for the needs of such groups, with
a single service.
Second, there are the non-progressive forms of
dementia, which share to some extent the same problems,
although they do not progressively decline. Cases of post head-
injured patients displaying behavioural problems and cognitive
deficiencies are one such example.
(In the next section on 'When ?', issues about the
difficulty in differential diagnosis are discussed.)
Having made this distinction in the definition of the
term dementia, the standard clinical diagnostic criteria available
to classify it, will be briefly mentioned. These allow some
distinction between the different types of dementia to be made.
The Feighner Criteria for Organic Brain Syndrome (Feighner et al
1972), and the American Psychiatric Association, DSM3R criteria,
(APA 1987), are discussed later.
There exist further agreed criteria to aim to provide
more reliable clinical diagnoses during life, such as the National
Institute for Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA) criteria for Alzheimer's type
dementia (McKhann et al 1984). There is currently work to
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attempt to provide an internationally agreed set of criteria for
Lewy Body dementia too.
At this point however, it is important to stress that the
most reliable way to establish a diagnosis, is retrospectively at
post-mortem. Even this can generate confusion when various
pathologies co-exist. Operational criteria are used for this too.
Perhaps as the molecular and genetic understanding of these
illnesses increases, it will be possible to define dementias in the
most accurate way of all, and during the lifetime of the patient.
This may indeed go together with the development of novel
treatment possibilities, as a natural consequence of the greater
molecular understanding of the conditions.
However until then, definition by clinical and
pathological means, is vitally important.
When?
Another factor which will influence any attempt to
define how great the problem is in a population, is the question of
its recognition. In other words, appreciating when it is possible to
make a diagnosis, and how straightforward this is. Morris and
Fulling (1988), consider the difficulty in the early diagnosis of
Alzheimer's Disease. This also becomes a discussion of the
mechanism and routes of referral.
Regrettably the diagnosis of presenile-onset dementia is
a very hard one to make, especially in its early stages. This is
unfortunate for the epidemiological approach but, far more
significantly, can greatly add to the difficulties of the sufferer and
the relatives.
Factors leading to such a delay exist in the difficulties in
early clinical diagnosis by the doctors, and in other subtle factors
intrinsic to the illness itself and its effect on the sufferer and the
family.
The onset and progress of very insidious and worrying
symptoms, may initially be explained away by the family as
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stress-related, or attempts made to "cover- up" and deny.
Consequently establishing when the onset of the illness took place
is notoriously hard to pinpoint. It is often the case that symptoms
have existed for a considerable period before a hospital diagnosis
is made. This point in time may well be the most accurate
available - since it had a specific date. Immediately the problem
of underestimating presenile onset cases becomes apparent, since
if symptoms began at age 64 but diagnosis is made at 66, this
case is lost, although it represents a bona fide presenile-onset
case.
Returning to the worried and confused family unable to
explain their relative's increasing difficulties in coping, the next
problem which arises is that of involving the family doctor. For
example, the person with the cognitive impairments may be very
unwilling to see the doctor, directly denying the deficit, or feeling
threatened by such a suggestion. Further delay ensues; further
tension and worry accumulates.
Because of the progressive nature of the condition, the
behavioural problems which would follow would lead to
increased levels of distress - thus making contact with the GP
almost inevitable at some stage of the illness. When eventually
the GP is made aware of the issues, it is more than likely that he
or she would refer to a specialist for diagnostic testing. At the
earlier age of onset the unexpected nature of cognitive decline
makes looking for treatable causes such as a tumour, much more
pertinent.
So, assuming that the GPs are not the only medical
personnel aware of the person and their family, who is involved
next?
It would depend partly on the local service organisation,
but also on the presentation problem, as to whether a
neurological or psychiatric referral would be made in the first
instance by the GP. For example any neurological abnormalities
would bias to a neurological referral and predominant behaviour
problems to a psychiatrist. Allen and Baldwin (1995), compared
the case notes of 28 patients with presenile dementia presenting
24
to a neurology service with 26 who had presented to a specialist
old age psychiatric department. It was concluded that specialist
old age psychiatric services in Britain have a role in the
management of patients with presenile dementia, but that
diagnosis should be undertaken by neurologists. Ryan (1994),
looked at misdiagnosis in dementia and compared the diagnostic
error rate and range of hospital investigations according to
medical speciality.
Even with the aid of scanning equipment, the diagnoses
of certain forms of dementia will be possible only on the grounds
of excluding other possible causes. Without positive evidence to
back up such a doom-ridden prognosis it is a particularly difficult
diagnosis for the doctor to declare. Furthermore in less clear-cut
cases, the use of serial assessments to document cognitive decline
might be the best solution, rather than basing the diagnosis on
the scant information of one visit to the specialist. The result of
this would be a further time lag until all concerned know what
they are facing.
The differential diagnosis of a primary degenerative
presenile onset dementia is very extensive, ranging from
depressive illness to space-occupying lesion. Several surveys
from neurological units, evaluated the in-patients consecutively
admitted to hospital with a presumptive diagnosis of dementia.
Since the majority of the patients were below the age of 65, the
results can be seen as an indication of what could be expected in
a presenile group. In some studies, about 15 % were not thought
to be demented after full evaluation, but to have some other
organic psychosyndrome or functional psychiatric disorder.
Marsden and Harrison (1972), studied the outcome of
investigation of patients with presenile dementia. They found
that of 106 patients admitted for investigation to a neurological
hospital with a presumptive diagnosis of dementia, 84 were
confirmed to have intellectual impairment or loss of learning and
memory function or both. A possible aetiology for the dementia
was found in 36 of the 84, the commonest being intracranial mass
lesions, arterial disease and alcoholism. 15 of the 106 were found
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not to be demented, most commonly being depressed. 15% of
cases had conditions that were amenable to treatment. Smith and
Kiloh (1981), studied 200 patients admitted consecutively to a
neuropsychiatric institute and confirmed the diagnosis in 164. 13
cases were found to have potentially reversible conditions,
representing 11.5% of those in the 45-64 year old age group, and
3.8% of those 64 and older. They recommended that those with a
provisional diagnosis of dementia be investigated early on in the
course of the illness. Freemon (1976), studied 60 patients with
progressive intellectual deterioration and found 18 (30%), to have
underlying disease of a potentially reversible kind. All their
subjects were male, with an average age of 62.2 years. Victoratos
et al (1977), examined 52 patients thought to be suffering from
dementia when first examined at a neurology out-patient clinic,
44 were below the age of 65 years. Of them, four had tumours,
and five had treatable causes.
The difficulties of making an early diagnosis are also
illustrated in two studies of groups of cases of presenile dementia
seen in psychiatric settings. In the study of Ron et al (1979), a
follow-up study of patients diagnosed with presenile dementia,
revealed a high incidence of wrong diagnoses. Of 52 cases, 51
were followed up between five and fifteen years on and the
initial diagnosis was rejected in 16. Nott & Fleminger (1975),
followed up 35 patients diagnosed as having presenile dementia
and in only 15 cases did progressive deterioration confirm this.
Prevalence is a function of incidence and also of various
factors related to the timing of the illness. As has already been
indicated above, the definition of onset can be at the time of
symptom onset or at the age of diagnosis; and the latter is
probably the more reliable of the two. The definition will affect
the comparison of age-specific rates when based on age at onset.
The progress of the illness, its duration and overall survival time
will likewise be influential on the figures. Dealing with a
heterogeneous condition means that differences between
subgroups may get lost in overall figures, unless they are
separated out.
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Also the age range in question has to be decided on.
Obviously the cut off point here is 65, but at the lower end should
a line be drawn ? Usually the age of 40 or 45 is taken but it is
reasonable to assume that onset after the age of 30 will
effectively exclude cases of learning disability, as the effect of
dementia on the developing nervous system is hard to
differentiate.
Vital for prevalence figures is to have an accurate
estimate for the population of the relevant age, in the area. There
also needs to be specified, a defined period of time, during which
the patient group was identified for the study.
Where & How ?
As the previous quote by Liston indicates, the studies
that do exist can give conflicting results for prevalence figures.
What could account for such an inconsistent picture found
between studies ?
To explore this further it is necessary to ask questions
about how the cases were ascertained, and scrutinise in detail the
methodology used for each. For estimating the population of
people with the problem, how extensive has the search been,
what has been the case definition, and what have the inclusion
and exclusion criteria been ?
Some health services have computerised patient
registers which enables the identification of a particular group of
people, with a specified diagnosis. However these systems are
prone to problems, due to factors such as inaccurate data,
duplications, misclassification and miscoding.
Some groups have looked at case note information, and
depended on the clinical information provided for diagnoses,
rather than on live individual assessments. Such surveys
however mean an inevitable drop out due to missing notes and
incomplete information to meet criteria etc.
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Further attrition occurs when the study involves
contacting subjects, for example due to death, or to finding that
people have migrated away from the area, or simply because the
person may not wish to participate in the study. Attrition will
inevitably lead to incompleteness, which is the nature of clinical
studies.
Other pertinent questions would be :
Have all potential parts of the service been explored? For
example, psychiatric (general adult psychiatric and psychiatry of
old age), neurological and medical sources, including those of the
elderly? Have in-patient, out-patient (including memory clinics)
and day hospitals been included? What of community contacts
such as nursing homes, both private and public, and day centres?
It has already been indicated that the majority of cases
would be likely to be referred to these services. A very small
number of people could theoretically be missed - say, if they
were living rough and not registered with a GP, or with such
concomitant problems (such as heavy alcohol abuse) as to make
assessment of underlying cognitive decline very difficult.
Brief Literature Review of Epidemiological Figures.
Some prevalence studies have used data collected from
populations within which are a substantial proportion of cases
below the age of 65. Studies taking presenile cases only, are few,
and the number of cases ascertained usually small, with
correspondingly large confidence intervals. The case-finding
techniques differ too. However, the prevalence rates for Presenile
Dementia of the Alzheimer's Type (PDAT) are consistent across
the studies. Thus the cases being identified must be similar. Not
all studies were based on population sampling and individual
assessment. Those that are, are probably biased towards the
severer forms of the illness. Likewise hospital cases are also going
to be severer too.
Sulkava et al (1985), in the Finnish national study, used
personal interviews and psychological tests to make a diagnosis
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and based their rates on a probability sample of the general adult
population. Their figure for primary degenerative dementia, for
30 - 64 year olds, were = 32.7/100,000 (2 cases, population =
6120).
Schoenberg et al (1985), also used interviews and
neurological examinations to detect dementia, and included all
households and institutions, in Copiah County, Mississippi. For 40
- 64 year olds, the figures for PDAT were = 18.2/100,000 (1 case,
population = 5489). In their 1987 figures, the calculated
incidence rate for probable presenile Alzheimer's were =
2.4/100,000.
In the Rochester study, USA, Kokmen et al (1989), used
a system of ascertainment incorporating general practice records
and nursing homes, the so-called "centralised medical record-
linkage system". The group's 1988 figures for PDAT, for 45 - 64
year olds, were = 31.8/100,000 (3 cases, population 9431).
Molsa et al (1982), describe a Finnish urban study,
where the diagnosis was supported by neurological testing and
laboratory investigations. Hospital data and reports from
community agencies were used. The prevalence figure for
degenerative dementia, for 45 -64 year olds, were =
46.7/100,000 (17 cases, population = 36,409).
In terms of incidence studies, the rates of Treves
et al (1986), were obtained by a method based on retrospective
case-note review of cases entering institutions and informants
were interviewed to determine the date of onset. This was a
nationwide epidemiological study of presenile dementia of the
Alzheimer's type in Israel, for those under the age of 60 years.
The Israeli National Neurologic Disease register and clinical
records of all patients discharged from hospitals between 1974
and 1983 with a neurologic or psychiatric diagnosis suggestive of
dementia were reviewed. The age of onset was taken as between
43 and 60 years. The annual incidence rate of the population at
risk, aged between 40 -60 years, were = 2.4/100,000.
Newens et al (1993a), published figures for clinically
diagnosed Presenile Dementia (PSD), under 65, of the Alzheimer's
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type, in the Northern Health Region, for the years 1979 - 1986.
This was based on the case ascertainment through medical and
other care agencies, by case note review. They argue that
prevalence would be 25% under-estimated if in-patient data
alone were used, rather than their system of day hospital, and
neuroradiology records being included as well. From the same
source, Newens goes on to say:
"The assessment of true need requires data collated from a
variety ofhealth social and voluntary sources, underlining the
importance ofcompleteness and accuracy in health information
systems."
Their figures for the Northern Health Region, for 45-64 year olds
were:
Alzheimer's (PDAT) = 34.6. (227 cases, pop = 655,800).
Vascular =11.7
Other (Secondary) = 27.0
Total = 73.3.
The point prevalence was estimated at 34.6/100,000.
The annual incidence at 7.2/100,000 for those aged 45-64. The
annual incidence at 3.4/100,000 for those aged 40-60.
The pattern was of diagnosis followed by a period in
community care. They estimated that for an average health
district with a population of 60,000, between the ages of 45 and
64, about 20 people would be identified with PDAT. Furthermore,
>50% of them required hospital or community support for over 5
years.
McGonigal et al (1993), did a retrospective review of
hospital records (of patients <75 years old with various diagnoses
of dementia) who had been admitted to psychiatric hospitals, as
well as from neurology out-patients and general hospital records.
This was to ascertain the cases of PDAT in Scotland between 1974
and 1988, with the onset 40-64 years. The minimal incidences,
between the ages of 40 and 64, were 22.6/100,000 for probable
Alzheimer's and 40.5/100,000 for broad Alzheimer's.
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Denominators for incidence were taken from the 1981 census .
The annual incidence of probable AD = 1.6.
The paper was criticised as its rates were based
predominantly on admission to psychiatric hospital. The
classification for MID type dementia was based on the Hachinski
score and did not appear to take into account the group of mixed
aetiology.
The various studies are compared in the following
tables, after Newens (1994a).
Comparison Between Studies of Incidence Rates of PDAT
per 100.000 per annum.











































































CI = Confidence Interval.
*
= Confidence interval not calculable from authors' published data.
N.B. dates shown are the period covered by the study not that of publication.
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* calculated for other studies from the published data
NHR = Northern Health Region
CI = Confidence Interval.
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Putting The Medical Genetics of Dementia in Context.
It is now clear that many of the major diseases of
unknown cause, for example vascular disease, diabetes,
rheumatic disease, mental illness, and cancer, have an important
genetic component. Until the advent of the 'new genetics', (the
study of inheritance at the molecular level) in the early 1980's,
little was known of the way inwhich genetic factors contributed
to the causation of common disorders. The advances in molecular
biology have allowed the development of the methods required
to isolate and determine the fine structure of human genes, and
to study their function in vitro. This has allowed the
understanding of many diseases in terms of their molecular
pathology. As well as allowing an approach to prevention, the
molecular understanding could eventually lead to definitive
therapies for many genetic disorders.
By being able to define the main genes involved in
increasing the likelihood of developing a particular disease, the
difference between the gene product in affected and non-affected
individuals, would potentially lead to the understanding required
to prevent and manage the condition. A good introduction to the
subject is given by Weatherall (1991), and a recent review by
Yates (1996).
Application of the methods of the 'new genetics' to
mental illnesses, has inherent difficulties, as outlined below.
The 'New Genetics' Applied to Mental Illnesses.
In an article by Alper (1993), some of the difficulties of
establishing the genetic basis of mental disease are discussed.
Another review is given by Owen and Craddock (1996). During
the late 1980's, genetic linkages were reported for schizophrenia
and manic depression. However, it is now known that the
evidence for the reported linkages is not as convincing as it
originally appeared to be.
One of the main difficulties is that defining the
phenotypic boundaries for linkage studies is a complex task.
There is no single set of objective criteria for the diagnosis of a
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mental disease, as there is in the diagnosis of physical diseases.
Even the diagnostic criteria of guidelines such as the DSM3R (APA
1987) are not uniformly applied. Some researchers might use a
broad definition, diagnosing the condition if only a few of the
most important symptoms are present, while others might use a
more narrow definition, requiring that most, or all of the
symptoms associated with the disease be present.
Another assumption of linkage analysis is that the
illness is caused by a single diallelic Mendelian locus. The mode of
transmission of mental disorders is unclear. The evidence for a
genetic basis of a disease can be enhanced by adjusting the
degree of penetrance assumed for the genotype. Many traits are
incompletely penetrant; not all individuals with a particular
genotype will manifest the associated phenotype. The degree of
penetrance for any of the major mental disorders (assuming they
have a genetic basis) is unknown. The locus may display
incomplete penetrance which is age dependent. Thus, the age-at-
onset function also needs specifying.
Because of aetiological heterogeneity (different genetic
and non-genetic mechanisms underlying different subsets of the
illness), the correct mode of inheritance parameters for a given
pedigree is uncertain. A true given mode of inheritance in a
family may involve more than one locus e.g. a disease may result
from the interaction of alleles at more than one locus.
These considerations also apply in the genetic study of
the dementias.
Defining the Dementia Types for Study.
The genetic basis of Huntington's Chorea and Down's
Syndrome, have been established. The genetic and molecular
basis of Alzheimer's Disease is still uncertain and great efforts are
currently underway to elucidate it. The following discussion will
largely be based on a review of the knowledge of the molecular
genetics of Alzheimer's Disease. The genetics of vascular
dementia, and other types of dementia, such as Huntington's, will
also be considered.
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Developments in the field have been extremely rapid,
making the literature review of the area a daunting task. During
the summer of 1995, the rate at which new Alzheimer-linked
genes were being published, was one a month! The following
review will aim to give the background to the current
understanding of the genetics of dementia, as up-to-date as can
be.
Some discussion is given to the overlap between various
dementia and neurodegenerative disorders, and other
interconnecting themes emerge. Ben-Shlomo et al (1996),
highlight some of these issues. For example, the amyloidoses as a
set of conditions, allow the relevant knowledge gained from the
study of the prion diseases to be applied to the molecular study
of Alzheimer's Disease. The p-protein in Alzheimer's Disease and
Down's Syndrome, and the PrP protein in Scrapie and Creutzfeldt-
Jacob Disease are discussed in the paper by Roberts et al (1988).
In the discussion on the Apolipoprotein E e4 allele (APOEe4)
findings in different conditions, the common threads between
different disorders is again evident. The vascular effects, via free
radicals, of p-amyloid in Alzheimer's disease, reported by
Bradbury (1996), is another example of how the molecular
processes involved may provide links between Alzheimer's and
vascular dementia.
Vascular Dementia.
As reviewed by Wright (1991), the molecular basis of
vascular dementia, is poorly understood, as compared with
Alzheimer's Disease. Rating scales exist to help to distinguish this
from Alzheimer's Disease, but the existence of mixed states
remain a problem in obtaining a 'pure sample' of cases. Few
satisfactory family studies have been conducted, but those done,
show an increased morbidity risk in the first-degree relatives of
probands compared with the general population, hence indirectly
implicating genetic factors. Twin studies provide little evidence
for or against a genetic hypothesis (Jarvik et al 1980). However,
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predisposing factors such as hypertension do appear to be under
some degree of genetic control (Mongeau 1987). A rare autosomal
dominant form does exist, as identified by Sourander and
Walinder (1977). Another rare autosomal dominant type of
cerebral haemorrhage, caused by a cystatin C defect, called
congophilic angiopathy (CAA), is described by Ghiso et al (1986).
Palsdottir et al (1988), similarly reported a mutation in the
cystatin C gene causing hereditary brain haemorrhage.
Linkage of a hereditary type of Multi-infarct dementia
on chromosome 19 (CI9) has been reported. The CADASIL locus
on C19 has been found to be associated with stroke and dementia.
Familial hemiplegic migraine is also linked to the same locus, for
example, see Joutel et al (1993). Tournier-Lasserve et al (1993),
mapped to 19ql2, a gene causing an autosomal dominant
cerebral arteriopathy with subcortical infarcts and
leukoencephalopathy, as did Jung et al (1995).
St. Clair et al (1995), report the evidence of probable
locus heterogeneity in a large Scottish pedigree with a hereditary
Multi-infarct dementia unlinked to the chromosome 19ql2 locus.
At the time of this publication, there were seven reports on the
condition, variously known as: chronic familial vascular
encephalopathy; hereditary multi-infarct dementia; or cerebral
autosomal dominant arteriopathy with subcortical infarcts and
leucoencephalopathy.
The Transmissible Dementias. Spongiform Encephalopathies, or
Prion Diseases.
The historical relevance of these diseases to the study
has already been mentioned in the Introduction: Historical
Perspective.
The Prion Protein (PrP) plays a significant role in the
aetiology of Creutzfeldt-Jacob Disease (CJD), Gerstmann-
Straussler-Sheinker Syndrome (GSS) and Kuru, and similar
neurodegenerative diseases in animals e.g. Scrapie in sheep and
Bovine Spongiform Encephalopathy (BSE) in cattle. These
dementias can be experimentally transmitted to a variety of
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animals through intracerebral inoculations of infected brain
homogenates.
CTD. Was first described in the early 1920's. It is a rare
disease (one in a million) with a rapidly deteriorating course. It is
confirmed by neuropathological findings of spongiform changes in
the brain, astrocytic proliferation and neuronal cell loss and
occasionally amyloid plaque deposition. Most cases are sporadic
but 10-15% are inherited and show a mainly autosomal dominant
pattern of inheritance. A small number of cases are due to
iatrogenic transmission. It has already been mentioned that Will
et al (1996), reported on cases apparently representing a new
variant of CJD, which may be unique to the U.K. The possibility is
raised that they are causally linked to BSE.
GSS. Was described in the late 1920's, and presents as a
cerebellar syndrome, with a slower course, with dementia
emerging later on in the disease. It is almost entirely familial, the
mode of inheritance likewise being that of autosomal dominance.
Neuropathological changes are similar but here the extraneuronal
amyloid plaque deposits are common and spongiform changes
may be slight.
Kuru. The Fore speaking people of Papua New Guinea,
were found to have an acquired prion disease as a result of the
tribal tradition of ritual cannibalism of infected tissue.
The Prion Protein (PrP), is a 253 amino acid protein
which appears to be resistant to inactivation by heat, UV light,
formalin and X-rays. In the disease form, the prion is largely
composed of an abnormal isoform (PrPsc), derived from the
cellular protein produced in normal brains (whose function
remains unclear). It is expressed in a wide variety of cells and
tissues. The PrP gene is encoded on the short arm of chromosome
20 in man. It is a single-copy gene of simple structure and
organisation. The highest concentration of PrP mRNA occurs in
the brain in neurons (Kretzschmar et al 1986). Various post
translational modifications of PrP occur.
The accumulation of the abnormal isoform causes the
disease. It is still unknown how a purely proteinaceous agent has
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the ability to induce the production of the abnormal protein form.
The abnormal isoform of the PrP in the host, is host encoded. It
was postulated that a nucleic acid genome for the agent was using
the host PrP as a coat. But there is no evidence for this. The PrP
appears to be a molecular chaperone required for its own
assembly, and it seems that the abnormal isoform is misfolded in
a way that caused others to assume the same configuration.
Weissmann (1991), describes a unified theory of prion
progression. However, there may be more than one mechanism
for abnormal isoform production. Table 1 shows the known
mutations in the human PrP gene.
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102 proline - leucine GSS Hsiao et al
(1989).
117 alanine - valine GSS Doh-Ura et al,
(1989).
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96 4 Goldfarb et al
(1991a).
120 5 Goldfarb et al,
(1991a).
144 6 Owen et al (1990).
168 7 Goldfarb et al
(1991a).
192 8 Goldfarb et al
(1991a).
216 9 Owen et al (1990).
The insertion mutation was also demonstrated in an
affected member of a pedigree where the illness was originally
suspected to be familial Alzheimer-type dementia, Collinge et al
(1990). As mentioned, this was one piece of evidence that raised
the possibility that prion diseases may not be so rare as
previously thought. A range of familial and sporadic dementias
were therefore screened for the insertion mutation and also for
the point mutations that had been detected at that time, i.e. the
mutations in codons 102, 117 and 200 (Owen et al 1991). The
only mutation detected in a total of 101 samples was an insertion
that was detected in five apparently unrelated individuals. Two
of these individuals had clinical diagnoses of familial Alzheimer's
disease and the diagnoses of the remaining three individuals
were Pick's disease, Huntington's disease and presenile dementia
with myoclonus and extrapyramidal symptoms, providing further
evidence of the diversity of clinical presentation associated with
this mutation. The genotype, neuropathology and clinical
phenotypes of these diseases are therefore diverse.
The demonstration that GSS and familial CJD are
associated with a wide variety of mutations in the open reading
frame (ORF) of the PrP gene has greatly strengthened the notion
that the PrP plays a central role in the pathogenesis of these
diseases. In particular, transgenic mice harbouring the equivalent
of the codon 102 mutation in man, spontaneously develop
neurological disease and neuropathological changes consistent
with spongiform encephalopathy (Hsiao et al 1990). As
mentioned, the mechanism by which the normal PrP isoform is
converted into its abnormal isoform remains unknown, although
in the case of humans carrying point mutations or insertions in
the ORF of the PrP gene it has been suggested that mutant PrP
molecules might spontaneously convert into the abnormal
isoform. If this process was relatively inefficient, it might explain
why individuals with such mutations do not develop the disease
for decades (Prusiner 1991). Although human prion diseases are
rare, the detection of mutations in the ORF of the PrP gene in a
range of atypical dementias suggests that these diseases must be
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considered. Only when the normal cellular function of the PrP and
the mechanism of replication of the abnormal isoform are
elucidated will a rational therapy for prion-related diseases
become a realistic possibility.
Huntington's Chorea.
Introduction.
This is a condition inwhich choreiform movements are
combined with dementia. It is a relatively rare condition, with a
variably reported prevalence. Myrianthopulos (1966), considered
4-7/100,000 of the population to be a reasonable overall
estimate. An astonishingly dense focus was reported in the Moray
Firth area of Scotland, of 560/100,000 of the population (Lyon
1962).
The disease is associated with a single autosomal
dominant gene with virtually 100% penetrance. A family history
is not always forthcoming, perhaps due to the early death of a
parent, lack of detail due to illegitimacy or inadequate history, or
concealed and circumscribed knowledge in the immediate family
circle. The condition may also arise due to the occurrence of
spontaneous new mutations.
Huntington's Chorea was one of the first conditions
inwhich the genetic location for a disorder of completely
unknown aetiology was located using restriction fragment length
polymorphisms (RFLP's). In 1983, the disease was located to a
gene on chromosome 4 (Gusella et al 1983). But it was only about
ten years later that the gene itself was found. Currently, although
the gene responsible has been localized by linkage analysis, to the
short arm of chromosome 4, the precise mechanism by which the
molecular and biochemical defect cause the neuronal
degeneration, is unknown.
RFLP linkage.
The discovery of restriction endonucleases (REs)
provides an opportunity to approach the analysis of genetic
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diversity. In the genome are harmless base changes that produce
or remove sites: variability is inherited in a simple Mendelian
fashion. The inherited difference in the size of DNA fragments
(RFLPs) provides a large number of linkage markers for following
mutant genes through families. Also, in addition to single point
polymorphisms there are regions of the genome inwhich the
length of DNA between specific RE sites varies between different
persons; and variability is inherited. These hypervariable regions
offer a rich source of genetic markers.
For this method to proceed, the DNA is purified and
digested. The mix of differently sized fragments is subjected to
electrophoresis on an agarose gel. After separation of the
fragments according to their size, the DNA in the gel is denatured
by alkali treatment, and the separated fragments are transferred
to a nitrocellulose filter by Southern blotting. The filter is then
exposed to a radioactively labelled gene probe and the position of
the fragments containing the gene determined by
autoradiography. Different enzymes can cleave around the gene
being studied and a map can be built up.
RFLP linkage analysis can be used to determine
chromosomal location of loci in single gene disorders. It is not
necessary to know anything about the gene or its product and it
is therefore possible to determine the sites for conditions of
completely unknown cause. If the study is of the inheritance of a
gene for a product that is not identified, and there are RFLPs
close enough to the gene, it should be possible to use them as
markers to follow the inheritance of the particular gene through
families. If the RFLP site is known, then the adjacent gene can be
found.
RFLP changes in the DNA at the tip of the short arm of
chromosome 4 have been known for many years but it was only
in the early 1990's that the actual gene was precisely identified
at position 4pl6.3 (MacDonald et al 1993). The specific
abnormality was a polymorphic trinucleotide repeat (CAG)n that
is expanded and unstable. With the gene identified, the size of the
44
repeat can be monitored, to make the diagnosis in anyone and
thus eliminate the need for linkage analysis
Mutational Mechanism: Trinucleotide Repeat Expansions.
The genetic abnormality is similar to that found in
myotonic dystrophy (CTG)n, spino-bulbar muscular atrophy
(CAG)n, and fragile X syndrome (CGG)n.
The diseases mostly display some degree of unusual
inheritance pattern, such as incomplete penetrance or genetic
anticipation (with the severity of the symptoms increasing and,
or, the age of onset decreasing in successive generations). This
mechanism can be understood in the context of the behaviour of
unstable and expanding trinucleotide repeats.
MacDonald and the Huntington's Disease Collaborative
Research Group (1993), reported the identification of the HD gene
and its transcript, referred to as IT15 (for interesting transcript
15). This identifies a 10.4 kb message predicting a 348 kD
protein. Near the 5 prime (5') end of the message a repeat of 21
CAG trinucleotides was observed predicting a polyglutamine
stretch in the protein. This trinucleotide repeat was found to be
normally polymorphic with an allele length ranging from 11 to 36
CAG repeats with 98% of normals having alleles at or below 24
triplets. Among patients with HD, this repeat expands to between
42 and approximately 100 repeats. The increase of glutamines
beyond 44 residues is likely to result in a gain-of-function.
The length of the repeat appears to be correlated with
the severity of the disease, such that juvenile cases fall within the
high end of the abnormal allele lengths. But repeat length
accounts for only about 50% of the variance in age of onset. Other
factors may be modifying genes, which influence the effects of
the abnormal IT15 allele. The repeat lengths vary from
generation to generation with both expansion and contraction
occurring and an overall tendency to increase over the
generations. This could be a way that the disease could become of
increasing prevalence. The sex of the transmitting parent has a
significant influence on the magnitude of the repeat-length
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changes. When transmitted from the mother, repeat-length
increases or decreases within a range of approximately four CAG
units, with a mild tendency towards repeat-length increase.
When transmitted from the father, there is a much larger range
of expansions, up to a doubling of paternal repeat length. The
early-onset of symptoms in Huntington's appears to be associated
with paternal transmission.
In summary, the change in the CAG trinucleotide repeat
would predict a variable number of glutamines within the HD
protein (termed huntingtin).
The Mechanism of Action of the HD Trinucleotide Repeat.
The DNA sequence of the gene and predicted protein
sequence, bear no significant extended similarity with any other
previously reported sequence, making any inferences concerning
the normal function of this gene impossible.
The mechanism of the repeat expansion remains poorly
understood and even if it is similar in different diseases, the
consequences of the expansion may be unique. Any explanation
of the manner in which trinucleotide repeat expansion causes HD
must deal with its selective toxic effect on cells in the striatum,
despite apparent expression of the gene in many other tissues.
Regional differences in splice-variant expression could
play a role in the pattern of pathology. An alternative explanation
for the regional specificity would be somatic instability of repeat
number, but it is unlikely. The susceptibility of the striatum is
likely a function of a unique feature of these neurons. A
precedent exists in familial amyotrophic lateral sclerosis, where
some cases are caused by a point mutation in Zn2+/Cu2+
superoxide dismutase. The enzyme is expressed widely but only
specific neuronal populations are affected.
The expanded repeat is not a simple inactivator of the
gene but many other possibilities for the mechanism of action
remain. If the (CAG)n stretch is expressed as polyglutamine in the
gene product, then the mechanism of action might be at the
protein level. The complete dominance of the disease phenotype
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could then be explained by the mutation conferring a new
property on the protein. Such a property could fall into many
categories, including for example, the increased affinity for a
normal substrate, or the ability to interact with a new cellular
component, or the capacity to inactivate the normal gene product
and alter its localization in the cell. If the (CAG)n is in the gene's
5' untranslated region and even if it is in the coding sequence, it
could have its effect at the RNA level, conferring a new property
on the RNA, such as altering its efficiency of translation, its half-
life, its ability to bind regulatory or other factors, cell localization
and splicing patterns. Finally the (CAG)n repeat could have its
effect at the DNA level, altering the regulation of transcription of
the gene, or possibly another gene in the immediate vicinity.
The expansion in Fragile X syndrome can lead to
transcriptional silences, whereas in myotonic dystrophy the
change is in message stability. In Spinal and Bulbar Muscular
Atrophy (SBMA), Huntington's Disease (HD) and Spinocerebellar
Ataxia type I (SCAI), the change is in the length of the glutamine
tracts perhaps separating critical domains and leading to a gain-
of-function mutation.
Further theories are discussed in Albin (1995). The
Huntingtin protein possesses the leucine zipper motif associated
with gene regulatory proteins. Furthermore, polyglutamine, is a
sequence found commonly in transcription factors. Several
hypotheses have been put forward to explain the effects of
excessive CAG repeats. It has been suggested that polyglutamine
stretches are potential substrates for transglutaminases which
cause crosslinking of proteins and the formation of permanent
glutamyl adducts. Alternatively, the length of the polyglutamine
tract may influence the efficiency of transcriptional factors with a
probable optimal length. A variant of the gene-regulation
hypothesis has also been put forward. Excessive CAG repeats
might cause Huntingtin to act as a sink for transcription factors
that possess polyglutamine stretches and so disrupt neuronal
function, or polyglutamine aggregates could result in insoluble
and ultimately toxic precipitates within neurons.
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Another variant of the transcription regulation
hypothesis, is the mechanism as with the CTG triplets in myotonic
dystrophy. They potentiate the stable nucleosome formation at
the site of triplet expansion. The generation of aberrant
nucieosome positioning by expanded triplets could lead to
blockade of transcription or the alteration of local chromatin
structure, or both. These effects could influence the expression of
genes that contain the repeat and those nearby.
Another theory is that the Huntington protein may
undergo normal processing to produce polyglutamine-containing
polypeptides. These might not be catabolised adequately. The
effects of polyamines, such as the potentiation of N-methyl-D-
aspartic acid (NMDA) receptor activation and modification of
mitochondrial function, could be relevant in the mechanism.
Barinaga (1996), reports on the more recent finding that
huntingtin may interact via its polyglutamine region with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). GAPDH is a
key enzyme in glycolysis, the essential metabolic pathway by
which cells convert sugar glucose to energy. The mutant proteins
in Huntington's Disease may shut energy production down by
interfering with GAPDH.
Repetitive Sequences.
These repetitive sequences, have been found in the
genomes of all other organisms although they are more common
in mammals than bacteria. Although they are normally seen
outside genes, in the so-called "junk" regions, they also occur
fairly often inside the DNA of certain key types of genes e.g.
transcription factors, which control the gene action and
embryonic development. With triplet expansion disease the
symptoms worsen with each generation as the unstable sequence
lengthens. These diseases are all found to affect the nervous
system. The build up of repetitive sequences may have played a
part in the evolution of complex organisms. They are more
common in animals made up of billions of cells. The CAG repeat
has accumulated in certain transcriptional factors during
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evolution. These are involved in a complex web of interactions
between proteins. They would therefore be especially crucial in
the evolution of the human brain. For the mechanism to occur,
there is the need for a triplet sequence in a sensitive area that
has grown unwieldy and become unstable and an error-prone
copying machinery that makes mistakes in the process of cell
division. The gene causing HD has a longer triplet array in
humans than other primates even in the non-diseased form.
Perhaps the "critical mass" effect is at work such that the
presence of one more triplet triggers the problem. Psychiatric
conditions that do not follow Mendelian inheritance are good
candidates for such mechanisms.
Table 2 shows some other conditions and the
trinucleotide repeat expansions associated with them:
Disease Triolet Chromosome
Unwanted triDlet outside eene
Fragile X-A GGG X
Fragile X-E and mental retardation ax: X
Myotonic Dystrophy CFG X
Unwanted triolets inside aene




Machado-Joseph disease CAG 14
Spinal and bulbar muscular atrophy CAG X
Spinocerebellar ataxia CAG 6
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Diagnostic Implications.
The most immediate impact of delineating the (CAG)n
repeat expansion in HD is the capacity to directly diagnose
individuals based on their DNA alone. After the discovery of DNA
markers for HD in 1983, it was possible to perform
presymptomatic or prenatal diagnostic tests using linkage
markers. But this was cumbersome and prone to inaccuracy and
was only applicable to at risk individuals for whom several
family members were willing and able to donate their DNA.
The PCR amplification of the triplet repeat should
revolutionize the testing procedure and provide a reasonably
inexpensive method, applicable to any at risk individual, without
the need for relatives taking part. But there are complicating
factors that must be considered for the diagnostic use of the
repeat. For example, the current distinction between a
chromosome that can cause HD and one that does not is only 3
repeat units. It is currently impossible to draw a firm conclusion
from repeat lengths in the 34-38 unit range. Also, from linkage
analysis over the past few years aimed at delineating the HD
candidate region, several individuals were identified, who were
diagnosed with the disorder, despite inheriting a normal
chromosome.
The carefully designed counselling programmes for
presymptomatic testing should certainly not be abandoned, but
modified, to include the peculiarities of this direct test.




Alzheimer's Disease is believed to be the commonest of
the primary dementing illnesses. It is a leading cause of
morbidity in the elderly and is also important at a younger age.
For a more definite diagnosis, neuropathological confirmation is
also required. The differentiation from other dementias and the
possibility of overlap with these conditions, is crucial to clarify.
The possibility of the molecular understanding of the illness may
therefore provide the best diagnostic tool available.
i). Clinical Genetics.
There are several difficulties in the genetic study of this
condition. First, as already stated, the diagnosis depends on the
clinical diagnosis in life and the subsequent histopathological
confirmation on death. Second, because it usually has a late age of
onset, susceptible individuals may die of unrelated things before
acquiring the condition. At risk relatives may be studied at too
early an age, and retrospective diagnosis means unavailable data.
Alzheimer's is a familial condition, and this is most
clearly demonstrated by looking at the relatives of cases of
presenile dementia. Heston et al (1981), studied the relatives of
autopsy-proven cases and found higher rates of illness in the
relatives, particularly in early-onset rather than late-onset cases.
These findings are widely interpreted as supporting the view that
early-onset Alzheimer's Disease has a greater genetic component
than late-onset cases.
Heyman et al (1984), studied forty cases of onset prior
to the age of seventy years, and a series of matched controls. The
aim was to identify the presence of illnesses among subjects'
parents, aunts, uncles, sibs, children and grandchildren. Dementia
was more frequent among the families of patients (55.3.%)
compared with controls (14.5 %). But the reliability of reports and
certainty of diagnosis, are not good with this method.
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Alzheimer's Disease with onset between the ages of 60-
70 years, is generally sporadic, although studies report that
between 16-41% have an affected first degree relative. In
general, a presence of dementia in the family history is obtained
in 30-50 % of cases (Wright, 1991).
There exist rare pedigrees inwhich inheritance follows
an Autosomal Dominant pattern, providing the best evidence to
implicate genetic factors in the aetiology of Alzheimer's Disease.
These are known as cases of Familial Alzheimer's Disease (FAD).
But there are no consistent clinical or neuropathological features
to allow distinction from sporadic cases. Most of these examples
are of cases whose disease onset has been in the presenium. The
low intrafamilial variation in the age of onset has been studied by
Van Duijn et al (1991). It is estimated that only 0.1% - 1% of all
Alzheimer's Disease cases are FAD, and the majority do not show
such striking patterns of familial transmission.
Another important clinical observation was that adults
with Down's Syndrome appear to be at high risk of developing
the Alzheimer's pathology, at a relatively early age, see Kolata
(1985). This is thought to be due to the extra chromosome 21 that
they carry.
The evidence from the concordance rates in monozygotic
and dizygotic twin studies, demonstrates that genetic
susceptibility is insufficient as a cause for developing the
condition, see Wright (1991).
The best genetic model to explain the transmission, is of an
autosomal dominant gene with age-dependent penetrance,
working on a multifactorial genetic and environmental
background. There exists evidence for familial effects but little
indication as to whether this really reflects a substantial genetic





As mentioned, there is a known link between adults
with Down's Syndrome (trisomy 21) and Alzheimer's. People with
these conditions develop a similar pattern of brain pathology, as
described by Mann (1988). Therefore chromosome 21 was the
first autosome to be tested by a linkage analysis strategy, in
segregation studies with polymorphic markers from the
chromosome. The AD pathology in Down's results from an
overexpression of the amyloid precursor protein (APP) gene on
21q21.2 which codes for the pA4a peptide found in AD lesions.
St.George-Hyslop et al (1987), reported linkage between
Alzheimer's in four early-onset pedigrees and several DNA
markers on the long arm of chromosome 21. At about the same
time, the APP gene was mapped to the same region of
chromosome 21, suggesting that this gene could be in some way
be the cause of the disease. Initial excitement at this possibility
was followed by evidence not in its favour, as the regional
location of linkage was different from the APP gene, see Tanzi et
al (1987) and Van Broeckhoven et al (1987). Goate et al (1989),
found linkage of markers in other pedigrees, but at sites on
chromosome 21 even further from the APP gene. It was
postulated that aetiological and possibly genetic heterogeneity
exists with chromosome 21 linkage, restricted to a subset of
early-onset families. The initial results were thought to be due to
chance cosegregation.
As all cases were not C21 linked (Schellenberg et al
1991b and St. George Hyslop et al 1990), the APP gene was
reanalysed and more mutations in the APP gene were identified,
both in AD families and in families segregating haemorrhagic
stroke due to congophilic pA4a angiopathy (CAA).
The role of APP was stimulated by work on the rare
genetic disorder Hereditary Cerebral Haemorrhage with
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Amyloidosis of the Dutch type (HCHWA-Dutch), found in two
villages in the Netherlands. The pathology is of severe (3-amyloid
deposition in the cerebral blood vessels, which causes death by
middle age of cerebral haemorrhage or survival with a dementia
syndrome like that of Multi-infarct dementia, see Haan et al
(1991).
The p-amyloid is coded for in exon 17 of the APP gene,
and the angiopathy caused by the protein is found in both
HCHWA-Dutch and AD. In HCHWA-Dutch, however, there is
absence of neuronal involvement (e.g. dystrophic neurites and
neurofibrillary tangles).
The continued interest in APP led Goate et al (1991), to
sequence exon 17 in their FAD pedigrees, revealing a mutation at
codon 717 of the APP770 transcript, causing a valine to isoleucine
substitution. It has been found in a few other FAD families since.
Chartier-Harlin et al (1991), has since found a mutation in codon
717 segregating with the disease, resulting in a valine to glycine
substitution, and Murrell et al (1991), another resulting in a
valine to phenylalanine substitution. Finding three mutations in
the same codon strongly suggests that they are pathogenic. But
they are rare, and not found in many cases of FAD, nor a large
number of non-familial cases.
Mullan et al (1992a), identified a double mutation at
codons 670 & 671 in exon 16, changing lysine to asparagine and
methionine to leucine respectively.
In the CAA related haemorrhagic stroke cases, in
families with HCHWA-Dutch, a mutation was identified by Levy
et al (1990), affecting codon 693 of the APP, changing glutamine
to glycine, (at the site of cleavage). Hendricks et al (1992),
reported a mutation at codon 692, adjacent to that causing
HCHWA-D, and changing alanine to glycine. This was relevant for
both patients with the haemorrhagic stroke type illness and those
with presenile onset dementia of the AD type.
The APP mutations are summarised in table 3.
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Table 3. Known APP Point Mutations.
Point mutation. Exon. Amino acid
substitution.
Author.
670 16 lysine-asparagine Mullan et al (1 992a).
671 16 methionine-leucine Mullan et al (1 992a).




















The APP gene is implicated in having a key role in the
pathogenesis of AD. Also of note is that the phenotypes resulting
from the mutations are varied, leading in the one case to a
dementia and in the other to cerebral haemorrhage. This may
raise an issue as to whether Alzheimer's should be separated
from other neuropsychiatric phenotypes.
Figure 1, shows a schematic diagram of the primary
structure of the p-amyloid precursor protein. The molecule
depicted here, is the largest of the known APP transcripts,
comprising 770 amino acids. Several regions of interest are
indicated at their correct relative positions, such as a 17 residue
signal peptide which occurs at the N-terminus, and two sites of
glycosylation (CHO), found at residues 543 and 571 (CHO).
The amyloid p peptide (ApP) fragment, is indicated by
the dark box, and includes 28 residues just outside the
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membrane plus the first 11-14 residues of the transmembrane
domain.
Figure 1. Schematic Diagram of BAPP-7-70. After Selkoe (1991).
Domain.
Relation Between APP Mutations and APP Processing.
The relation of APP mutations to AD pathogenesis can be
studied either in vivo by constructing transgenic animals, or in
vitro by transfection experiments using either a mutated cDNA or
a Yeast Artificial Chromosome (YAC) containing the mutated APP
gene. Transgenic overexpression of one of the mutations in APP
was achieved by Games et al (1995), showing age-linked cerebral
deposition of (3A4a is accompanied by pathology in mice.
cDNA transfection experiments have indicated that the
AD related APP mutations at codons 670/671, 692 and 717
interfere with the normal processing of APP causing either an
overproduction of pA4a or generating a longer pA4a that is more
prone to aggregation.
The alteration of several gene products may underlie the
progressive dysfunction and dystrophy of neurons and glia that
occur in the limbic and association cortices and in certain
subcortical nuclei that project to them. Attempts to place the
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observed morphological and biochemical changes into a temporal
sequence of pathogenesis is a challenge.
There is a marked decrease in choline acetyltransferase
aswell as many other transmitters, and numerous functional and
anatomical classes of neurons are altered in AD. There are also
the characteristic depositions, plaques and tangles, which are
described below.
The neurofibrillary tangles, are fibrous deposits of pairs
of 10 nm twisted filaments in neuronal cell bodies. They are
associated with tau protein, certain forms of which appear to be
abnormally phosphorylated. In addition they are often associated
with ubiquitin. The tangles and tau can be seen as a nonspecific
response by certain CNS neurons to a variety of insults.
The plaques, consist of a central deposit of extracellular
amyloid fibrils (unpaired and about 8 nm in diameter),
surrounded by dystrophic neurites and activated microglia and
fibrillary astrocytes. They are also present in cases of dementia
associated with trisomy 21 and to a lesser extent also occur in
normal aging. The fibrils closely resemble the biochemically
diverse amyloid filaments that accumulate extracellularly in non-
neural tissues, in a variety of unrelated systemic amyloidoses.
Amyloidoses, is a general term in pathology that
designates diseases in which deposits of 5-10 nm proteinaceous
fibrils (amyloid) accumulate progressively in the extracellular
spaces of tissue and their vasculature. Filaments are usually
composed of proteolytic fragments of normal or mutant gene
products, but in each case the particular polypeptide varies.
The amyloid fibrils under present discussion also occur in the
walls of some cerebral and leptomeningeal blood vessels, in AD.
Glenner and Wong (1984), first reported the composition
of amyloid filaments as being an amyloid p-protein (ApP or
pA4a). The initial cloning of ApP cDNA's revealed it to be a
proteolytic fragment of a 695 residue precursor protein, pAPP,
whose sequence predicted a glycosylated polypeptide spanning
the membrane once near its c-terminus. The 39-42 residue ApP
region is shown in figure 1.
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Other proteins in the p-amyloid deposit are of interest,
since they may be crucial in the pathogenic process, a-1-
antichymotrypsin (a serine protease inhibitor) and complement
factors are present, suggesting that there is an inflammatory
process occurring within the plaque. Also present are heparin
sulfate proteoglycans and serum amyloid p component protein.
The latter may be important in delaying the cells ability to digest
amyloid fibrils. It is likely that other proteases and protease
inhibitors will also be found in association.
Figure 2 shows a flow diagram of how mutation in APP
leads to disturbance of proteolytic processing which leads to AD
pathology.
Mutation ( e.g .on chromosome 21.)
i r
Deregulation of gene transcription
1 r
Increases or altered pAPP mRNA's
Excess or mutant polypeptides
i
(constitutive cleavage prevents ApP being formed)




Toxic consequences to the cell.
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BA4a: cause or effect?
Do the amorphous ApP deposits precede or follow the
alterations in neuritic and glial and vascular cells and
extracellular substances? The basis for the pro- and anti-amyloid
factions is discussed in Marx (1993). There is in vitro evidence
that people with a particular hereditary form of AD with a
mutation in the p amyloid gene, had an increased amount of
amyloid produced. It was a key issue as to whether intact and
normal nerve cells in culture secreted p amyloid, or whether
neurons had to be damaged to release it.
As stated above, the APP is inserted into the membrane
of the cell and two thirds of the p amyloid sticks out, with the
rest buried. Most of the extracellular part is clipped off by
secretase which precludes p amyloid production. Other enzymes
could cleave the molecule at different places, but as one end
remains buried, it would be inaccessible to cutting enzymes
unless the membrane were damaged. This would favour the
reasoning that p amyloid is a by-product released by dying cells.
Evidence then appeared that the secretase was not the
only way APP is broken down and alternative pathways in cell
lysosomes contain the p amyloid molecule too. This could occur in
healthy cells. Furthermore, p amyloid was also found in the CSF of
AD and control cases.
Besides early onset FAD, two other diseases
characterised by early and excessive ApP deposition have been
linked to alterations of chromosome 21, namely Down's and
HCHWA-Dutch, as described. Genetic defects on chromosome 21
can cause a form of FAD marked by early and severe ApP
deposition. Some FAD gene defects may alter the regulation of
pAPP transcription resulting in the increased biosynthesis of one
or more isoforms in selected cells or tissues and the presentation
of an excess number of precursor molecules for proteolytic
processing. In both FAD and Down's, some portion of these excess
pAPP molecules are not subjected to constitutive cleavage within
the ApP region but undergo alternative proteolysis. Other
mechanisms for enhanced ApP fragment production could be
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mutations altering the primary substrate, or by alternative
splicing of the ApP, leading to different fragment lengths and
altered susceptibility to deposition.
Altered regulation of the pAPP gene, or other gene
products modifying APP post translationally could result in ApP
deposition. For example, by reduced secretase or increased
protease activity.
The result of the multiple cellular and molecular changes
that are brought about by augmented ApP deposition and plaque
maturation is the progressive dysfunction and death of many
neurons (including profound synaptic loss). The selective
vulnerability of neurons has been difficult to explain. The
biochemical reasons for greater or lesser vascular deposition of
ApP among AD patients and between patients with AD and
HCHWA-Dutch, is also required.
Therapeutic approaches will be the result of the







































Because most early onset AD does not cosegregate with
C21 and mutations in the APP gene are not found in all cases,
other chromosomes have been tested. This led to the
identification of a second and more important locus at 14q24.3.
In 1992, four groups found linkage of Alzheimer's
Disease with a new locus in the middle of the long arm of
chromosome 14: Schellenberg et al (1992); Mullan et al (1992b);
St.George-Hyslop et al (1992); and Van Broeckhoven et al (1992).
The linkage was to a site proximal to a serine protease
inhibitor, a 1-antichymotrypsin (ACT), and distal to the protease
cathepsin G. Two genes on the YAC contig were also of potential
interest, the cellular oncogene c-fos and the transforming growth
factor b 3 subunit (TFGB3). c-fos was a potential candidate as the
APP gene promoter contains a binding site for the transcriptional
activating complex of c-fos, but infact it turned out not to be
relevant. Another candidate included the heat shock protein
HSPA2, which like c-fos responds to neuronal stress and could in
theory cause over-expression of APP.
Sherrington et al (1995), published more findings about
the gene on CI4. This appears to be responsible for 70-80% of
early onset familial cases of AD, comprising up to 10% of cases in
total. The group began by collecting pedigrees of early onset
Alzheimer prone families, of diverse ethnic origin, inwhich the
disease was linked to C14. Using positional cloning, they searched
the 14q24.3 region for DNA markers near the gene that would
help narrow the search area, by defining regions of interest.
Having identified two stretches likely to carry the gene, they
used direct hybridization with complementary DNA to recover
transcribed sequences from these regions, including some cDNA's
with complex and conserved structures that recommended them
as candidate genes. By searching for sequence differences in
these genes between affected members of 6 tightly linked
pedigrees and a group of controls, they came upon SI 82 in which
5 different nucleotide changes (that altered the predicted amino
acid sequence) occurred only in family members affected with
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AD. The evidence was strong that this was a true finding, since
the mutations were absent in the controls and the substitutions
occurred in highly conserved domains and appeared unchanged
in the murine homologue.
The primary structure of the longest open reading frame
predicted a 467 amino acid protein in both man and mouse. SI 82
contains 7 hydrophobic, putatively membrane spanning domains.
It may therefore be a protein embedded in a cell membrane,
which could be a receptor, channel protein or structural
membrane polypeptide i.e. involved in transport, signal
transduction or ion transport. It has similarity with the 465
residue protein SPE-4 from the nematode worm Caenorhabditis
Elegans, which has the function of transporting protein between
cellular compartments during the formation of sperm, see
Harrison (1995a). Levitan and Greenwald (1995), investigated the
true function of SI 82 and found the facilitation of lin-12-
mediated intercellular signalling, specifying cell fate, by the C-
elegans gene sel-12. This gene encodes a protein, similar to that
encoded by the SI82 Alzheimer disease gene.
How could this link in with the p amyloid hypothesis?
The families with these mutations are developing plaques and
tangles about a decade earlier than those individuals with pAPP
mutations. The Ap peptide (the principal component of the
plaques) is secreted by pAPP expressing cells (e.g. neurons, glia
and endothelial cells). Normally the APP is carried by vesicles to
the cell membrane where it is clipped in the middle. The
formation of Ap occurs in mildly acidic membrane vesicles, see
Selkoe (1994). Even in normal brains, it has been shown that
some APP in lysosomes is clipped to form p amyloid. A mutation
in the APP gene, or a change in the transport of the molecule
could tip the balance in favour of overproduction or
amyloidogenesis. Thus, mutations in SI82, or an alteration in its
hypothetical role in membrane trafficking intermediaries, might
allow pAPP to stay longer in amyloidogenic (or less in non-
amyloidogenic) organelles, and so enhance Ap production. There
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is evidence from Querfurth et al (1995), that increased Ap
secretion may occur in the cells of the C14 linked cases.
By May 1996, at the Lancet Conference on the Challenge
of the Dementias, over 28 mutations in the Presenilin I gene had
been reported, the majority being missense mutations especially
in exons 5 and 8. For example, Clark et al (1995), reported on the
structure of the SI 82 gene and six novel mutations, and Cruts et
al (1995), described two more novel mutations. Wragg et al
(1996), comment that Presenilin I accounted for about half as
much of the risk for late onset Alzheimer's Disease as did ApoEe4,
in their series.
Chromosome 1.
Apart from the chromosome 21 and 14 loci, a third
autosomal dominant locus was localized to chromosome 1 (lq31-
42), as reported by Levy-Lahad et al (1995 a & b). Harrison
(1995b), also comments on the new gene. This gene was
responsible for AD in the Volga German kindreds who the group
studied, with mean onset ages between 50.2 and 64.8 years. The
gene appears to be relevant in both early and late onset forms of
the disease. The Volga Germans emigrated from the Hesse region
of Germany, to Russia in 1763 - 1765. They established 60
farming villages on the banks of the Volga river and remained
culturally distinct.
One strategy to isolate the responsible gene, was to test
for mutations in candidate genes. (The other used YACs to clone
the region as defined by linkage analysis). The first candidate
gene was lq31 encoding Cathepsin E, a protease present in
elevated amounts in the brains of AD patients and capable of
cleaving APP at the p-secretase site. This was not apparently
altered in affected individuals. The second candidate was a
homologue to SI82, the recently cloned C14 gene. The entire
coding region of this so-called F-T03796 gene was screened for
mutations, in affected individuals from the kindred, and the
mutation was found at codon 141, substituting isoleucine for
asparagine. The amino acid sequence predicted by F-T03796
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exhibits about 67% homology with the SI82 sequence and to a
similar degree with the mouse S182. The three mammalian genes
are similar to the Caenorhabditis elegans genes as described
above.
The codon 141 mutation in this gene and some of the
reported mutations in SI82, occur in sequences conserved
between the chromosome 1, and human and mouse SI82 genes.
Hydropathy plots predict the encoded protein to have 7
transmembrane domains and is referred to as STM2 (the second,
seven-transmembrane gene associated with AD). Within the
putative transmembrane domains the sequence similarity
between STM2 and SI82 is 84%. The mutations may adversely
affect the insertion or anchoring of these proteins in the
membrane. Rogaev et al (1995), reported the cloning of the E5-1
gene. Analysis of the nucleotide sequence in the ORF, revealed
two missense substitutions at conserved amino acid residues, in
affected members of pedigrees with a form of Familial
Alzheimer's Disease. They found that these individuals had a later
age of onset of dementia, between 50-70 rather than 30-60 years
old.
Although the normal cellular functions of STM2 (E5-1 or
Presenilin II) and SI82 (or Presenilin I) are unknown, if they are
functionally similar to those of spe4, they may be involved in the
cytoplasmic partitioning of proteins. Mutations in them could
alter the intracellular protein trafficking of APP and ultimately
lead to altered APP processing and increased production of Ap.
They may also function as G protein-coupled receptors or ion
channels. They may be different subunits of the same receptor
complex. Similarity to sel-12 would indicate a possible function of
mediating intercellular signals, and cell fate decisions important
in neurogenesis.
65
Figure 4, shows the simplified features of the seven
transmembrane proteins (STM's), based on STM-2. It is an
integral membrane protein with 7 membrane spanning domains
and a large exposed loop between the 6th and 7th





hydrophilic acidic domains, divergent sequences.
sequences conserved between Presenilin I and IE.
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Chromosome 19.
In the section earlier on the genetics of vascular
dementia, chromosome 19 has already been mentioned.
The identification of Apolipoprotein E e4 (APOEe4) as a
genetic risk factor in Alzheimer's Disease, is a classic example of
how biological studies of (3A4a associated proteins can lead to the
identification of candidate genes in AD.
The long arm of C19 was first implicated in late onset AD
by Schellenberg et al (1987), who found an association between
familial AD and the allele at the polymorphic Apolipoprotein CII
(ApoCII) locus. This was confirmed by Pericak-Vance et al
(1991).
Strittmatter et al (1993), reported that the frequency of
the APOEs4 was increased in late onset AD patients (50%)
compared with controls (16%). The APOE and ApoCII genes are
part of a gene cluster 40 kB apart.
Subsequent studies confirmed that sporadic and familial
late-onset AD are associated with APOEe4, see Corder et al (1993)
and Chartier-Harlin et al (1994). Corder at al (1993),
demonstrated that the APOEe4 has a dose effect on the risk of AD,
age of onset and survival, in both familial and sporadic late-onset
forms of the disease. The risk for Alzheimer's Disease increased
from 20% to 90%, and mean age at onset decreased from 84 to 68
years with an increasing number of APOEs4 alleles, in 42 families
with late onset AD. One APOEeT increased the risk of late onset
AD three fold compared with those with no APOEe4 alleles.
APOEe.4/APOEe4 homozygotes had an eight fold increased risk.
The effect was strong enough that 80% of homozygotes would
develop AD by the age of 80. Saunders et al (1993), also
demonstrated how APOEe4 is associated with late-onset familial
and sporadic Alzheimer's Disease, in comparison with the general
population.
The strong association between APOEe4 dose and
susceptibility to late onset AD suggests that the gene plays a
causal role in the pathogenesis of AD. (The alternative would be
that the effect was of linkage disequilibrium, with the pathogenic
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allele of a nearby gene.) However, late onset AD occurs with no
APOEe4 alleles, so either AD is polygenic, with APOEe4 a major
effect gene, or AD is genetically heterogeneous.
APOEe4 has also emerged as a risk factor for early onset
AD, see Okuizumi et al (1994). Van Duijn et al (1994), showed an
increased risk of early-onset Alzheimer's Disease, for APOEe4
heterozygotes, only in subjects with a positive family history.
Norman et al (1995), have shown that APOEe4 is enriched in
presenile cases but find no evidence that it affects the rate of
progress of the disease, although the degree of pathology may be
increased. The clinical information came retrospectively, from
case notes and informants.
It has also been suggested that by gene-gene interaction
of the APOEb4 and APP loci, the presence of APOEe4 reduces the
age of onset in patients with APP mutations, see St. George Hyslop
et al (1994). In familial AD the onset age respectively decreased
or increased when APOEe4 or APOEe2 alleles were present, and a
similar effect was observed in AD families segregating the
APP670/671 or APP717 mutations. In the HCHWA-Dutch families
and the AD/CAA family, segregating respectively the APP693 and
APP 692 mutations, no effect of the APOE genotype was detected
on the clinical expression of the disease. No modulation of age of
onset is detected in the C14 linked AD families. A potential gene-
gene interaction between APOEe4 and ACT has been reported by
Kamboh et al (1995).
Recent studies suggest that APOEe2 is associated with a
protective effect in late onset AD, see Chartier-Harlin et al (1994),
Corder et al (1994), and Rubinsztein et al (1994). The protective
effect appears to be independent of the over-representation of
APOEe4 in late onset cases.
Extending APOEs4 testing to other neurodegenerative conditions.
Alzheimer's. Parkinson's and Lewv Body Disease.
There is a debate as to the risks conferred in other
conditions such as Parkinson's Disease (PD). Arai et al (1994),
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demonstrated that APOEe4 is a risk factor contributing to the
emergence of Alzheimer's Disease type dementia in Parkinson's
Disease. The results were of an increase frequency of AP0Ee4 in
those patients with Parkinson's Disease and dementia, but not PD
alone. However the work of Marder et al (1994), did not
substantiate this. Using different criteria for dementia, they
found no association of the APOEs4 allele with patients with
dementia in Parkinson's Disease. Benjamin et al (1994), found the
frequency of APOEs4 greater in both AD and Lewy Body Dementia
but as shown previously, not in Parkinson's Disease. Hansen et al
(1994), suggest that APOEe4 can account for much of the overlap
between AD and LBD.
APOEe4 is therefore a definite risk factor for late-onset,
familial and sporadic Alzheimer's Disease and also cortical Lewy
Body Disease. This is further substantiated by the work of
Pickering-Brown et al (1994) and Galasko et al (1994). The
evidence for its association with Parkinson's Disease, is less
certain. But it is likely that it is at least one of the determinants
as to whether cortical dementia occurs in patients with Lewy
Body Disease.
McKeith (1995) points out the usefulness of
investigating individuals with Lewy Body pathology, in order to
clarify the overlap between Alzheimer's Disease and Parkinson's
Disease, and to define the aetiology of the dementia in these
conditions. Clinically these issues are unclear. Hughes et al (1992),
looked at the clinico-pathological details of 100 cases of idiopathic
Parkinson's disease. They questioned the concept of Parkinson's
being a distinct morbid entity.
The Venn Diagram in figure 5, shows the overlap
between the different pathologies (tangles, plaques and Lewy
Bodies). Chromosome 22 has been implicated as relevant to the
dementias characterised by tangle pathology.
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Figure 5: Overlap Between Plaques, Tangles


































There is an overlap in the pathologies and molecular
lesions, for example as demonstrated by Lantos et al (1992), that
Lewy Bodies were found in cases where the 717 APP mutation
was present. Furthermore, the cytochrome P450 debrisoquine 4-
hydoxylase mutant B allele (CYP2D6B), has been found to be a
susceptibility gene for Parkinson's Disease. Saitoh et al (1995),
found that CYP2D6B was over-represented in the Lewy Body
Variant of Alzheimer's Disease, suggesting that the gene may be
involved in cognitive impairment in Parkinson's Disease and the
Lewy Body Variant of Alzheimer's Disease. The interaction of the
APOEc4 and CYP genetic traits at the molecular and cellular levels
may result in the altered expression of the two genetic traits.
Chen et al (1995), found the association of the CYP2D6B mutant
allele with Lewy Body formation in both Parkinson's Disease and
the Lewy Body Variant of Alzheimer's Disease and with the
milder synaptic pathology in pure Alzheimer's Disease without
Lewy Bodies. They suggested that depending on the contribution
of other genetic and environmental factors, this mutant allele
may be involved with different aspects of neurodegeneration.
Other.
Rubinsztein et al (1994), looked at cases of Multiple
Sclerosis, Parkinson's Disease, Schwannomas and late onset
Alzheimer's Disease. This was to test the hypothesis that if
apolipoprotein E mediated transport of lipids is the rate limiting
step in the process of the response to central nervous system
injury, then the functional differences between the alleles would
be associated with varying predispositions to neurodegenerative
and demyelinating diseases. They postulated that if
apolipoprotein mediates cholesterol uptake, and limits neuronal
growth, then the APOEe2 allele would slow CNS tumour growth.
The group simply confirmed APOEe4 as a risk factor for
Alzheimer's Disease, and APOEe2 as a factor reducing risk.
Amouyel et al (1994), looked at cases of Creutzfeldt
Jacob Disease, and found that the APOEe4 allele was a risk factor
for the disease, in both definite and probable cases, and for
patients with and without prion protein mutations. In affected
subjects, the APOEe2 allele delayed the occurrence of death,
independently of other known mutations influencing the
phenotype of the disease. They comment that these effects on
neurodegenerative disease associated with APOE alleles suggest a
strong involvement of the APOE locus in brain metabolism.
APOEe4 has also been associated with Multi-infarct
dementia, see Shimano et al (1989), and Noguchi and Murakami
(1993). This may be a direct causal effect as the APOEe4 would
lead to increased low density lipoprotein (LDL) Cholesterol levels
and lead to an increased risk of thrombosis.
The APOE allele system has also been investigated in
Down's Syndrome. Royston et al (1994), found that the APOEe2
allele promoted longevity and protected Down's Syndrome adults
from developing dementia. Avramopoulos et al (1996), has
looked at the distribution of APOE alleles in the parents of Down's
Syndrome children. They found that APOEe4 may be a risk factor
for meiosis II non-disjunction in young mothers.
The importance of the APOEe.4 allele in predicting the
outcome after head injury has also been of interest. Roberts et al
(1991), demonstrated the deposition of pA4 in the brain after
head injury. More recently, Nicoll et al (1995), showed that
APOEe4 is associated with the deposition of A0P following head
injury. Alberts et al (1995), demonstrated a strong association
between the APOEe4 gene and a poor neurological outcome after
intracranial haemorrhage, and Sorbi et al (1995), confirmed and
extended in vivo, the possible role of APOE genotype in
determining a genetic susceptibility on the effect of head injury.
Henderson et al (1995), found that APOEe4 was a risk factor
but not sufficient (even in the homozygous form) to cause
cognitive decline and ultimately a diagnosis of dementia of the
Alzheimer type. In this study, 638 people were interviewed and
followed up. Those with one or two APOEe4 alleles were found to
be more likely to have a family history of Alzheimer's Disease.
Petersen et al (1995), showed APOE status to be a predictor of the
development of Alzheimer's Disease in memory-impaired
individuals.
Mechanism Of Action.
The APOE gene lies in the apolipoprotein cluster in
chromosome 19ql3.2, and APOE plays a role in nerve
development and repair. The three common alleles APOEe2,
APOEe3, APOEe4 have a major impact on the total and LDL-
Cholesterol levels in the serum and are highly correlated with the
risk of atherosclerosis and cardiovascular disease.
Apolipoprotein E is expressed in large quantities in the
brain, where it binds to p-amyloid with an affinity that is highest
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for the APOEe4 isozyme. Wisniewski et al (1993), suggested it
may act as a pathological chaperone that binds to soluble p
amyloid and promotes a conformational change leading to fibril
formation by reducing the amyloid solubility. This in turn would
predispose to deposition of diffuse plaques. However, this may be
a secondary phenomena.
Diedrich et al (1991), have shown that APOE mRNA and
protein expression are increased in AD. So, deposition maybe the
consequence of APOEe4 acting elsewhere, such as receptor
mediated endocytosis of APOE-p amyloid complexes, followed by
their dependent dissociation in primary lysosomes. APOE maybe
pathogenic intracellular^, as it is associated with tangles. APOEe4
does not bind to tau, and microtubules are stabilised by tau
binding. It could be that abnormal tau phosphorylation reduces
the microtubule stability, and leads to degeneration and cell
death. APOEe4 may enhance this.
The importance of APOEb4 is that it represents the first
identified molecular genetic risk factor for common Alzheimer's
Disease. Results suggest that multiple genes may contribute to an
increased susceptibility, but that one alone would not be
sufficient to cause the disease.
Rubinsztein (f995), has reviewed the role of
apolipoprotein E in lipoprotein metabolism, neuronal growth and
repair and as a risk factor for AD.
Other Candidate Genes.
Svnuclein Proteins.
Synuclein/non-amyloid p component of Alzheimer's
Disease amyloid (NAC) proteins are found in presynaptic
cholinergic nerve terminals that degenerate early in Alzheimer's
Disease, and are found closely linked to p-amyloid fibrils in senile
plaques.
Synuclein /NAC proteins provide a potential molecular
link between the degeneration of cholinergic nerve terminals and
the formation of plaques, and might have a primary role in their
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development. Synuclein proteins have been reviewed in an
article by Brookes and St.Clair (1994). Apart from synuclein a or
NACP (NAC precursor), synuclein p or gamma synuclein, maps to
chromosome 17 and has been implicated in the genetic aetiology
of rare frontal lobe degenerating conditions, such as Steele-
Richardson Syndrome (SRO).
A cDNA was cloned for an unrecognised component of AD
amyloid deposits, NAC, from a precursor NACP, see Ueda et al
(1993). Immunochemical analyses of AD brains (with antibodies
raised against two separate fragments of the NAC peptide),
showed staining of amyloid on diffuse primitive and mature
plaques, as well as on cerebral blood vessels. Electron microscopy
reveals localisation of NAC peptide specifically on amyloid fibrils,
and therefore differs from other plaque components where co-
association with amyloid is only demonstrable with the light
microscope. This suggests that NAC-peptide and amyloid are very
tightly linked. Yoshimoto et al (1995), suggest that NACP
stimulates the aggregation of the amyloid.
The match with rat synuclein revealed 90% homology,
and the proteins translated were 95% identical. Thus the genes
are equivalent within different species. The gene is encoded on
chromosome 4, and exists as a potential candidate in the aetiology
of Alzheimer's Disease.
Synuclein was first isolated from the cholinergic-rich
synapses of Torpedo fish, and the rat gene was subsequently
cloned. The expression of the latter mirrors the distribution of
typical AD pathology. The protein appears to be located at the
synaptic junction between two main types of neurons implicated
in AD; the choline acetyl transferase (ChAT) positive neocortically
projecting magnocellular cholinergic neurones of the nucleus
Basalis of Meynert and cortical pyramidal neurones containing
muscarinic receptors that use phospholipase C as a second
messenger. Bowen et al (1994), suggested that disturbed
cholinergic transmission might encourage the deposition of
amyloid plaques, and the function of synuclein/NAC might
therefore provide a crucial molecular link into this process. Being
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presynaptic, it may be involved in nerve terminal degeneration
and promote amyloid deposition in a variety of ways. Perhaps
certain isoforms exist that confer an increased susceptibility to
AD by such processes.
Mitochondrial Genes.
Details of the nuclear genes encoding enzymes of
oxidative phosphorylation (OxPhos) and the evaluation of their
possible involvement in human inherited dementia, is given by
Wallace (1992 a & b).
A number of disorders of Ox Phos are due to mutations
in the Electron Transport Chain (ETC) enzyme subunits, encoded
by the mitochondrial genome. Dementia features as a symptom in
many of these disorders and the disorders possess multiple
overlapping pathologies. The activity of the Ox Phos cycle varies
in different tissues, with myoblasts and neurones requiring the
greatest oxygen supply. The precise defect which results, is
reflected in the severity and specific pathology in each tissue.
Considerable evidence now suggests that mitochondrial defects
are relevant to the aetiology of AD and PD, in which brain
pathology is the primary abnormality. Other factors, both genetic
and environmental, are presumably involved in the precipitation
of neurological symptoms. Other features of mitochondrial
disorders are the occurrence of minor symptoms, such as
widespread optic nerve degeneration, and the early
mitochondrial changes in frontal cortex dendrites in AD.
The enzyme components for Ox Phos are multi-subunit
complexes in the inner mitochondrial membrane, numbered 1 to
V, aswell as adenine dinucleotide translocase, and the ETC itself.
65 of the 78 enzyme subunits are encoded by nuclear DNA
(nDNA). Of the nDNA components, less than a half have been
cloned. The nuclear sequences comprise a complex family of
genes and pseudogenes, about which relatively little is currently
known.
Mitochondrial DNA (mtDNA) has been fully sequenced,
as the mitochondrial genome is relatively small. It is complex, in
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part due to the fact that it has a high mutation rate. The mtDNA
content of a cell can comprise various different genomes and the
content of any tissue will be of a mixed population of sequences,
a phenomenon known as heteroplasmy. The accumulation of
abnormal mtDNA with ageing reflects the reaction of free radicals
with mitochondrial nucleic acid. When mutant mtDNA's are
inherited, and individual starts with less 'reserve capacity' and is
therefore more vulnerable to this progressive decline.
Parker (1992), demonstrated cytochrome oxidase
deficiency in Alzheimer's Disease. Soong et al (1992), investigated
the levels of a specific mitochondrial DNA deletion measured in
twelve different brain regions of adults. Striking variation among
anatomical locations was found. The authors suggest that this
represents the tip of an iceberg of the spectrum of somatic
mutations produced by oxidative damage. Corral-Debrinski et al
(1992), examined the role of somatic mitochondrial DNA (mtDNA)
mutations in human ageing by quantifying the accumulation of a
common nucleotide pair deletion in various parts of the brain.
They suggested that somatic mtDNA deletions may contribute to
the neurological impairment often associated with ageing. Lin et
al (1992), did work on the detection of point mutations in codon
331 of mitochondrial DNA encoding part of a dehydrogenase
enzyme, in the brains of people with Alzheimer's Disease. It is
also of interest that the free oxygen radicals, which destroy
neurons, are naturally defended against by Superoxide Dismutase
(SOD). This enzyme is easily measurable in the red blood cells.
The Cu/Zn Superoxide Dismutase (SOD-1) is encoded for on
chromosome 21.
Hutchin et al (1995), investigated a mutation at point
4336 of the mitochondrial DNA, that was represented at an
increased frequency in individuals with Alzheimer's Disease.
Ikebe et al (1990), found an increase of deleted mitochondrial
DNA in the stiatum of patients with Parkinson's disease and
senescence.
Does a relationship exist between mutations in the
nuclear encoded OxPhos enzyme subunits and the inherited
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dementias? The involvement of the nDNA in the aetiology of the
disease has not yet been evaluated. But, as for the mtDNA, it is
likely that nuclear gene mutations will cause disorders, perhaps
with other groups of symptoms, including inherited dementia.
Trinucleotide Repeats. See discussion of Huntington's Disease.
ACT
The a 1-antichymotrypsin (ACT), a serine protease
inhibitor, is encoded for on chromosome 14. It has been
mentioned in the context of the history of the search for the locus
of major importance on this chromosome, but actually lies far
from it. Proteases and protease inhibitors may cause the
abnormal cleavage of the APP molecule and are therefore
candidate genes for contributing to the genetic understanding of
Alzheimer's Disease. Kamboh et al (1995), present some of the
background to a 1-antichymotrypsin as a candidate gene. Like
apolipoprotein E, ACT binds to p-amyloid peptide (A|3P) with high
affinity in the filamentous deposits found in the AD brain and
serves as a strong stimulating factor in the polymerization of ApP
into amyloid filaments. In AD brains, ACT expression is enhanced,
particularly in areas that develop amyloid plaques, suggesting it
plays an important role in the pathogenesis of AD. The paper
shows that a common polymorphism in the signal peptide of ACT,
confers a significant risk for AD. It is also shown that the APOEe4
gene dose effect associated with AD risk, is significantly modified
by the ACT polymorphism. This work identified a unique
combination of ACT and APOE genotypes as a potential
susceptibility marker for AD. It shows that ACT behaves as a
modifier gene, altering the AD risk conventionally associated with
the APOEe4 allele. Wragg et al (1996), report that this has not
been repeated.
VDRL R.
Okuizumi et al (1995), reported on the genetic
association of the Very Low Density Lipoprotein Receptor gene
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(VLDL-R gene) with sporadic Alzheimer's Disease.
HLA-A2
Payami et al (1991), found that HLA-A2 or a closely
linked gene confers a susceptibility to earlier-onset sporadic
Alzheimer's Disease in men.
Summary.
How is it possible to study the majority of cases which
do not show autosomal dominant transmission? An alternative to
the linkage strategy is to study the affected families using non-
parametric methods of linkage analysis such as the affected
pedigree member method, and the extended sib-pair analysis.
Neither require the mode of transmission to be specified.
Further candidate genes and loci are likely to be
identified by studies of early-onset FAD families and looking at
the genes involved in the expression and metabolism of APP.
A complimentary approach is to study individual genes
for allelic association, looking either directly for functional
mutations that determine disease susceptibility or for DNA
polymorphisms that are in linkage disequilibrium with them. This
can be done by studying multiply-affected families and
population samples of unrelated patients and controls. This
approach has the advantage of being able to detect genes of
relatively small effect. It is especially applicable as candidate
genes are identified and may prove more effective than linkage
studies in allowing the identification of the contribution of genetic
factors to the common form of AD.
The molecular genetic approach has been very
successful in the analysis of early-onset FAD, as it is mainly
inherited as an autosomal dominant disease, which allows the use
of the positional cloning strategy. This is based on cosegregation
analysis of the disease with polymorphic genetic markers of
known chromosomal localization, in multiply affected families.
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Once the chromosomal location is found, the gene is isolated
based on its position, using gene cloning techniques.
Using this method it has been shown that in about 5% of
the families with early onset FAD, the disease cosegregated with a
mutation in the gene coding for the APP located at chromosome
21q21.2. The S182 gene, localized at chromosome 14q24.3 seems
to be responsible for about 70% of early onset FAD, and of the
remaining 25% of the families, a gene located on chromosome 1 is
another cause. This gene has striking similarity to that on
chromosome 14.
The APOEs4 is located at chromosome 19ql3.2 and
confers a higher genetic risk for the development of both late-
and early-onset AD on individuals carrying 1 or 2 APOEe4 alleles.
This effect starts from an age of at least 50 years old, and seems
to influence other aspects of the course of the illness too.
Other autosomal dominant forms of AD await
identification. How these and APOEe4 triggers or modifies the
cascade need determining. The genetic factors in other familial
and sporadic cases must be identified and other susceptibility
genes are likely to exist. Environmental factors also need
clarifying and therapeutic agents to halt the pathology need
developing. A reliable diagnostic test may also become available
as a result of the genetic understanding. With a more
sophisticated classification of the dementias based on molecular
subtypes, it may be possible to predict the clinical course of an
individual's dementia.
It is likely that a combination of environmental factors
and genetic loci (genetic risk factors) are interacting in the
majority of cases of Alzheimer's Disease, to give rise to the
condition.
Table 4 overleaf summarises the findings.
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Table 4: FAD genes and other genetic influences.
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The Implications Of Genetic Testing.
This topic is mentioned as it is of crucial importance in
the context of the rapid development of the field. It is not
however discussed in detail here.
Some of the issues involved in the genetic testing for
Alzheimer's Disease are discussed in the paper by Lovestone and
Harper (1994), and the clinical application of APOE testing is
discussed by Roses (1994). The role of APOE testing in the
differential diagnosis, rather than the prediction of Alzheimer's
Disease is discussed by Roses (1995). Breitner (1996) and Tanzi et
al (1996a), give guidance as to the clinical use of the test. Poirier
et al (1995), commented on the use of the APOE status as a
predictor of cholinergic deficits and treatment outcome in
Alzheimer's Disease. Karlinsky et al (1994), present the discussion
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of issues in molecular genetic testing of individuals with
suspected early onset familial Alzheimer's Disease, based on the
APP mutations.
As discussed, in a very small proportion of cases with
clear familial patterns of inheritance, mutations in chromosome
21, 14 and 1 have been found to be responsible for the illness.
For the small proportion of AD showing clear familial inheritance,
with a recognisable genetic mutation, the presymptomatic testing
of those at risk is feasible, but only in the framework of
counselling and support.
Furthermore, the identification of APOEe4 as a genetic
risk factor, raises the possibility of developing predictive or
diagnostic tests. Such predictive testing raises ethical concerns,
some of which apply to Huntington's Chorea. But for AD, the
condition is more common, and there would be a greater demand
for the service. Currently, it is only possible to indicate
susceptibility by these tests.
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Method :
IV. Ascertainment of the Sample.
The ethical approval for the study was obtained from
the Lothian Research Ethics Sub-Committee for Psychiatry and
Clinical Psychology, in July 1993.
The aim of the case ascertainment for the study, was to
identify a population patients with presenile dementia, who had
been identified by hospital contact, within a defined period of
time, and who were currently alive, in the Lothian area. The
issues relevant to the gaining of as complete a sample as possible,
and some of the biases introduced in the study are discussed
elsewhere. The method used in the study is described here.
The main method of case identification was to use the
Lothian Psychiatric Case Register (LPCR), listing referrals to the
Psychiatric Service, but in addition, the records of the Neurology
Services were also checked. All the relevant International
Classification of Diseases Ninth revision, ICD9, Mental Disorders
(WHO, 1978) diagnostic codings were used, to ensure that as
complete a search was done as possible. The Lothian Register
covered the City, East and Mid Lothian and a separate search of
records was also made at West Lothian. A map of the area is
shown in the context of mainland Scotland, on the next page. The
approximate population between the ages of 30 and 70 years old,
is 350,000 (Census Lothian Region, 1991).
In addition, the responsible consultants in the service
were all contacted to ensure no cases had been missed. Some
cases were identified by word of mouth.
The sample came from those whose illness had been
diagnosed between the years 1988 to the end of 1993, and who
were 65 years of age or under at the time of diagnosis.
The cases were those with a first time diagnosis of
presenile dementia, at contact or admission or discharge, for out¬
patients and in-patients. By looking at the dates of births, the
people who were 65 or under at the time of diagnosis were
identified.
Map of Mainland Scotland, to show the
location of the Lothian Area.
W = West Lothian.
C = City of Edinburgh.
M = Mid Lothian.
E = East lothian.
82
It became apparent that, if the search were extended
any further back than 1988, the majority of people under review
had deceased; and so the cut-off year 1988 was kept.
Great care was taken to try to find as many of the case
notes as possible. The Feighner Criteria for Organic Brain
Syndrome, Feighner et al (1972), were applied to each set of case
notes. The criteria are broad-based and are given here:
Feighner Criteria for Organic Brain Syndrome.
This diagnosis is made when either criterion A or criterion B is
present.
A. Two of the following manifestations must be present. (In the
presence of muteness the diagnosis must be deferred.)
1) Impairment of orientation.
2) Impairment of memory.
3) Deterioration of other intellectual functions.
B. This diagnosis is also made if the patient has at least one
manifestation of (A) in addition to a known probable cause for
organic brain syndrome.
Lothian Psychiatric Case Register Surveys.
Three separate searches of the register were infact
made. The first search included only a restricted group of
diagnoses to be searched for. The second search requested other
categories of diagnoses which the target group may have fallen
into.
For out-patients, the following register diagnostic
categories were included;
01, for senile dementia
02, for other dementia (e.g. Multi-infarct).
For in-patients, the following ICD9 codes were included:
290 Senile and presenile organic psychotic conditions.




294 Other organic osvchotic conditions (chronic).
294.1 Dementia in conditions classified elsewhere.




333 Other extrapyramidal disease and abnormal movement
disorders.
333.4 Huntington's' Chorea.
(This category was later excluded, see discussion in Method:
Contact.)
From this search, a total of 200 cases were found to
meet the Feighner criteria, on inspection of the case notes.
A third register search was made, of those cases who
had an outpatient diagnosis of 03 (other organic condition), with a
subsequent diagnosis of one of the diagnoses listed above. At the
time of the diagnosis of dementia, the subject would have to be
65 or under.
From this, a further 14 cases were found, who met the
Feighner criteria. In total, from the register searches, 214 cases
were found.
Alcohol Related Diagnoses.
Because of the inclusion of cases of Alcohol-related
dementia, a separate search of the register was made to find such
cases. The diagnostic categories included were:
291 Alcoholic psychoses.
291.1 Korsakoffs psychosis, alcoholic.
291.2 Other alcoholic dementia.
From this a further 14 cases were found to meet the
Feighner criteria, and in total, including the other searches, the
number of Alcohol-related cases was 44.
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Cases From The Neurology Department.
The neurology records were also inspected for the study.
The benefits of the computerised Psychiatric Register became
very apparent, as the neurology records were haphazard in
comparison. Only the clear cases of dementia were kept. Cases of
hydrocephalus, and alcoholics who had sustained head injuries,
were excluded. It is of note that the neurology cases of
Parkinson's did not necessarily state if there was associated
dementia and hence many possible cases could have been
excluded because of this.
There was some overlap in the referral between this
group and the psychiatric service, particularly at the time when
the Medical Research Council, Brain Metabolism Unit (MRC-BMU)
had been involved in research into dementia.
A total of 15 cases were found from the neurology
department who had not been discovered previously.
Other Ascertainment.
From the records kept at West Lothian , a further 13
cases were identified. Individual contact also brought 34 cases to
the study. This seems rather a high figure, and illustrates the
problems of any register being totally inclusive of all cases.
During the course of the study, after the period of case
ascertainment, various other cases were referred, but were not
included.
At the stage of inspecting the case notes, further
attrition of the sample became apparent, due to death, or to
wrong diagnoses, or to being too old (or diagnosed pre-1988), or
to being out of the area. Some of the wrong diagnoses, without
documented cognitive decline, were: bipolar illness; depression;
schizophrenia; learning disability; personality disorder; alcohol
abuse. Some of the wrong diagnoses were due to miscoding,
which is one of the inaccuracies arising from this method. Some of
the case notes were not traceable.
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Any cases excluded were double-checked and a note
kept of why the exclusion had been made, including those found
to have already deceased at this stage of the ascertainment. The
case note inspection also provided the opportunity of collecting
various items of data as described in the Method: Battery.
The results of the ascertainment are given in the Results.
The further details of ascertainment, after contact was attempted,
is given in the chapter on Method: Contact.
Further information not given here, is available on the
data obtained from the register, for example a year by year
breakdown of the ascertainment figures.
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Method:
V. Choosing an Assessment Battery.
Page. Contents.
86-90. Consideration of testing battery.
90-93. Complete Assessment Schedules.
93-96. i) Demographic Data.





105-110. iv) Neurocognitive Testing.
111-114. v) Neurological Assessment.
The second assessment
114-115. Carer Stress Scales.
In 1383, a lady called Emma De Beston, formerly of
Cambridge, was assessed for idiocy, with the following
assessment battery:
I. In what town she was?
II. How many husbands she had had?
III. How many days there were in a week?
IV. How many shillings there were in forty pence?
V. If she would rather have 20 silver groats than forty pence?
Neugebauer (1978).
The assessment of impairment in dementia, has
developed greatly since then.
The next step, having identified the target population as
described, was to decide on a suitable assessment battery for the
group. Currently, there are not any instruments in existence,
designed specifically for younger dementia sufferers.
Furthermore, the group under study here, was diverse
in aetiology and severity, so that the study covered a broad range
of conditions and stages of disease. Several key points were
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necessary to consider for the purpose of deciding what tests to
use, both academic and pragmatic. The tests were chosen taking a
balanced account of the need to provide scientific value and
clinical usefulness. Another feature of this study was to provide
an opportunity to revisit the subjects after a period of a year
(between 12 and 15 months) and therefore to measure the rate
of decline of each individual.
Some of the main issues to consider in choosing the
testing instruments are given below in points 1-6. The
assessment procedure is given in the Appendix: Protocol.
1. Appropriateness to subjects and relatives
The tests had to be applicable to the study population in
terms of brevity and acceptability. Could the subjects
concentrate long enough, and were the tests easy enough, to allow
the majority of that population to attempt them? The population
would cover a range of severities and so the instruments used
would have to be as broad-based as possible, but not to the
extent of losing valuable information, or only providing a
superficial picture for an individual.
The interviews also depended on a reliable informant,
and the questionnaires needed to be appropriate for them too.
The emotional strain apparent at the interviews made this a very
real consideration. The level of the informant's contact with the
affected person was also of relevance, and their reliability was
important for good data. For consistency, wherever possible, the
same informant was used at both assessments.
2. Standardised and well used.
Needless to say, the tests used, ideally had good
validity and reliability data, which whenever possible, was
relevant for the age group being investigated. The use of
recognised instruments also allows for comparisons to be made
with other work in the field. It was also important to use a
complete instrument rather than an edited version, even if
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surplus information was gathered, it could be ignored at a later
date.
3. Covering all areas of interest.
At the start of the study it was necessary to consider all
the data that would be needed to provide a comprehensive
picture of each individual. But constraints of time and logistics
made it necessary to look carefully at the level of detail
potentially collected, and balance the problem of too little detail
on many things, or too much detail on a limited number of items.
The areas necessary to consider were:
i) A review of the case notes to fill in details: addresses of
informants and GP's; date of referral; diagnosis; investigation
results; relevant history from notes.
ii) An interview with an informant, for the demographic
details of each subject: past health; family history; social history;
and any other relevant information, including the history of the
onset and progression of the subject's symptoms. Also a chance to
assess the impact on the carer and the opportunity to ask about
the supports used and available to each .
iii) The behavioural and psychopathological assessment
of the individual, with the information from an informant most
closely involved with caring.
iv) A cognitive examination of the subject including a
measure of their previous IQ, when possible.
v) A physical examination with particular emphasis on the
nervous system and the assessment of any extrapyramidal
features.
vi) The collection of a blood sample, for immediate freezing
and later DNA extraction.
vii) Discussion of Post-Mortem.
viii) Application of diagnostic criteria to the data in order
to confirm case fulfillment.
Taken as a whole, the assessment would also provide a
measure and description of the general level of functioning
for each individual. From the evidence collected (including data
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from all parts of the interview and including a historical
perspective) a diagnosis would be possible. After the repetition
of the tests, it would be possible to detect progressive
deterioration. The severity of the condition could also be
quantified.
The possibility of cases inwhich a global score would
appear satisfactory but specific impairments be gross, would
have to be identified.
4. Comparison after one year.
The study was designed to repeat the visit to each
individual and their informant, after a year. The same
instruments were used on both occasions, so a direct comparison
could be made between the scores at each visit. The interval of a
year allowed a sufficient time to elapse to see a deterioration,
rather than pick up short-term fluctuations in an individual's
state. The tests at the first assessment would provide a baseline
of function so that subsequent change could be measured.
The study aimed to identify possible predictors of
decline, and see if patterns emerge to suggest subgroups of
early-onset dementia. There would be likely to be differences
between the groups, such as between Alcohol-related dementia
and Alzheimer's, but it would also be of great interest to see if
differences occur within the Alzheimer population.
5. Time constraints of single investigator.
There were also time constraints from the
interviewer's perspective. Apart from the issue of the amount to
reasonably expect the interviewee to tolerate, there was the need
for logistically making the visits of a reasonable length, so that
the potential number of cases could be seen, by a single
investigator, for the two assessments, during the time of the
study. When the tests were familiar to the examiner, the first
assessment took about three hours, and for the second, about two.
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6. Location of the individual with dementia.
The group interviewed were in a variety of settings:
home, nursing home and hospital. The instruments needed to be
able to cover this diversity. However, the setting occasionally
influenced the scoring. For example, wandering out of the
building is prevented when the subject is on a locked ward, or
spending time in bed during the day may not be part of the ward
policy. A patient newly admitted to respite, may be apparently
more disorientated initially, and this could involve increased
episodes of incontinence and disorientation. The judgement of
what would constitute constructive activity, especially within the
hospital setting, becomes subjective.
Having reviewed the possible options as to the
instruments available for the study, it was of great value to
discuss the advantages and disadvantages of each with more
experienced researchers in the field.
Based on the decisions using the advise from this, the
pilot study was then carried out and minor adjustments made to
the battery, following the lessons learnt.
Complete Assessment Schedules.
The CAMDEX.
The Cambridge Examination for Mental Disorders of the
Elderly, CAMDEX, Roth et al (1986), is a single, standardised
instrument with all the components needed to make an accurate
clinical diagnosis of the most common forms of dementia. It aims
to detect dementia at an early or mild stage, but covers a range of
severity and different types of dementia. It also allows the
detection of depressive and other psychiatric symptoms, and
provides an overview of behavioural problems. It is designed for
use with patients in a medical setting, and with general
population samples of the elderly, in epidemiological enquiries.
The CAMDEX can also be used to match criteria relevant for a
differential diagnosis of dementia, and incorporates a number of
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scales which yield estimates of the severity of dementia or
cognitive impairment. Burns et al (1990b), used the informant
interview and CAMCOG sections of the CAMDEX, in their study.
It provides a sensitive and considered interviewing style
in a potentially upsetting area, as exemplified by the suggested
introductions: for the informant interview:
"I'm going to ask some questions relating to changes in behaviour
and character of....These changes don't always appear., and may
not be relevant to him/her. But we ask these ofeverybody
because the replies might prove valuable in helping people who
do have difficulties."
and for the CAMCOG:
"I am going to ask you some questions now which have to do with
your memory and concentration. Some of them seem rather easy,
others may be difficult, but we need to ask everyone the same
questions."
Several parts of the CAMDEX were used for the study,
these were:
i) A structured interview with a relative or other informant to
provide independent information regarding the subject's general
mental functioning, previous history, everyday competence and
adaptation, current symptoms and previous medical history. In
the rare instances where no informant was available (and the
degree of competent independent living cast some doubt on the
diagnosis), the structured interview was done with the subject,
incorporating questions regarding the previous personal and
medical history and the family history.
ii) A brief physical examination including a neurological
examination.
iii) A record of a range of laboratory findings and radiological
investigations. Whenever available, blood count, levels of vitamin
Bf 2 and folate, urea and electrolytes and results of liver function
tests, Venereal Disease Reference Laboratory tests (VDRL), skull
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X-ray and computed tomographic (CT) scan, were recorded. (This
was completed when the case notes were inspected.)
iv) The cognitive examination, referred to as the CAMCOG.
Apart from the CAMDEX, several other complete
assessment batteries exist. Among them are the Consortium to
Establish a Registry for Alzheimer's Disease, CERAD (Morris et al
1989). This includes an assessment for non-AD dementias:
vascular; dementia with Parkinson's; dementia syndrome of
Depression; Alcohol-related dementia; less common forms such as
focal cortical syndromes e.g. Frontal Lobe Dementia, Progressive
Aphasia, or Progressive Supranuclear Palsy (PSP).
The Geriatric Mental State Schedule (GMSS), Copeland et
al (1976), is a full mental state examination, and can be combined
together with the history and aetiology schedule (HAS),
computerised as the AGECAT system (Dewey et al 1992). The
Revised Elderly Persons Disability Scale, REPDS (Fleming and
Bowles, 1994), covers an assessment of physical problems; self-
help skills; confusion; behaviour; sociability; psychiatric
observation; and nursing dependency. It is popular with nursing
staff, and also useful in more general terms, in ward audit.
Validity data exists for institutions only. Rosen et al (1984),
reported on a new rating instrument, the Alzheimer Disease
Assessment Scale, specifically designed to evaluate the severity
of cognitive and non-cognitive behavioural dysfunctions in
Alzheimer's Disease.
There are also scales developed for assessment in severe
dementia, including The Guy's Advanced Dementia Schedule of
Ward et al (1993), and that of Panisset et al (1994). Ritchie and
Ledesert (1991), describe the development and validation of a
scale for the assessment of intellectual functioning and adaptive
behaviour in the severely dementing elderly. Albert and Cohen
(1992), have also developed a reliable and valid test of cognitive
function for severely cognitively impaired individuals. Saxton et
al (1990), also developed a neuropsychological battery for
severely impaired individuals, covering a range of functioning in
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fundamental cognitive abilities, such as nonverbal social
behaviour, simple matching tasks and colour identification.
In the next four sub-sections of this chapter, the areas of
review covered in the assessment are discussed in more detail.
i) Demographic data.
ii) Behavioural and Psychopathological rating scales
iii) Neurocognitive testing.
iv) Neurological assessment.
In each, some of the different options available are
discussed and reasons given for the eventual choice. Specific
problems and shortcomings became apparent gradually during
the time of the study, and are discussed in the next chapter.
i) Demographic data.
Section H of the CAMDEX schedule was the most obvious
choice for the basis of collection of demographic data. It
comprises of a structured interview, in the absence of the subject,
with a relative or carer who knows the subject well. The
interview should be face to face whenever possible, but
satisfactory information can be obtained by telephone interviews.
The nature of the interview, relationship of the informant to the
subject, and a rough idea of how often they see the subject, are
all coded. Any personality change, difficulty in functioning in
everyday life, or indications of cognitive difficulty observed by
the informant are noted. Items which permit the Dementia Scale
of Blessed et al (1968), to be scored are incorporated in this
section. Questions referable to the presence or absence of
depressive or paranoid phenomenology, are included. A history of
the onset of the illness, family history and past history are
investigated. The items referring to everyday activities are of
interest in the assessment of behavioural problems too, and the
enquiry into depressed mood complements the Cornell scale, as
discussed later.
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In the CAMDEX interview, the family history of Down's
syndrome and leukaemia, amongst other conditions, are enquired
into. This is because of the evidence available at the time the
interview was compiled on the association, see Heston and Mastri
(1977). Another schema for taking a family history was used by
Breitner and Folstein (1984). The reliability of the family history
method in genetic studies of Alzheimer's Disease and Related
dementias is discussed by Silverman et al (1986). But the more
widely recognised and used CAMDEX El informant interview was
used. For example, the question relating to a family history of
dementia is: "Did any ofhis/her relatives have trouble with
memory, or get very confused and have to go into a home to be
looked after?" The response is recorded for female relatives
(mother, sisters and daughters) and male relatives (fathers,
brothers and sons). Aswell as taking the data from the CAMDEX, a
family tree was drawn for each individual to make an additional
check on any missed features of interest, in more distant family
members. No further verification of this information was made.
In addition to this informant interview, there were
several other details which seemed important to gather. This
gave rise to the 'data sheet' which included the following sections:
A. The onset and presenting symptoms.
Because of the often insidious onset of dementia (as
discussed in the Introduction: Epidemiological Issues, it is of
interest to know what the first signs of something being wrong
were. But the information is retrospective and to some extent
subjective. This question was simplified to four main areas of
functioning: memory loss and disorientation; mood and
personality change; movement disorder; and other. In a paper by
Chenoweth et al (1986), the issue of early symptom recognition
was investigated in much greater detail than was possible in this
study. Most of their 289 family informants, described several
ways inwhich their relative experienced memory impairment and
difficulty in performing the usual activities of daily life.
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B. Current medical health and medications, and additional
symptoms
Although the CAMDEX informant interview deals with
some questions regarding cardiovascular history, the possibility
of a more detailed series of questions was explored. This however
was not persued but note taken that there was no way of
standardising the data. For example, for evidence of a past MI,
ECG evidence and a fuller description of the symptoms would be
required.
Some additional symptoms such as headaches, dizziness,
and myoclonic jerks, were also included.
C. Additional details of alcohol consumption, past and present.
This was included in the hope that it would provide a
clearer picture of heavy alcohol consumption. Infact it did not
really help to achieve this.
Brandt et al (1983), in their study of cognitive loss and
recovery in long-term alcohol abusers, give a guide to estimated
excessive past drinking: with at least a 10 year history of daily
alcohol consumption and abstinence at least one month, but no
more than 59 months at the time of testing. Consuming a
minimum of 6 drinks daily (85 mis alcohol) and an average of 12
drinks daily (170 mis). Another definition is given by Rosen
(1993), who defined alcohol over-use as having the minimum of
6 units per day (14 mis of ethanol) for 10 years.
D. Social history including educational achievement,
occupation etc.
E. Risk factors not included elsewhere.
Some of these questions were formulated with particular
interest in the risk factors for prion dementia. They were based
on the questions used by the Creutzfeldt-Jacob Surveillance Unit
(Dr. R. Will, personal communication.)
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The added question as to the whereabouts of each
subject, and with whom they were living, was also of value,
especially when assessing the impact of disturbed behaviour, and
service provision issues.
In the first interview, the supports used by the carers
and the subject were enquired into. The second interview gave a
chance to structure this approach, and is discussed later.
ii) Behavioural and Psvchopathological Rating Scales.
The importance of the non-cognitive features
(psychopathological symptoms and behavioural disturbance) in
Alzheimer's Disease have been emphasised by Burns et al
(1990b). There are several reasons why these symptoms are
important. The strains they place on the carers, and the
disruption they cause, make them extremely relevant for health
care planning. Also, the behavioural and psychopathological
profiles, and the patterns of their changes with time, may provide
clues as to different subtypes of dementia. By investigating the
neuropathological correlation in Alzheimer Disease patients with
and without psychiatric symptoms, light may be shed on the
neuropathology of the functional disorders.
The means by which information about the
phenomenology is obtained is the main methodological problem.
The severity of the illness makes the reliance on relative's and
caregiver's reports essential. See Hope and Patel (1993), and
Patterson and Bolger (1994).
Behavioural Features.
Burns et al (1990b), have demonstrated that
behavioural change is a common accompaniment to dementia. It
is these problems which pose the greatest burden on carers, and
are the most common reason for involvement with the medical
profession, see Teri et al (1989). Behaviour in the context of
dementia is most simply defined as the observable acts which can
be measured. Examples of the phenomena to be included are:
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aggressive behaviour; sleep; sexual behaviour; eating; and activity
disturbance or wandering.
The development of a variety of methods for the
assessment of disturbed behaviour, allows for far greater
accuracy in describing the problem. The purpose of the
assessment has to be considered, in order to choose the most
appropriate test. In this study, the purpose is to describe fully
and concisely the behavioural phenomena in each individual, and
to indicate the effects of these on the main carers.
Methods will be discussed as those involving
information gathered from the carer and then from the subject.
Methods involving the collection of information from the carers.
From what has been said above, carers are therefore the
main source of information on behaviour. Rating scales,
structured or semi-structured interviews, can be used to collect
the information. Although the semi-structured approach is likely
to be the most accurate, it is a time consuming exercise.
Furthermore, some instruments have been designed for use by
the home-based carer, whilst others are for completion by
nursing staff in institutional settings. An area of potential
inaccuracy arises because of the biases that may operate from
such reports, and little work has been done to elucidate these. For
example, some carers may be more, or less likely to report
difficulties. The individual carer tolerance may affect the severity
of the disorder reported, as much as the actual severity of it, see
Teri et al (f 989). In many areas of behavioural assessment it is
impossible to know what the motive behind an action is. Some
degree of observer-based bias will come from the subjective
judgement of the nature of the action. An example of this is the
lady who continually and ineffectually trails a duster over the
surfaces of her room. Is this purposeless activity?
The Present Behavioural Examination (PBE), Hope and
Fairburn (f992), is the only semi-structured interview whose
main aim is to study behaviour in dementia. The interview is
done with the main carer, and covers behaviour over the
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preceding month. It consists of 121 items, and is therefore a
lengthy procedure, although subsections can be used on their
own. It provides data on behaviour in dementia, investigates the
course and nature of abnormal behaviour, and studies the
relationship between abnormal behaviour and other features of
dementia, such as cognitive impairment.
Greene at al (1982), used The Behaviour and Mood
Disturbance Scale, which measures the behaviour likely to cause
stress to the carer. It is a rating scale for completion by the main
carer of home-based patients. Less than a half of the 31 items are
behavioural. The Behaviour Severity Rating Scale of Swearer et al
(1988), is a global behavioural and mood rating scale, which can
be used in any setting and has been used over the telephone. It
was designed to provide a relationship between disease severity
and behavioural disturbance. Rabins (1994), reports on the
validity of a brief caregiver-rated, Brief Behaviour Symptom
Rating Scale (BSRS) for use in the cognitively impaired. The
Behaviour Rating Scale for the Consortium to Establish a Registry
for Alzheimer's Disease, is described by Tariot et al (1995).
Many other examples of instruments exist, which cover
items that are not strictly behavioural. Other scales are more
specific to a particular behavioural problem. Reichman et al
(1996), demonstrates that negative symptoms are prominent in
patients with Alzheimer's Disease and distinct from the
depression. The scale used is for the Assessment of Negative
Symptoms in Alzheimer's Disease. Scales specific to agitated
behaviour, incorporating elements of aggressive behaviour and
activity disturbance, include the Disruptive Behaviour Rating
Scale of Mungas et al (1989). This is a rating scale for use in
institutions, which comprises four items, termed "dimensions of
disruptive behaviour". Two items concern aggressive behaviour
and two concern activity disturbance. The severity of the
behaviour is measured on the basis of the nature of the
intervention response to the behaviour. Ratings are made on the
behaviour over a seven day period. A total disruptive score is
generated. Reliability and validity data both exist.
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Other rating scales focus specifically on aggressive
behaviour. The Rating of Aggressive Behaviour in the Elderly
(RAGE) of Patel and Hope (1992), is a rating scale for use in
institutions after a period of three days inpatient assessment. The
reliability and validity have been established, and the instrument
appears to be sensitive to change. Its main uses are in the
longitudinal assessment of the natural history of aggressive
behaviour, for treatment trials, and in the study of the
relationships between aggressive behaviour and other variables.
The chosen scale was the Behavioural Rating Scale taken
from the Clifton Assessment Procedure for the Elderly (CAPE-
BRS) of Pattie and Gilleard (1979). This was developed from the
Stockton Geriatric Rating Scale, SGRS (Meer and Baker 1966). This
was used by Burns et al (1990b), and Forstl et al (1993). The
CAPE-BRS, excludes items that are non-applicable outside hospital
settings, and those with poor inter-rater reliability, see Gilleard et
al (1977). The CAPE-BRS has been used to see how behaviour
affects the nature and degree of nursing care required in
demented patients. The behaviours enquired into are very broad,
and do not target specific problem behaviours. By analysis of the
items covered in this schedule, compared with other possible
scales, it seemed that it comprehensively included the majority of
important areas. It has a clear and easily scored system that
neatly divides into four main areas of behaviour: Physical
disability (Pd); Apathy (Ap); Communication difficulties (Cd);
Social disturbance (Sd). It is also convenient because it is
completed by an informant, either by a member of nursing staff
or a home-based carer.
The information collected refers to the behaviours over
the preceding two weeks. Any recent deterioration of health
would be additionally noted as this would have an effect on the
Pd score, and if the condition were a delirium, there could also be
short-lived psychotic phenomena. These would be of relevance in
scoring on a psychopathological assessment scale. The CAPE-BRS
also has a note of any visual or auditory problems which may be
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biasing the scores, especially of the communication section. These
do not get included in the scoring system though.
However, this behavioural rating scale was only part of
the entire behavioural assessment eventually decided on for the
study. From the review done, it seemed that it would be valuable
to include the PBE, but the time involved for this was not
practical. Second, it was of interest to look for featues of the
Kluver-Bucy Syndrome in this group. Sourander and Sjogren
(1970), drew attention to the frequency of behavioural
abnormalities suggestive of temporal lobe dysfunction in
presenile Alzheimer's disease. These phenomena were
reminiscent of the Kluver-Bucy syndrome in animals after
bitemporal lobe excision. Visual agnostic difficulties were often
the first focal deficits to be noted, especially inability to recognise
the faces of relatives or self in a mirror. Late phenomena
included strong tendencies to examine and touch objects with the
mouth ('hyperorality'), and tendencies to be stimulus-bound to
contact and touch every object in sight ('hypermetamorphosis').
Hyperphagia was often a terminal phenomenon, with
indiscriminate eating of any material. The emotional changes of
apathy and dullness were similarly reminiscent of the
pathological tameness of monkeys with the Kluver-Bucy
syndrome. The authors found such signs in over 75% of their
sample, some of them with the full picture. The question set, used
by Burns et al (f 990b), covers these areas. For further discussion
and use, see Forstl et al (f993).
A novel instrument which combined a concise version of
the PBE and incorporated questions covering the Kluver-Bucy
Syndrome, was used in the study. This work is in press, (Allen et
al f996). The Manchester and Oxford University ScalE for the
Psychopathological Assessment of Dementia (MOUSEPAD), takes
the form of a semi-structured interview with the informant. It
takes both a present and historical perspective, and contains 59
items. This was available for the study before its publication
(personal communication Professor A. Burns), and certain items
were removed from the schedule, by the second assessment. The
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questions cover the following psychiatric features: delusions;
hallucinations; reduplications; and misidentifiactions. And the
following behavioural features: agitation; wandering; sleep;
eating; and sexual behaviour. A separate depression scale is
required to cover mood adequately. Both symptom severity and
frequency are rated, and the duration relative to the onset of
dementia, aswell as the presence in the last month. It takes 15-
30 minutes to administer.
Methods involving the collection of information from the patient.
Because of the often impaired nature of insight in these
conditions, self-report or interview-based scales are of limited
value in behavioural assessment.
The Behavioural Pathology in Alzheimer's Disease,
BEHAVE-AD (Reisberg et al 1987), is however an example of an
assessment based on an interview with the patient, with its
principal aim to evaluate treatment outcome. Only seven of the
items are concerned with behavioural problems.
Direct Observation.
It could be said that the gold standard for behavioural
assessment is by direct observation. But such procedures require
a number of steps to be taken. First the identification and
definition of the target behaviour, and then the adequate training
and practice at rating by observers. Control of factors such as
observer reactivity and bias have to be allowed for, and issues of
reliability considered. Furthermore the level of arousal during the
observation periods has to be adequate and representative of the
general level. Such methods are not discussed further here, and
were not suitable for the purpose of this study.
Indirect objective measures.
For example the use of pedometers and electronic
monitoring have been used to assess hyperactivity, and
electroencephalographic recordings can provide information
about sleep disturbance. Physiological markers of diurnal
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variation, weight change and biochemical indices of nutrition, and
measurement of sex hormones are other possible approaches.
However these measures may not infact be directly enough
related to the overt behaviours seen, to make them of use.
Psvchopathological Features.
A full review of the measures of psychiatric symptoms
in Alzheimer patients is reviewed by Weiner et al (1996). Some
of the various instruments are described here, and those used in
this study described.
Psychotic Symptoms.
In the work by Burns et al (1990b), the range of
psychopathological features found in Alzheimer's Disease were
studied and found to highly relevant and common. Disorders of
thought, perception and mood were looked at, aswell as the
behavioural problems. As mentioned, one area of difficulty is the
carer reported system, inwhich lack of clinical sophistication may
lead to symptom misreporting. Many of the instruments used to
investigate behavioural problems also include psychotic
symptoms. For example the PBE includes a checklist of items
covering psychopathological phenomena, taking about ten
minutes to complete.
The General Mental State Schedule (GMSS) of Copeland
et al (1976), is a comprehensive instrument covering current
psychiatric symptoms, based on the Present State Examination
(PSE) of Wing et al (1974). This was too extensive for use here,
although a shorter telephone version also exists. Other scales
include: the Columbia University Scale for Psychopathology in
Alzheimer's Disease (CUSPAD), of Devanand et al (1992); and the
Neuropsychiatric Inventory (NPI) of Cummings et al (1994).
Reisberg and Ferris (1985), report on a clinical rating
scale for symptoms of psychosis in Alzheimer's Disease. Ballard et
al (1995a), used a specially devised instrument, the Burns
Symptom Check List, to screen for the prevalence and frequency
of psychotic phenomena, together with the degree of insight and
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distress caused by them. They required this because of the
absence of any other instrument of sufficient detail, and with
validation from previous research. Many of the questions are
based on the symptoms from the description in the work of Burns
et al (1990b). There are sixteen questions with several specific
prompts which are put to both the patients and informants.
The assessment of these symptoms in this study was
done using the MOUSEPAD, which covers the phenomena of
delusions and hallucinations fully, in addition to its extensive
questioning in the area of behavioural disturbance.
Affective Symptoms:
The Assessment of Depression in Dementia.
A review by Abrams and Alexopoulos (1994), and that
of Burns (1991a), discuss the importance of affective disorders in
Alzheimer's Disease. As with the other psychopathological
features, different disturbances may reflect different subtypes.
The symptoms also affect the carers, and are potentially
treatable. A variety of approaches have been used to assess
depression in dementia. Some instruments rely on the care
giver's evaluation, some on clinical interview and some on
observation, or a combination of these approaches. The use of the
dexamethasone suppression test and depressive signs, in subjects
with dementia, has been described by Katona and Aldridge
(1985).
There are a number of difficulties in obtaining
information about depression in subjects with dementia. First,
there is overlap in the clinical manifestations of depression and
dementia, and second, the demented person is unable to provide
accurate information about their mood and inner life. Also, there
is a narrow range of depressive symptomatology addressed by
the instruments designed for the severely demented subjects,
with the added difficulty of the transient nature of depressive
symptomatology in cognitively impaired individuals.
104
Cummings et al (1995), used a variety of standardised
instruments to assess mood changes in 33 patients with
Alzheimer's Disease, and found the frequency of depression
ranged from 6 -30% depending on the diagnostic criteria
employed.
One potential mood assessment scale not used was that
of Sunderland et al (1988), where ratings are based on direct
observation and a semi-structured interview of the patient.
Another fairly representative scale used in research with
demented elderly subjects is the Hamilton Depression Rating
Scale of Hamilton (1967).
In this study, as part of the CAMDEX history schedule,
relatives were asked whether they regarded the patient as
depressed or not. A past or current history of depression was also
noted, defined as treated by a doctor with antidepressants. In
addition, the Cornell Scale for Depression in Dementia, CSDD was
used (Alexopoulos et al 1988). It quantifies depression in
dementia patients, and was developed from a literature review of
depressive manifestations in cognitively intact and demented
patients, by the consensus of an expert panel. It evaluates a
broad spectrum of depressive signs and symptoms and includes
items from other depression scales. It includes nineteen items in
five rationally determined domains of depressive symptoms:
mood related signs, behavioural disturbances, physical signs,
cyclic functions and ideational disturbances. Each item is rated on
a three-point scale according to both severity and frequency of
disturbance. It is completed by clinicians on the basis of their
direct observations and interviews with the patient and
caregiver. It was devised to measure changes in symptoms with
disease progression and treatment. While the small range of
rating points tends to yield good reliability, it may also make the
scale relatively insensitive to change. It takes about twenty
minutes to complete. In a paper by Vida et al (1994), the
performance of the Cornell Scale for Depression in Dementia is




The points made at the start of the section on choosing
an assessment battery all apply here too. In addition, it is worth
looking in greater detail at a few points which arise specifically
from this area of investigation. Also see Morris and Kopelman
(1992).
There is an empirical expectation, that by using tests
which are sensitive to damage in specific brain regions, it would
be possible to measure the functioning of these areas, in the
different cases of dementia being researched.
There is a large amount of literature to demonstrate the
differentiation of different types of dementia, based on the test
performance profile. Infact, the neurocognitive profile can be
used as one source of evidence in deciding on the differential
diagnosis, but in isolation is not sufficient. Deary et al (1991),
have investigated the neuropsychological profile found in
Korsakoffs Psychosis. Hansen et al (1990), also reported on the
distinct pattern of neuropsychology found in the Lewy Body
variant of Alzheimer's disease, with greater deficits in attention,
fluency and visuospatial processing. Sahgal et al (1992), suggest
that short-term mnemonic processes mediated by temporal lobe
structures, could be more severely affected in senile dementia of
the Lewy Body type. The work of Kopelman (1986), describes the
differences in clinical testing of memory, between organic and
functional disorders. Evidence for the existence of subtypes
within Alzheimer's Disease, is given in the Discussion.
Furthermore, as the disease advances, the patterns of
impairment may change. For example in Alzheimer's,
impairments may progress from temporal damage (manifest by,
for example, memory difficulties) to frontal damage (manifest by,
for example, language problems) and then to parietal damage
(manifest by, for example, wandering behaviour).
It would be useful to have the possibility of specific
areas of cognitive function investigated in detail, aswell as a more
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global description. However, such investigation requires very
much greater emphasis on neurocognitive function than was
possible in this study, whose aim was to cover a greater breadth
of clinical findings. Furthermore, despite the potential here, in
practice it is very difficult either early on in the course of the
illness, or at greatly advanced stages, to distinguish between the
different causes or types of dementia and to identify distinct
patterns of neurocognitive deficits.
A more practical issue, is the consideration of the
approach towards the subject, in this area of testing. If insight
exists, the testing will be confronting them with their problem
and could be an intensely painful reminder of their predicament.
The words of Alban (1996) are of relevance here:
"without memory, the individual is dislocated from her past and
locked in a present whose context (s)he no longer
understands (s)he may only live in the "now", but within that
narrow time frame, he can both suffer and feel pleasure."
In this population, the prerequisite of understanding the
reason for the testing is usually met only to a limited degree, if at
all. Hence compliance can be more difficult to obtain. The need for
establishing empathic rapport is very great, and careful
consideration of non-verbal cues (such as restlessness or anxiety)
should be made. The experience must be as gentle and non-
upsetting as is possible. It is also worth considering the best
order for the tests to be done in, to maintain subject cooperation
at the optimal level.
There are day to day fluctuations in mental state. There
may also be more major fluctuations, due for example, to acute
confusional states in secondary illnesses. Other conditions, such as
Lewy Body Dementia, are characterised by fluctuations in
performance. It would be hoped that such fluctuations would
become insignificant when looking at the results of the group as a
whole. It is also necessary to take note of any additional
information about the subject, that would affect the results of the
testing, such as: current health and treatment; articulatory or
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dysphasic problems; and any sensory impairments, such as visual
or auditory.
Possibilities and Choices.
The requirements for this part of the interview, were to
establish where possible, a measure of the premorbid, and
current intellectual, cognitive and general memory function. The
repetition of this after an interval of a year would provide a
measure of the rate of decline. This discussion is divided into:
measurement of premorbid IQ_and current intellectual, cognitive
and memory function.
Premorbid Intelligence Measurement.
This provides a useful measure to assess subsequent
degeneration, and also enables a judgement to be made as to
whether the subject is currently impaired. The effect premorbid
intelligence may have on the subsequent development of
dementia is discussed later.
The National Adult Reading Test (NART) of Nelson and
O'Connell (1978), requires the subject to read a series of
irregularly spelt words, with the correct response impossible to
give on phonological grounds alone. The authors showed it to be
comparatively insensitive to dementia, in a sample aged 20-70
years. It can be used to estimate the premorbid IQ, having been
standardised, most recently against the Wechsler Adult
Intelligence Scale-Revised, WAIS-R (Nelson and Willison 1991).
However, the validation of the NART, on the elderly and elderly
Alzheimer group, has not always been consistent. See O'Carroll
(1986,1987,1992, 1995).
The limitations of the NART, are that it is unsuitable to
use if the subject has eyesight problems, aphasia, or speech
production difficulties, such as slurring. The test only applies to
first languages. Also, it has not been standardised on a large
enough sample of elderly patients, and it is poor at discriminating
between IQjs in the very low or high bands. There is also some
evidence it does not hold as well in some conditions such as
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Huntington's Chorea, see Crawford (1988), although this group
has been excluded from this study.
In order to provide consistent rating of the test, each
subject was tape-recorded, in order to allow for review. Some
subjects found it easier to use the individual card format of the
test, showing one word each page. In cases where a subject
scored <10, the Schonell reading test was done (Schonell 1942).
This comprises an even more basic reading test from which lower
score IQjs may be calculated.
Current Intellectual, Cognitive and Memory Function.
CAMCOG.
What was eventually chosen to cover the areas of
current cognitive function, memory and learning, was the
Cognitive Examination (CAMCOG) part of the CAMDEX. From this
the shorter Mini Mental State Examination (MMSE) of Folstein et
al (1975), can be calculated. Schmand et al (1995), looked at what
constituted a significant score change on the Mini Mental State
Examination. They found that in individual patients, in the
absence of other indications of a dementing process, a
deterioration of more than five points after one year, would lead
to the suspicion for a genuine cognitive decline. The Abbreviated
Mental Test Score (AMTS) of Thompson and Blessed (1987), can
also be calculated from the CAMCOG.
The CAMCOG includes subscores for : orientation;
language; memory (remote, recall and recognition); praxis;
attention; abstract thinking; calculation; perception; verbal
fluency; and comprehension. It includes elements of various other
test batteries: picture recognition (but not as extensively as in the
Rivermead subtest); recall (likewise less extensive); similarities
(as in the WAIS-R) ; verbal fluency (one test); and clock-face
drawing. The clock-face drawing test involves parietal function,
frontal planning and semantic memory, see Lezak (1995). It has
been used in a study by Bourke and Castleden (1995), comparing
it with the pentagon drawing test in Alzheimer's Disease, and by
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Gnanalingham et al (1996), differentiating Lewy Body and
Alzheimer type dementia syndromes.
A score of <80 on the CAMCOG, is indicative of acquired
cognitive impairment. There is good validation data available on
it, and it has been shown clinically to provide differentiation
between different patient groups and dementia aetiologies. Its
advantages are its ease of administration, in terms of test
material and timing. It takes between 20 and 40 minutes to
complete, and has the ability to look at individual areas of
function (as described above) aswell as gaining an overall global
score. It was designed to cover a range of severities and different
aetiologies, which made it suitable for the heterogeneous
population in the study. Criticism of it, is that it is not very
sensitive in the early stages of dementia. But this is not relevant
in this study, as the diagnosis has usually been made. It has been
used widely and is suitable as a tool for retesting after a year,
without the need for new material. Infact it only provides fairly
crude information on individual areas of function, which tend to
all be highly correlated. Greifenhagen et al (1994), demonstrated
an overlap and potentiation of different cognitive deficits in
Alzheimer's Disease, by principal component analysis of empirical
CAMCOG data.
The alternative to using the CAMCOG, would have been
to use a series of different tests.
Alternative Tests.
The most commonly used tests for measuring fluid
intelligence (verbal and non-verbal) are: the Wechsler Adult
Intelligence Scale Revised, WAIS-R (Wechsler 1981); Mill Hill
Vocabulary Scale (Raven 1958); and Raven's Coloured Progressive
Matrices (Raven 1965).
Several studies report that some of the WAIS subtests
are more sensitive to brain damage, and that the performance
subtests are more vulnerable to dementia, leading to
verbal/performance discrepancies. However not all dementing
patients deteriorate like this - some show a uniform decrement,
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some have greater verbal IQ's premorbidly and occasionally
verbal IQ deteriorates faster than performance IQ. Attempts to
distinguish between Alzheimer's disease and Multi-infarct
dementia, and between dementia and functional disorders on the
basis of WAIS profiles is difficult.
Another possible measure for current intelligence was
The Quick Test, see Ammons and Ammons (1962), and Frith et al
(1991). This involves the subject matching a series of words to
the picture to which each is relevant. It has a good correlation
with the WAIS, but little validation data exists for it.
The clinical tests of memory do not reflect the
complexities nor the boundaries between the types of memory.
There is indirect contamination of memory functioning by
intellectual decline and also, specific impairments may affect
memory abilities. Thus the overall memory score may ignore the
complexities of the deficit. There are three main scales used: the
Wechsler Memory Scale Revised version (Russell 1975);
Rivermead Behavioural Memory Test (Wilson et al 1985); and
Recognition Memory Test (Warrington 1984).
Another aspect of memory, semantic memory, is most
widely tested by a verbal fluency test. These are duscussed in
Lezak (1995). A naming and word finding deficit occur early in
dementia (Huff et al 1986 and Kirschner et al 1984). The test
involves the retrieval of words to a letter (e.g. F, A, S) or category
(fruit, flower, animals) on cue, see Hart et al (1988) and Miller
(1984). There is good validation data for its use at different ages.
It has been compared with the NART, see Crawford et al (1992).
It also gives a crude measure of one aspect of frontal decline.
Other tests of frontal function include the Wisconsin Card Sorting




A variety of neurological signs which can be elicited in
subjects with dementia, may help to clinically differentiate
between various types of the illness. Obviously the individual
stage of the illness in each subject, will also determine to what
extent the neurological signs are apparent. For example, in
Alzheimer's disease, later on in the course of the illness, focal
neurological signs, spasticity, hemiparesis and rigidity may occur.
In vascular dementia, Birkett (1972) found that neurological
abnormalities predicted arteriosclerosis more accurately than any
other mental feature. Minor focal signs, such as unequal tendon
reflexes, extensor plantars and impaired pupil reactions, may be
found. Signs of pseudobulbar palsy occur, and syncope is
common.
Parkinsonian features may be conspicuous in
Alzheimer's Disease. As described in the Introduction: Genetics ,
there is an area of overlap in the dementia types of Alzheimer's
and Lewy Body and the dementia associated with Parkinson's
Disease. Ditter and Mirra (1987), studied a series of clinically
suspected and autopsy-confirmed cases of Alzheimer's Disease
and correlated pathologic findings and available neurologic data.
They found exrapyramidal signs, especially rigidity, noted in
many Alzheimer Disease patients, to be related to co-existent
Parkinson's Disease pathology. Hansen et al (1990), examined the
Lewy Body variant of Alzheimer's Disease, which is marked by
extrapyramidal features and myoclonus.
Pick's Disease tends not to have gait and muscle tone as
frequently affected, and only occasionally shows Parkinsonian
features. Although not included in the cohort, Huntington's Chorea
may present with choreiform movements, or less often with an
unsteady gait, a tendency to fall and clumsiness in general. In
Lewy Body Dementia the main neurological features are
Parkinsonian, with rigidity, resting tremor and gait impairment.
In the spongiform encephalopathy, Creutzfeldt-Jacob Disease,
neurological signs may include: cerebellar ataxia; spasticity and
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progressive paralysis; extra-pyramidal rigidity; tremor; and
choreoathetoid movements. The involvement of the anterior horn
cells can lead to muscular fibrillation and atrophy, especially of
the small hand muscles. Other signs include speech disturbances,
parietal lobe and cortical visual problems. Sensory problems are
not apparent, but brain stem involvement can lead to nystagmus,
dysphagia and uncontrolled lability. Frequent myoclonic jerks are
common.
In terms of a specific feature such as epilepsy,
differences across the various forms of dementia are apparent.
Sim et al (1966), found that fits happening early on in the course
of the illness were more common in non-Alzheimer type
presenile dementia. In Alzheimer's, epilepsy is said to occur in up
to 75% of cases, in vascular dementia about 20%, Huntington's 3%
and in Creutzfeldt-Jacob Disease as a possibility only, see Lishman
(1990).
In terms of the neurological examination, as mentioned
previously, it is important to have an examination which could be
tolerated by the individuals concerned, inwhich some basic data
could be collected even when the subjects were unable to
cooperate. As with the cognitive testing part of the examination,
it was important to know the current health and medication of
the subject, as these would influence the neurological
examination. An informant could also add valuable information,
not necessarily apparent during the examination, on the presence
or absence of certain signs such as epilepsy or myoclonic jerks.
Burns et al (1991b), rated myoclonus as being present when a
'brief shock-like muscular contraction' occurred during the
physical examination or interview with the subject. Some aspects
of the neurological assessment could be examined during the time
spent with the subject, for example during the cognitive
examination. The subject's speech, presence of tremor and writing
could all be assessed during the CAMCOG, and were relevant to
the Webster scale.
The physical examination check list, as used in the
CAMDEX schedule, was completed. In addition, the Brief
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Neurological Examination was done, see Owens (1985). This tests
gross motor function, including cerebellar and cranial nerves. The
Webster scale for Extra-Pyramidal Symptoms (Webster 1968),
was also used. The items on self care and seborrhea were
excluded. A data sheet with some additional questions was also
included and covered the testing of primitive reflexes, aswell as
providing the opportunity to describe any abnormal movements.
The significance of frontal release or primitive reflexes,
has been debated. It has been said to be no more than a measure
of diffuse dysfunction. Primitive reflexes have been studied by:
Youssef and Waddington (1988), on a mixed group of subjects
with schizophrenia and bipolar illness; Paulson and Gotleib
(1968), in the aged; Girling and Berrios (1990) and Burns et al
(1991b) in Alzheimer's Disease; and Basavaraju et al (1981) in
dementia. Bakchine et al (1989), investigated the significance of
primitive reflexes and extrapyramidal signs, as indications of
diffuse cortical dysfunction and their relationship to age and
cognitive impairment. They found a significantly lower Mini
Mental State score correlated with the number of primitive
reflexes and in particular, the snout, sucking and grasp reflex. In
the study of the neurological signs in Alzheimer's Disease by
Burns et al (1991b), the primitive reflexes were also tested. For
this study, the Hoffman, grasp, palmomental, jaw, snout, sucking,
glabellar and Babinski reflexes were decided as appropriate.
Two areas of potential interest, akathisia and soft signs,
were not included. Akathisia, the motor restlessness accompanied
by a subjective feeling of tension in the limbs, would have been
too difficult to rate in a population whose ability to provide
subjective judgements was limited. For example the scale devised
by Barnes (1989) requires the participation of the subject. Soft
signs are stated to reflect fronto-temporal and fronto-parietal
abnormalities. However it could be argued that they represent a
broad group of different signs, of no clear significance. King et al
(1991), used ten of the widely used soft signs in a study of
chronic schizophrenia. The signs were: mirror movements; speech;
right/left confusion; finger-thumb opposition and mirror
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movements; pronation-supination; foot taps right and left; face-
hand sensory inattention; graphaesthesia and hopping on right
and left.
Having decided on the instruments to be used, the data
sheets were prepared and the published tests obtained. Each first
assessment package had the assessment overview as a front
sheet, followed by the consent from and then the case note data.
Second Assessment.
For the second assessment, a front sheet provided an
opportunity to briefly review the outcome of the previous
assessment. The parts of the first assessment re-tested were:
CAMDEX H (the items concerned with the history of the present
difficulty); the MOUSEPAD, CAPE and CORNELL; the CAMCOG; and
the complete physical examination.
Additional parts of the assessment, provided the chance
to detail the carer needs more fully. In a data sheet, the supports
available and satisfaction with the service, were enquired into.
Current treatment and changes over the year in the major areas
of interest, were asked for.
Carer Strain Scales.
Various instruments exist to identify and measure the
stress of carers. The Relatives Stress Scale (RSS), of Greene et al
(1982), is a 15-item scale designed to measure the stresses
experienced by a relative who is caring for an elderly dependent
in the community. The questions relate to such topics as the
effect the dependent is having on the relative's social life and
mood state, and assesses negative feelings of the relative towards
the dependant. Another scale is that used by Morris et al (1988).
The emotional well-being of the caregivers was investigated
using a rating scale to measure strain, and the Beck Depression
Inventory (Beck et al 1961) to measure the current level of
depression. A questionnaire was developed to measure marital
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intimacy (both past and present). Another assessment is
described by Gilleard (1984).
The questionnaire chosen to measure the strain on
informal care providers in this study was The Caregiver Strain
Index, CSI, validated by Robinson (1983). The results of his work
indicated that the CSI was a brief, easily administered instrument
which was therefore usefully included in the assessment to
examine relations involving dependency and care. However it
was not specifically designed for carers of subjects with
dementia, nor presenile dementia, where the informal care giver
is often the spouse, rather than an inter-generational family
member. This was given to the carer when relevant, to aim to
quantify the strain on them, either currently or retrospectively.
The next chapter of the Method will go on to describe the
process of making contact with the subjects in the study.
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Method:
VI. Contacting the Sample and Data Organisation.
Having described how the cases were identified and
notes reviewed in the Method: Ascertainment, and then, how the
battery was chosen, in the last chapter, this chapter will describe
how the pilot and study itself was run. This describes the
organisation involved in contacting and visiting the families and
their relatives, and obtaining the necessary consent for this. The
pilot study provided the opportunity for the familiarisation with
the testing material, and organisation of questionnaires and
equipment. Changes to the battery and observations on the
instruments used, could then be made. The need for a very
empathic and supportive approach became apparent. The
requirement was for the study to be completed within three
years. This included not only the time necessary for the visits,
but also to sort the data, and organise the running of the study.
The pilot involved a group of about 20 cases. From the
complete list of potential cases, a representative sample for the
pilot study was obtained, by taking the equivalent percentage of
each type of dementia, as was represented in the group of 290.
From the case note review, the address of the next of kin
had been noted, aswell as the General Practicioner's telephone
number and address. A table of these was created to detail each
case more efficiently. This list of all the potential cases was
alphabetically arranged, and each given a number. The CP's and
consultants involved were easily identified which made the
contacting for consent more efficient. Another overview chart,
enabled the progress of contact and case assessment for each
subject to be visually accessible.
Making contact with the cases.
The first step, was to make contact with the CP's and
consultants for each case, by letter. This was to explain the study,
and ask their permission to approach the next of kin, or main
carer for each subject. This also provided the opportunity to
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gather any relevant recent information about the subject's
current state and whereabouts, and any problems the family
might be in. The most appropriate person to make contact with
was also established. On occasions, the contact was felt to be
inappropriate, because of family stresses or the diagnosis being
questioned. If no reply was received after two weeks, contact
with the doctor was established by telephone.
Having obtained the consent from the GP and
responsible consultant, the next of kin was then written to.
Occasionally the subject would be contacted too if this was
appropriate. It became necessary at this stage to ensure that all
forms for the study, which could be seen by the participants,
were labelled in terms of being a memory study, rather than with
the term dementia, which sometimes felt inappropriate.
If no contact was made following the first letter, the
address was rechecked and a second copy sent. Following this, if
no contact was received, a phone call was made where possible.
When the subject was in long term care, a message could also be
relayed to the family via the ward staff. If no contact was made,
the GP was informed. All the study records of the cases not
included were kept, together with the details of why the contact
was not successful, or the case was not included.
The usual form of response was by telephone, and this
initial discussion allowed the arranging of the time for the first
visit. The visits were usually at the home of the next of kin, but if
preferred, at the hospital. The visits were arranged to be at the
most suitable time for the carer.
All the letters, information sheets and the study protocol
sent out, are in the Appendix: Protocol.
The first visit.
The first visit would start with a careful explanation of
the study and provide an opportunity for any queries to be
raised by the relatives. At this stage, the consent form was
signed, by the next of kin, and the subject where possible. Most
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often, the rest of the interview would naturally follow this, but if
preferred, an alternative date could be made for the next visit.
If the subject was at home, they could be seen on the
same occasion or a follow-up visit arranged. Many subjects were
in long-term care, and the visits would be made separately there.
The interview with the informant generally took about
two hours and the examination of the subject about one and a
half hours, if the subject was able to do the cognitive testing. At
the end of the examination of the subject, blood was extracted.
The details of the blood collection are given in the Method:
Genetics.
After the visit.
After the completion of each visit, the relevant part of
the overview was checked off, so a plan of the project progress
was easily reviewed. A letter of thanks was sent following the
visits, and if any matter had arisen requiring the GP's or
consultant's attention, they were notified. Examples included
concern over a lady living alone who lacked appropriate services,
or the finding of hypertension on physical examination. Another
situation was where the wife of a subject was abusive in manner
at the interview, and through contact with the day hospital where
the husband attended, it was explained she was abusing alcohol.
When there was concern over how a relative or carer was coping,
this was also discussed. Recent contact with the hospital service
would make the reading of the recent medical notes of value, for
the opinions of those involved and details of the subject's
problem.
The data was entered into the data base. There were
about 655 variables for each individual. The diagnostic criteria
were applied as described below. Other aspects of data
organisation were: the use of the Office of Population Censuses
and Surveys, OPCS (1980), to apply the classification of
occupations to each case. Also, the translation of the raw NART
scores into IQ, scores on the WAIS-R.
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The second visit.
This generally took about 2 hours in total.
Between 12 to 16 months after the first visit, contact
was again made with the main informants. This was facilitated as
the first visits had already been done, and the consent obtained
for the second contact. The majority of re-contact was made by-
telephone. The list of first assessment visits were placed in
chronological order, providing a strategy for the follow-up visits.
The aim of the second assessment, was to establish and
quantify the pattern of decline for each case , and investigate the
carer's needs more fully. Additional questions and check items
from the first assessment, were also included.
Note on Post-Mortem Examination.
This initially seemed to be a difficult topic to broach
with relatives. It was certainly more appropriate to discuss at the
time of the second visit, in cases where the subject was in long-
term care and at a severe stage of the illness. The issue was
raised as a discussion point rather than with the view to a
definite decision being made. A previously designed information
sheet was not used.
There is also the need to raise the awareness of the
clinicians who are in contact with the subjects and their relatives
at the time of death.
The importance of the information gained at post¬
mortem in contrast to the relatively imprecise premorbid
diagnoses, made trying to gather this information a real priority.
At the Neuropathology Department at the Western
General Hospital, Dr. J.Ironside and Dr. J. Bell kindly agreed to
examine any of the sample who died, where the next of kin had
agreed to the examination.
The low number of neuropathological post-mortem
examinations of the subjects who died in the follow-up year, was
a disappointment.
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Preparation before the second assessment.
In advance of the visits, a folder was complied for each
case, with some key points to help orientate the second
assessment. The date of the first assessment was noted and the
contact address and whereabouts of the subject and their next of
kin, provided. If the subject had not met the DSM3R criteria at
the first visit, this was indicated. Also, a note was made if the
cognitive testing had not been possible at the first assessment,
and whether the discussion of post-mortem examination would
be appropriate. A case vignette was prepared on each (see
Appendix: Case Studies).
The visit.
The same informant was used at the first and second
assessments, whenever possible. Occasionally, when the
informant was a member of the nursing staff in long-term care,
this was not possible. Inter-rater reliability was sometimes
checked by comparing the responses from staff in long-term care
and the relatives, if they were visiting regularly.
At the follow-up visit, the telephone number of a social
worker involved in setting up a group for carers and the
assessment of carer needs in Lothian, was given. If required, they
would also be made aware of other carer groups in their area.
In cases where the subject had deceased during the
follow-up period, the questionnaires were completed by the
informant, to describe how the subject was at the time before




A note of anyone wishing to receive a resume of the
study was also made. Thankyou letters were again sent out after
each visit.
After each visit the data was again entered into the data
base, and any change in DSM3R status or severity noted.
Data Base Organisation.
A data base was organised for the 126 cases seen, placed
in the ascending order of study number. A note was kept of any
missing data.
Diagnostic Criteria: Inclusion and Exclusion Criteria.
The decision was made before contact was attempted, to
exclude cases of major head trauma, Huntington's Chorea and
Down's Syndrome, see Discussion. Alcohol-related diagnoses were
included.
The DSM3R dementia criteria (APA 1987), were applied
in each case. These are given below. Other diagnostic criteria
mentioned can be found in the references given. The 4th Edition
was not available until after the beginning of the study, in 1994,
and so was not used.
DSM3R Criteria For Dementia.
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A. Demonstrable evidence of impairment in short- and long- term
memory. Impairment in short-term memory (inability to learn
new information) may be indicated by inability to remember
three objects after five minutes. Long-term memory impairment
(inability to remember information that was known in the past)
may be indicated by inability to remember past personal
information (e.g. what happened yesterday, birthplace,
occupation) or facts of common knowledge (e.g. past Prime
Ministers, well-known dates).
B. At least one of the following:
(1) impairment in abstract thinking, as indicated by
inability to find similarities and differences between related
words, difficulty in defining words and concepts, and other
similar tasks.
(2) impaired judgement, as indicated by inability to
make reasonable plans to deal with interpersonal, family, and
job-related problems and issues.
(3) other disturbances of higher cortical function, such as
aphasia (disorder of language), apraxia (inability to carry out
motor activities despite intact comprehension and motor
function), agnosia (failure to recognise or identify objects despite
intact sensory function), and "constructional difficulty" (e.g.,
inability to copy three-dimensional figures, assemble blocks, or
arrange sticks in specific designs).
(4) personality change, i.e. alteration or accentuation of
premorbid traits.
C. The disturbance in A and B significantly interferes with work
or usual social activities or relationships with others.
D. not occurring exclusively during the course of Delirium.
E. Either (1) or (2):
(1) there is evidence from the history, physical examination, or
laboratory tests of a specific organic factor (or factors) judged to
be etiologically related to the disturbance.
(2) in the absence of such evidence, an etiologic organic factor can
be presumed if the disturbance cannot be accounted for by any
non-organic mental disorder, e.g. Major Depression accounting for
cognitive impairment.
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The criteria for Primary Degenerative Dementia of the
Alzheimer Type, Multi-infarct Dementia and Dementia Associated
with Alcoholism, and the criteria for severity of Dementia, can be
found in the DSM3R (APA 1987) publication.
Having made each assessment, a data file was organised
to provide details on diagnostic criteria. As mentioned, all cases
had met the wide-based Feighner criteria for organic dementia,
from the case note survey. For each case, the parts of the DSM3R
criteria which were and were not met using clinical standards,
were recorded. The cases not meeting the DSM3R criteria were
kept in the study, for re-assessment.
The next step was to categorise each case into either
Alzheimer, Multi-infarct or Alcohol-related DSM3R Dementia. This
again posed problems, as it was often not clearly possible to
exclude all but one relevant aetiological agents. Therefore, it was
decided to have the possibility of overlapping groups.
The DSM3R severity ratings were used, although these
could be criticised for being too broad and subjective. The use of
a general scale, often incorporating behavioural items, such as
that of Blessed et al (1968), Hughes et al (1982), or Reisberg et al
(1982), was not felt to be an advantage.
Other Diagnostic Groupings-
Alzheimer's Disease.
The NINCDS-ADRDA criteria (McKhann et al 1984), were
also applied. Burns et al, (1990a), comment on the accuracy of
clinical diagnosis of Alzheimer's Disease, using the McKhann
criteria, and found these clinical criteria diagnosed pathologically
confirmed Alzheimer's Disease in 88% of patients. This was a
successful prediction. McGonigal et al (1992c), highlight the limits
of the clinical criteria and suggest improvements. McGonigal et
al's specifications for the minimum investigations required, to
allow the use of McKhann criteria are: normal Thyroid Function
Tests (TFT's), normal B12 or normal mean cell volume (MGV), and
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a negative Venereal Disease Research Laboratory test (VDRL).
Leach and Levy (1994) reviewed the McKhann criteria, and
discuss various problems to which they give rise to, and ways
these can be addressed.
Inadequate investigations (or access to the results) had
left many gaps in this data for the study, and a note of these
cases was kept. Also, efforts to tighten the definitions of alcohol
misuse, based on the number of recorded units consumed, was
confounded by the difficulties of taking an accurate history.
Vascular Dementia.
When there is a clear history of stroke and cognitive
impairment, and a temporal connection between them, the
diagnosis is straightforward. More usually, determining if
cerebrovascular disease alone causes dementia is difficult.
Diagnostic criteria exist to aid the diagnosis.
The DSM3R criteria for vascular dementia were used,
although these criteria are not validated and are regarded as
subjective. A series of risk factors, relevant to vascular dementia,
were also available for each case. These provided clinically-based
information as to the likelihood of the presence of this pathology.
The Hachinski ischaemic scale (Hachinski et al 1975),
diagnoses vascular dementia when a patient is given a score of
seven or higher. It is widely used, but has poor inter-rater
reliability. It was not therefore used in this study. Attempts to
correlate the clinical presentation with diagnosis confirmed at
autopsy, such as by Rosen (1980), verified the usefulness of the
Hachinski ischaemic score in differentiating between senile
dementia of the Alzheimer's type and vascular type.
Patients presenting to clinics with Multi-infarct
dementia, often have no history of stroke and no focal signs. A
study by St. Clair and Whalley (1983), assessed the value of
cardiovascular system examination (importantly blood pressure)
at the time of admission, in differentiating between Multi-infarct
dementia and Alzheimer's Disease.
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Vascular dementia is classified in the latest World
Health Organisation International Classification of Diseases, Tenth
revision, ICD-10 (WHO 1992). This sub-classifies vascular
dementia of: acute onset, multi-infarct dementia, subcortical
vascular dementia, and mixed or unspecified types.
Two new sets of criteria have recently been proposed.
The State of California Alzheimer's Disease Diagnostic and
Treatment Centre, ADDTC (Chui et al 1992). The other was by the
National Institute of Neurological Disorders and Stroke and the
Association Internationale pour la Recherche et L'Enseignement
en Neurosciences (NINDS-AIREN), a European panel of experts
(Roman et al 1993). Both require the presence of (a) dementia,
and (b) cerebrovascular disease, and (c) a relationship between
the two (such as the onset of dementia within three months of a
stroke).
Validation as to whether these criteria are more
sensitive is awaited. Drachman et al (1993), critically review the
NINDS-AIREN criteria. Apart from the ICD-10 and NINDS-AIREN
criteria, all these criteria are based on the Multi-infarct concept
of vascular dementia.
Lewv Body Dementia.
The proposed Operational Criteria for Senile Dementia of
the Lewy Body Type (SDLT), from the Newcastle group (McKeith
et al 1992), could be applied to each case too, as there is enough
data to do this. These were developed to detect predominantly
neuropsychiatry presentations. The Nottingham group also
proposed a set of criteria (Bryne et al 1991). These place more
emphasis on a requirement for Parkinsonian symptoms that may
be mild and occur late in the disease, and allow for diagnosis of
'possible' or 'probable' Lewy Body Dementia to be made.
Other.
The Cambridge MRC Multi-centre study for cognitive
decline in the elderly, headed by Professor N. Day, has produced
criteria for frontal lobe dementia, as part of their complete
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assessment, (personal communication with the group). These
criteria could also be applied.
Because the nature of this study was to include all cases
rather than seek out, for example, only cases of Alzheimer's type,
there were many cases not neatly fitting the criteria. Another
way to subdivide between the cases clinically, would be on the
basis of the presence or absence of risk factors.
There are difficulties involved in the neat application of
criteria to the group. It appears that without resource to
neuropathological confirmation, the most reliable (although not
always accurate) definitions, are often the clinical based ones, see
Gustafson and Nilsson (1982). Thus, clinically based diagnostic
criteria, in the absence of pathological confirmation, are useful as
a guide. They are not significantly enhanced by the application of
a computerised algorithm, which could at first sight, appear to be
a more objective approach. For example, using cut-off values
based on the CAMCOG interview, has not been found to enhance
the accuracy in applying criteria, (personal communication with
the Cambridge MRC Multi-centre study).
The resulting group of cases available for the study, was
a heterogeneous one, in terms of clinically defined risk factors,
and also because of the different stages of the illness that the
cases were investigated at.
Notes on the Assessment Battery,
The necessary instruction on each test was obtained, and
the pilot study provided the opportunity to try out possible
alternatives for the cognitive testing. For example, Raven's
Coloured Progressive Matrices had been a suggested item, but
was found very inappropriate in the pilot.
Several points arose from the experience of the
interviews, which will be discussed here. By looking at the
drawbacks of the assessment, data which is less objective can be
identified.
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Many of the group were at the severe end of the
spectrum, and so would be scoring at the lowest values possible,
for example on everyday activities and cognitive ability. Hence
any deterioration at the second assessment would not be
measureable, using these instruments.
The subjective nature of some of the questions also
became apparent. Many points become open to interpretation,
because communication is impaired in dementia. The perspective
of the carer tended to bias the results. Also, the differences
between ward and home-based perspectives became apparent.
For example, what would be noticeably disturbing behaviour at
night to a spouse, may be unobtrusive to a night nurse. The most
objective questionnaires which could be used to assess change,
were: the CAPE; CAMCOG; and neurological examination.
Various parts of the battery overlapped with others,
providing the opportunity for a check of internal consistency in
the informant. Reliability was a critical factor in obtaining good
data.
The estimation of the duration of symptoms, in the
historically orientated questionnaires, was a difficult area to
ensure accuracy, and inconsistencies were likely to have occurred
in certain cases.
The individual parts of the battery are discussed below:
The informant interview, CAMDEX H.
This is primarily a diagnostic tool, and the questions
about functioning in everyday activity, were not so helpful in
severely advanced cases, where the subject was scoring at the
worst level at the first assessment. It was more useful when a
subject was in the early stages of the illness, rather than in long-
term care. This section was not very sensitive to different
degrees of change, and so was not of great value at the follow-up.
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The CAPE-BRS.
This was completed by the main carer, either in the
home or ward. It seemed to be able to quantify the behavioural
problems in each case. However, it was not free from bias
introduced due to the rater's perception and interpretation of the
subject's behaviour. One interesting effect was noticed at follow-
up, in cases who had undeniably declined, that the rater would
feel the subject to be less confused and more easily
understandable. Two possible explanations for this are given.
First, if the subject was in long-term care, the staff could have
felt that the longer they had got to know the person, the more
they could communicate with them. Second, sometimes with
deterioration, the more agitated elements of behaviour were lost
and the subject could have appeared more compliant.
The Cornell Depression Rating Scale.
During the data collection for the study, it became
apparent that this scale was not incorporated into the assessment
easily. The data from it was rather patchy and has therefore not
been of particular value in the analysis. The description of the
number of individual cases on anti-depressants, is given instead.
The MOUSEPAD assessment.
The interdependent nature of some of the items on this
questionnaire, became apparent with its use. An example is, if
restlessness at night was present, then the question regarding
night time wandering would be much more likely to be present,
and vice versa. A belief of someone else in the house, would also
perhaps correspond with a visual hallucination and lead to the
subject conversing with the imagined figure, apparently
experiencing auditory hallucinations. In general a report of
delusions and hallucinations, requires a high degree of effective
communication on the part of the subject.
Factors such as whether the subject was in care, or on
medication, and the stage of the illness, also influenced the
results.
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In long-term care, the subject is unable to leave if the
ward is locked, and their food supply is regulated. Intervention
following a wandering episode at home, would be likely to result
in the door being locked, so further opportunities would be
reduced. Sedation may reduce overactivity, or settle disturbed
sleep.
Symptoms that were rapidly fluctuant or intermittent
were not easily identified by this instrument. Lewy Body
dementia is characterised by such fluctuations, see McKeith et al
(1994).
As the illness progresses, and verbal ability is reduced,
so verbal aggression would diminish. Many aspects requiring
motivation, would likewise reduce with time. The interview takes
a historical perspective to cover this, but perhaps fails to
highlight the external factors which may influence the results. In
this way, it may not only be the natural progression of the illness
which is described.
Neurological Examination.
The presence of an abnormal gait could have been due
to a number of different factors, not necessarily due to dementia.
There was not normative data available on such items, which
lessens the value of such information. Treatment with anti¬
psychotics and other health problems unrelated to the
neurological system or dementia, could produce immobility or
reduce the potential value of using the Webster scale. A subject
who becomes immobile would score lower overall on the Webster
scale, because the items would be unrateable, but could infact
have been significantly more Parkinsonian.
Cognitive Testing.
The variabilty in performance between the first and
second assessments would have to be taken into account and
would be described in the normative data available on this test.
Subjects scoring <5 at the first assessment, were not re-tested.
Hints were taken from the messages written, for
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example "I am tired" could be a clue to the subject getting
annoyed, and recognition of this could enable the successful
completion of the test. The use of patience and encouragement
also helped completion. The writing of the subject's name allowed
a sample of writing to be recorded, in some cases where it was
impossible to write a sentence.
The Carer Stress Index.
The Carer Stress Index (CSI), has several drawbacks,
which became apparent during its use.
Some of the questions are awkwardly phrased and
seemed to invite negative responses. For example, in defining
emotional adjustment in the family over the subject's illness, the
instrument describes an 'argument'. The definition of financial
strain also seemed unclear, and there were a variety of ways
inwhich indirect financial disadvantage could result from the
illness (see Appendix: Carers).
In interpreting this data, it would also be important to
consider the relevance of the CSI, in terms of where the subject
was when the CSI was completed, how long ago they were cared
for at home, if historical, and the likely severity at that time. The
mental wellbeing of the informant was also noted. When relevant,
the duration of time between entry into long-term care and the
second assessment (or death), was a measure of the time ago that
the subject was cared for at home.
It became apparent that the perception of stress varied
from one case to the next, and factors other than the subject's
illness, such as the carer's tolerance, were of relevance. This
theme is developed in the Appendix: Carers.
Subsequent phases of the study.
As was expected, once the contact was in progress, there
was attrition of cases for reasons given in the Results. Patience
was taken to try to trace each case and obtain consent. The
response from all people contacted and approached was generally
extremely helpful and cooperative. The interviews and
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examinations appeared to be of an appropriate length and nature
to avoid distress.
As the visits got underway it became important to keep
arranging the next set of visits, to maintain the momentum of the
study. The files with all relevant documentation were prepared in












Phase 2 19/4/94 4/6/94 (25-88)
Phase 3 7/6/94 26/8/94 (89-179)










At the first assessment 40 mis of blood was taken from
each of the subjects, when possible. This was occasionally difficult
when the subject was very disturbed, and was not always
possible. Five samples were not taken, in four cases as the subject
was not cooperative. One subject, without relatives, was in long-
term care, and consent was felt to be inappropriate. In several
cases, less than the 40 mis was taken. The use of anaesthetic
patches was not found to be particularly helpful. A paper by
Richards et al (1993), described DNA preparation from buccal
swobs or brushes, which could potentially avoid the need for
blood samples in this group of patients.
Having taken the blood, it was divided into four
Ethylenediamine tetra-acetic acid (EDTA) tubes, each of which
was labelled with the patient's study number and date of birth.
Within the next few hours, at most within the next 24 hours, the
tubes were taken to the Western General Hospital, Human
Genetics Unit, where storage space had kindly been given in the
freezer, kept at minus seventy degrees centigrade, before this, a
further separate blood storage number was also added to each
subject's individual set of tubes. In the freezer itself, the bloods
were kept in a series of labelled boxes, to enable easy access and
safe keeping. The blood was stored here until the DNA extraction
in the summer of 1995.
Control samples.
A control population was not a feature of the basic study
but was of crucial importance for the genetic analysis. A group
with similar sex and age distribution, of similar ethnic
background, but otherwise essentially random, was required.
These features would influence the distribution of other
pathology such as cardiovascular disease and the distribution of
genetic alleles.
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It also became apparent that it would be necessary to do
a basic check for any cognitive impairment of the control sample.
The Mini Mental State Examination (MMSE), was chosen for this
purpose and scores below 23/30 taken to be indicative of
impairment. Certain other questions were asked to each control
case, such as any family history of a dementing illness. The
consent form and data sheet, are given in the Appendix: Protocol.
The Church of Scotland Annual General Assembly
Meeting was held in Edinburgh in the Spring of 1995, and the
organisers very kindly allowed the approach of members for the
purpose of blood collection. Other members of the department
generously gave their time to help in the two days of intensive
control sample acquisition. Prior to this, ten control cases had
been colected from spouses of the study subjects.
Details of the age and sex distribution of the dementia
and control samples, is not given here. This data is incorporated
into the Genetic Results.
Of 122 dementia samples stored in the freezer, one was
mislaid, and one case, already excluded, had Huntington's Chorea.
A total of 120 dementia samples were therefore available for
DNA preparation from the dementia group. 119 cases were
analysed for all three loci.
Of the 165 control samples, 152 had all the three loci
analysed.
Extraction of DNA from the Blood Samples.
In the summer of 1995, the DNA preparation was
completed. Most resulting DNA samples, had a concentration of
50-200 ng/microlitre. The quality of the DNA was assessed, to
ensure it was undegraded, RNA free and PCRable.
The protocol for this is given overleaf:
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DNA Extraction Process.
For each 10 mis blood collected in EDTA tube.
Step 1. For cell lysis, add 30 ml buffer of
ammonium chloride (115mM)
potassium hydrogen carbonate (lOmM)
EDTA (0.1 mM)
Spin at 2.2 krpm for 10 minutes at 4°C, pour off supernatant.




Spin at 2.2 krpm for 10 minutes at 4°C, pour off supernatant.
Repeat twice. Resuspend in 4.5ml SET.
Step 3. Protease K treatment.
Make to 0.1% sodium dodecylsulphate
and add 25^1 of 20 (utg/pil protease K
Incubate at 37 °C for 2 hours.
Step 4. For organic extraction, add 10 ml of
phenyl (1) : chloroform (1)
Mix and spin at 2.2 krpm for 10 minutes at room temperature,
recover water phase. Repeat twice.
Step 5. Add
sodium acetate (3M) one tenth volume,
ethanol, two and a half volumes.
Mix and spin at 2.2 krpm for 10 minutes at 4°C, recover water
phase. Repeat twice.
Step 6. Resuspend pellet in 0.5 ml buffer
Tris (lOmM) : EDTA (ImM), at pH 7.5.
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Genetic Testing.
The Candidate Gene Approach.
In the molecular study of a disease, the genetic defect
must be located, identified and the defects characterised. This
requires the gene to be assigned a position or linked, the locus
defined and then the molecular pathology of the aberrant protein
described.
The linkage approach requires the collection of families
with multiply affected members, inwhich the phenotype and
mode of inheritance are defined. The determination of the gene
position is by random searching or the candidate gene or region
approach. The flanking markers are found by multipoint mapping
and international collaboration.
Once a gene is identified, it can be amplified and
analysed using the technique of Polymerase Chain Reaction (PCR)
on microtitre plates.
The dementia samples for the current study came from
a group of non-related individuals, with sporadically occurring
presenile-onset dementia, with a diverse range of aetiologies.
This was not therefore amenable to the linkage approach, nor
particularly to the association approach (for example between
siblings and markers). The genes already known to be relevant in
the familial forms of the disease were not of primary interest
here. Genes known to be risk factors and other reported
candidates, were of greater potential interest to study in relation
to this group.
In collaboration with Dr. Anthony Brookes, at the
Western General Hospital, Human Genetics Unit, decisions were
made as to the testing which would be suitable in the initial
analysis of the sample. The alleles chosen for typing were: APOE;
ACT; and VLDL-R.
The resource of the extracted DNA obviously remains for
future approaches, for example the testing of novel candidate
genes. The genes chosen and other novel candidate genes,
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especially with relevance to Alzheimer's Disease, are discussed in
the Introduction: Genetics chapter.
The genetic analysis began in January 1996. The
protocols are given below.
Apoliprotein-E Genotyping (e 2 /3 /4).
Assay.
A 227 bp fragment of the APOE gene coding sequence is PCR
amplified. The sequences of two polymorphic base positions is
detected by cleavage with HHal restriction enzyme (whose sites
are altered by these polymorphisms) and agarose gel
electrophoresis.
Primers.
As published by Wenham et al (1991), here called Wen 3' and
Wen 5'.








dATP, dTTP, dCTP, dGTP
Nucleotides












Perkin Elmer Cetus, 9600 machine
(96°C50"), (60°C30"), (72°C30"), 1 cycle
(96°C15"), (60°C30"), (72°C30M), 17 cycle






Mix, place at -20°C for 1 hour, spin in microfuge 15 minutes,
leave at room temperature to dry.
Hhal Digestion.
37°C for 2 hours.
Electrophoresis.
Run on a 4% low melting temperature agarose gel in TAE buffer
(40mM tris/acatate, 1 mM ethylene-diamine-tetraacetic acid, pH
7.6).
Diagnostic allele sizes.
£ 2, 91 bp, 81 bp.
£ 3, 91 bp, 48 bp.
£ 4, 72 bp, 48 bp.









a 1-antichvmotrypsin (ACT) Genotvoing (T/A) Assay.
Assay.
A 135 bp fragment of the ACT gene spanning the signal peptide is
PGR amplified. The sequence of a polymorphic base position is
detected by cleavage with BstNI restriction enzyme (whose site is
altered by this polymorphism) and agarose gel electrophoresis.
The base polymorphism codes for either a threonine (T) or an
alanine (A) amino acid.
Primers.




(N.B. G_is a C in the ACT gene but was altered to prevent forming
an extra BstNI site in the PGR product.)








dATP, dTTP, dCTP, dGTP
Nucleotides












Perkin Elmer Cetus, 9600 machine
(96°C50"), (53°C30"), (72°C30"), 1 cycle
(96°C15"), (53°C30"), (72°C30"), 17 cycle






Mix, place at -20°C for 1 hour, spin in microfuge 15 minutes,
leave at room temperature to dry.
BstNI Digestion.
37°C for 2 hours.
Electrophoresis.
Run on a 3% low melting temperature agarose gel in TAE buffer
(40mM tris/acatate, 1 mM ethylene-diamine-tetraacetic acid, pH
7.6).
Diagnostic allele sizes.
A (Ala) - 96 bp.
T (Thr) - 135 bp.









Very-Low-Density-Lipoprotein Receptor (VLDL-R) microsatellite
Genotvping Assay.
Assay.
A fragment of the VLDL-R gene 5'UTR is PCR amplified containing
a (CGG)n sequence (tri-nucleotide repeat). The number 'n' varies
and defines this polymorphism. Product sizes are determined by
denaturing polyacrylamide gel electrophoresis and fluorescence
detection of the PCR product labelled at one primers 5' end (using
ABI automatic sequencing gel apparatus).
Primers.
As published by Okuizumi et al (1991). Here called 'VLDL-F and
'VLDL-R', with the former labelled at its 5' end with a FAM
fluorescent moiety.








dATP, dTTP, dCTP, dGTP
Nucleotides











Perkin Elmer Cetus, 9600 machine
(96°C50"), (60°C30"), (72°C30"), 1 cycle
(96°C15"), (60°C30"), (72°C30M), 17 cycle
(96°C15"), (60°C30"), (72°C1:30"), 18 cycle.
Electrophoresis.
Products diluted 1/20 in water and 2^1 run on an ABI 373
automatic sequencing /genotyping device to determine allele
sizes.
Diagnostic allele sizes.
Range from 94 bp (n=4) to 115 bp (n=ll).




Aim of the statistical analysis.
The group of people with early-onset dementia, were
not compared with a control sample for the clinical part of the
data collection. For certain parts of the data collection, normative
data exists, such as for the CAMDEX interview schedule. However,
for the genetic tests, a control group was used.
The overall significance and applicability of any results
from the study must also be seen in the context of the biases
introduced in the sample selection, and these are discussed more
fully in the Discussion. Furthermore, the sample used consists of
individuals all at different stages of their illness.
At the outset it became apparent that although the
sample size was reasonable, by the time the different subgroups
(i.e. the different diagnostic categories) were being analysed,
numbers would become small, especially when missing data is
considered.
Rather than the study starting with a formal hypothesis
to be tested, the approach was that of exploratory data analysis.
A description has been given for the group as a whole, and the
different DSM3R groups, both for the first and second assessment,
for some of the different variables.
The populations studied were based on the DSM3R
groups: Alzheimer's; Multi-infarct; Alcohol-related; and a group of
those cases in overlapping categories. This combination group is
also referred to as the Mixed group. The only one overlap not
representing a combination with Alzheimer's, is one case,
between Alcohol and Multi-infarct dementia. But the term
'combined' group is used in a slightly different context in the
genetics results.
The data collected, determines the value of the results,
and the more objective the data the more solid are the
conclusions that can be drawn from the work. As already
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mentioned, the most objective parts of the battery, for the
measurement of change, were the CAPE, CAMCOG and
neurological examination. One-way analysis of variance was used
for the CAPE and CAMCOG in phase I of the study to compare
group means in the four diagnostic categories. This method is
described below.
Using data from the first assessment (phase I) and the
second assessment (phase II) of the study, the DSM3R groups
were analysed again using one-way analysis of variance to
determine whether there were differences in the extent of
change across the diagnostic groups. This and the analysis of the
neurological data are discussed in greater detail in the Measures
of Change section.
Using the CAPE, CAMCOG and neurological data from
both phases of the study, multiple linear regression analysis was
used to determine a relationship between the change scores
(improvement or deterioration) and age at onset, sex, duration of
illness, presence of a family history and diagnostic category. From
this, predictors (for example of deterioration), could then be
identified.
The analysis of the genetic results is given in the Results
section. Possibilities for future directions for the data analysis are
given in the Discussion.
One-way analysis of variance.
One-way analysis of variance has been used in Phase I
of the study to determine whether the observed differences in
the group means (for each sub-score of the CAPE and CAMCOG
assessments) can be attributed to sampling variability among
sample means or whether the four groups come from populations
with different means.
The statistical technique is used to test the null
hypothesis H0 : all four group means are equal. The assumption is
that equal variances of the four groups is necessary for valid use
of this test.
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The F-test statistic is an estimate of the variability in the
population based on (i) how much the observations vary within
each group and (ii) how much the group means vary among
themselves. If group means are equal in the population, then it
would be expected that (i) and (ii) are approximately equal. As
the F-statistic is a ratio of (i) and (ii), it would then be close to the
value one. The significance level p is calculated by comparing the
F-value obtained with the F-distribution.
A statistically significant F-value tells you only that the
population means are significantly different and gives no
information as to the pattern of differences.
Therefore the Bonferroni test is used to compare pairs of
means by adjusting the significance level to account for multiple
comparisons. From the Bonferroni test, statistically significant
differences between pairs of group means are shown.
This method was repeated when comparing the mean of
the differences of the CAPE and CAMCOG assessment scores
between each diagnostic group from Phase I to Phase II.
Measures of Change.
One-Wav Analysis of Variance.
The next stage of the analysis was to look for differences
between the two phases, to establish the degree of change
(improvement or decline), compared between the four groups for
the CAPE and CAMCOG assessments. This was achieved by
comparing the means of the differences between the two phases
using one-way analysis of variance.
The first assessment scores were subtracted from the
second, therefore a resulting positive score would indicate the
second assessment score was higher and a negative score that the
second assessment score was lower. Each individual subscore has
to be interpreted individually. In the CAPE, deterioration is
represented by an increase in scores (positive differences),
whereas for the CAMCOG, deterioration is represented by a
decrease in scores (negative differences).
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Chi-sauare.
For the analysis of the Neurological data, the X 2 test
was used to determine whether the diagnostic group was
independent of whether a change occurred between assessments.
Kruskal-Wallis one-way analysis of variance.
A total change score between assessments was
constructed for each individual, for both the Neurological
examination and the Webster scale. Using these scores the
Kruskal-Wallis one-way analysis of variance was used to test for
differences in changes between the four diagnostic groups.
The Kruskal-Wallis test is a distribution free test and
used as an alternative to one-way analysis of variance, with the
actual values of the data replaced by ranks.
Multiple Linear Regression Analysis.
Linear regression was used for the CAPE-BRS assessment
(physical disability, apathy, communication difficulties, social
disruption and CAPE total), the total CAMCOG assessment and the
neurological examinations (neurological examination and Webster
scale) to examine the relationship between the change scores and
a set of independent variables. The independent variables used
were: diagnostic group; age at referral (diagnosis); sex; duration of
illness; and whether cases had a family history of the illness.
From this analysis the best model was determined for
each change score in each of the assessment sub-groups. Care
must be taken in the interpretation, and each category analysed
separately. For example, a negative change score in the CAPE
assessment indicates an overall improvement going from phase 1
to phase II. A negative change score in the CAMCOG, suggests a
deterioration at phase II.










One-way Analysis of Variance.
177-179. Summary of Results, Phase I..
Second assessment (Phase ID.
180-188. Description.
Measures of Change.
189-201. Phase II-Phase I results.
202-203. Neurological data.
204-205. Multiple Linear Regression Analysis.
Genetic results.
206-210. Apolipoprotein E.
210-211. Very Low Density Lipoprotein-Receptor
211-212. cx 1-antichymotrypsin.




Descriptive Statistics for CAPE and CAMCOG.
Genetic Tables.
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Ascertainment of the study sample.
290 cases were identified for the study, and the































Total 557 (100%) 290 (52 %) 208 (37 %) 59 ( 11 %)
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Having inspected the case notes, the reasons why
208 cases were not included were as follows:
Table (2).
Survev. Total Not Wrong Death. Too old/ Out of




168 101 57 8 2
Neuro-
Records.
16 8 2 6 0
Word of
Mouth.
0 0 0 0 0
West
Lothian.















* Detail, not included here, is available on the 73 who died.
Contact was then made with the general practitioners
and responsible consultants of the 290 cases identified.
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From the initial clinical case note diagnosis, the 290
cases were made up of:
Table (3).
TvDe of Diagnosis. Number of Subjects. % of Subjects.
Uncertain type/
Atypical/
Mixed 75 25 %
Possible 60 21 %
Alzheimer's 49 17 %
Alcohol 44 15 %
Multi-Infarct 32 11 %
Huntington's Chorea 15 5 %
Head Injury 5 2 %
Down's 5 2 %
Rare * 3 1 %
Subcortical 2 1 %
Total 290 100 %
* The three rare cases were: Steele-Richardson Syndrome (SRO),
or Progressive Supranuclear Palsy (PSP); Myotonic Dystrophy
(MD); and Hereditary Spastic Paraparesis (HSP), see: Rother et al,
1976; Went et al, 1964; Bruyn et al, 1964; and Frey et al, 1972.
The case of MD had deceased, and the family of the case
with SRO, refused entry to the study. The case of HSP was
included.
If it was acceptable to the doctors concerned, then
contact was made with the families.
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Of the 290 cases, 164 were not seen, and the reasons for
this are shown below. It was also decided at this stage not to
include cases of Huntington's Chorea, Down's Syndrome, and
major head injury.
Table (4). Reasons For Case Non-Inclusion.
Reason Number of Cases % of Total
Deceased 50 30 %
Refused 40 24 %
Untraced 23 14 %
Unsuitable 21 13 %
Huntington's Chorea 14 9 %
Area 11 7 %
Down's Syndrome 5 3 %
Total 164 100 %
Of the cases who had deceased, the case note diagnostic
grouping was as follows: Alzheimer's, 9; Multi-infarct, 12;
Possibles, 5; Alcohol-related, 9; Not known, 8; Alzheimer's and
Alcohol, 1; Alzheimer's and Multi-infarct, 1; Alcohol and Multi-
infarct, 1; Parkinson's, 2; Myotonic Dystrophy ,1; and Huntington's
Chorea, 1.
The reasons for unsuitability were: No progressive
cognitive decline,10; Head injuries (including subarachnoid
haemorrhage, drug overdose and asphyxia), 5; Depression, 3;
Infarct, 1; Reversible alcohol-related, 1; and
Learning disability, 1.
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Case Register etc. Identified no. of cases = 557.
T
Case notes inspected.
Feighner Criteria Applied. 208 excluded
Deceased, n = 73.
Wrong diagnosis, n = 116.
Wrong age. n = 16.
Out of Area, n = 3.
\ r
290 cases identified.
Contact with Doctors etc. 164 excluded.
Deceased, n = 50.
Refused, n = 40.
Out of Area, n = 11.
Untraceable, n = 23.
Down's Syndrome, n = 5.
Huntington's, n = 14
Unsuitables. n = 21.
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126 cases seen for first assessment.
DSM3R criteria applied.
14 cases not met.
f
126 cases seen for second assessment.
DSM3R criteria applied.
2 cases refused.
12 cases not met.
18 deceased.
126 cases were seen at the first assessment for the
study and of these 112 met the DSM3R criteria for dementia
(89%).
The 14 cases (11 % ) not meeting the DSM3R criteria
were re-assessed at the second assessment. Detail not provided
here documents which parts of the criteria were not met for
these cases.
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Number of Case > 164 112 14
% of Total 57 % 38 % 5 %
Therefore, 126 cases were seen for assessment.
The results of applying the DSM3R and McKhann criteria
to the group of 112 are shown below:
Table (6). McKhann Criteria Applied to Cases Of
DSM3R Dementia Seen.
McKhann Criteria Number of Cases % of Total
Not Met 32 29 %
Met 80 71 %
Total 112 100 %
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Of those meeting the McKhann criteria, 48 were
probable and 32 possible, respectively 43% and 29% of the total,
n=112.
14 of the McKhann +ve group did not have adequate
investigations done, according to the case notes.
Table (7). DSM3R Criteria Applied to 112
Cases Of Dementia Seen.
DSM3R Alzheimer's. Multi-Infarct. Alcohol.
Tvoe.
Alzheimer's. 60 (53%) 17 (15%) 2 (1%)
Multi -Infarct 13 (12%) 1 (1%)
Alcohol. 13 (12%)
This is also displayed as a Venn Diagram:
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With n = 4 (4%) overlapping all 3 groups, and n = 2 not
fitting DSM3R categories. These latter two cases are known as
rare types or 'other', one case due to a combination of risks and
the other due to Hereditary Spastic Paraparesis.
Equating the DSM3R Alzheimer group
and McKhann group.
DSM3R Alzheimer =60
DSM3R Alzheimer + other = 23
Total = 83
McKhann probable = 48
McKhann possible =32
Total = 80
There were 3 cases which did not meet the tighter
McKhann criteria, two with cerebrovascular risk factors too
strong to be excluded as the primary cause, and one where the
alcohol and cerebrovascular risk factors were too great for
Alzheimer's to be the likely primary pathology. Obviously though,
a subjective element arises in the decision as to which pathology
is primary. These issues are raised again in the Discussion.
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Table (8). DSM3R Severity Rating At The First Assessment
For 112 Cases.
Severity Ratina Number Of Cases % Of Cases.
Severe 63 56 %
Moderate 36 32 %
Mild 13 12 %
Total 112 100 %
The issues of applying severity ratings is discussed
elsewhere. The DSM3R ratings were used, rather than, for
example, the scales of Hughes et al (1982) and Blessed et al
(1968).
For the different DSM3R groups, the severity ratings at
the first assessment were as follows.
Table (9).
DSM3R Severe Moderate Mild
Alzheimer 33 17 10
(n=60) (55%) (28%) (17%)
Multi-infarct 10 3 0
(n=13) (77%) (23%)
Alcohol 4 6 3
(n=13) (31%) (46%) (23%)
Mixed 15 9 0
(n=24) (62%) (38%)
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This is displayed graphically below:
Figure (1).
Severity Rating at the first Assessment










The following tables and figures all relate to a more
detailed description of the 126 cases seen. This includes the 14
possible cases who were not excluded from the study, but kept in
for the follow-up.
The general description of the group is not repeated in
the Results following the 2nd assessment, therefore an
opportunity to include the 2 cases who became DSM3R -i-ve by
follow-up are included in some of the descriptions of the group
divided according to DSM3R type. In these instances, n=114,




For the total 126 cases seen:
53 Males, (42 %) : 73 Females (58 %).
For the DSM3R +ve cases (n=l 14):
Table (10).
DSM3R grouD. Male Female
Alzheimer (60) 25 (42%) 35 (58%)
Multi-infarct (13) 2 (15%) 11 (85%)
Alcohol (14) 8 (57%) 6 (43%)





Sex Distribution In The Study Sample,











For the total 126 cases:
Average age at original referral = 58 years old.
Average age at first assessment = 62 years old.
For the DSM3R groups (n=114 at second assessment) :
Table (11).




Alzheimer (60) 41-65 58
Multi-infarct (13) 57-65 62
Alcohol (14) 44-64 55
Mixed (25) 52-65 59
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Socio-economic Group.
The socio-economic group (class I-V) distribution







Key to socio-economic group (class I-V), according to
occupation.
(As defined by The Office Of Population Censuses and Surveys,
HMSO 1980.)
I = Professional occupations IV = Partly skilled
II = Intermediate occupations. V = Unskilled
IIIN = Non-manual occupations. Army = Army personnel
IIIM = Manual occupations.
Social Class
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Table (12). Socio-Economic Group (Class I-V)


























































Known for 103 ( = 82 %) of the sample
Table (13).
Academic level. Number Of Cases. % Of Total.
Not Known. 23 18 %







Universitv. 9 7 %
Total. 126 100 %
Premorbid 10
Only 58 ( 46 %) of the sample were able to complete the
testing, as measured by the National Adult Reading Test (NART).
For the 9 people who scored more than 40 errors on the NART, a
Schonnel reading test was given on the 2nd assessment, these
results are not included.
Figure 4.




The mean premorbid IQfor the different DSM3R +ve
cases (n = 114), were:
Alzheimer's (only 23 of 60 able to do test) = 103.
MID (only 3 of the 13 able to do test) = 94.
Alcohol (only 12 of 14 able to do test) = 94.
Mixed group (only 7 of 25 able to do test) = 94.
The differences between the groups, were not
statistically significant.
Presenting Features.
The presentation was of: memory loss/ disorientation etc
in 83 (66%) of the sample; mood/ personality change etc in 19
(15%) of the sample; other features etc in 24 (19%) of the sample.
Current Treatment.
No documentation as to past or current tacrine
treatment was made.
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At the first assessment,
30 (24%) of the sample were on neuroleptic medication.
At the second assessment, a more formal enquiry of
current anti-depressant treatment was made;
of the Alzheimer's group (n=60), 7 were on antidepressants (12%)
of the MID group (n=13), 2 were on antidepressants (15%)
of the Alcohol group (n=14), 1 was on antidepressants (7%)
of the Mixed group, (n=25), 5 were on antidepressants (20%)
Selected Risk Factors.
For the group as a whole,(n=126).
Table (14),
Risk Factor Definite Cases % Of Total
Previous stroke. 19 15 %
Hypertension. 33 26 %
Diabetes. 12 9 %









Some of these have been described according to DSM3R
group (n=114). In this, and subsequent tables describing the
groups, the percentages in the horizontal rows, refer to the
named DSM3R group.
Table (15). History of Previous Stroke.
Dementia
Type.
Yes No Not known
Alzheimer's
n=60
2 (3%) 53 5
MID
n=13
9 (69%) 3 1
Alcohol
n=14
2 (14%) 11 1
Mixed
n=25
6 (24%) 13 6
Table (16). History of. or current hypertension.
Dementia
Type.
Yes No Not known
Alzheimer's
n=60
7 (12%) 49 4
MID
n=13
8 (61%) 5 0
Alcohol
n=14
2 (14%) 11 1
Mixed
n=25
14 (56%) 11 0
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Table (17). Previous Head Injury.
Dementia
TvDe.
Yes No Not known
Alzheimer's
n=60
5 (8%) 48 7
MID
n=13
2 (15%) 10 1
Alcohol
n=14
4 (28%) 9 1
Mixed
n=25
6 (24%) 16 3
Table (18). History of Parkinson's Disease.
Dementia
TvDe.
Yes No Not known
Alzheimer's
n=60






1 (7%) 13 0
Mixed
n=25
1 (4%) 23 1
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More detailed information is available on the cases with
a recorded family history.

























6 (10%) 0 1 (7%) 3 (12%)
The following are the family histories, of cardiovascular
risk factors, for the DSM3R groups:
Table (20).







Infarction. 30 (50%) 6 (46%) 6 (43%) 11 (44%)
High Blood
Pressure. 15 (25%) 4 (31%) 3 (21%) 5 (20%)
Stroke.
22 (37%) 7 (54%) 3 (21%) 8 (32%)
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None of the differences in family history, reach
statistical significance.
The duration of the illness is difficult to accurately
define, as discussed in the Introduction: Epidemiological Issues.
Two measures are given here:
The First:
Table (21). Years Between First Contact With The Services
and First Assessment For The Study.
Years Number Of Cases % Of Total
0 to 1 8 6 %
1 to 2 14 11 %
2 to 3 29 23 %
3 or more. 75 60 %
Total 126 100 %
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The Second:
From the behavioural questionnaire, the relative's
estimate of the duration of the dementia was enquired into:
Figure (5).
Duration Of Symptoms, in Years, for the Total Group:
3 cases (2%) of the 126, had a duration of unknown duration.
40
0-3 3-6 6-9 9-12 12-15
Duration in years.
Table (22).
Duration Of Symptoms for the DSM3R Groups:
DSM3R group Range of duration. Mean duration.
months months and vears.
Alzheimer 11-156 75 (6.3 years)
Multi-infarct 36-96 69 (5.8 years)
Alcohol 12-120 55 (4.6 years)
Mixed 12-144 77 (6.4 years)
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Data from the first assessment provided information as
to the whereabouts of the sample and the relatives involved:
Figure (6).








Alone Other Family Spouse Long Term
Living With
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From the MOUSEPAD behavioural and
psychopathological questionnaire, symptoms of non-cognitive
disturbance were recorded:
Delusions.
The total number of cases of the 126 seen, with a
delusional belief recorded at some stage of the illness was 45
(36%), the most common types are shown in the following table:
Table (23).







Someone else being in
the house
16 13 %
For the DSM3R groups, n=114, the distribution of
delusions is as follows:
Table (24).
DSM3R Groun Delusions
Alzheimer (n=60) 26 (43%)
Multi-infarct (n=13) 5 (38%)




The total number of cases of the 126 seen, with any of
the types of auditory hallucination enquired into, at some stage of
the illness, was 11 (9%).
The total number of cases of the 126 seen, with any of
the types of visual hallucination enquired into, at some stage of
the illness, was 19 (15%).
Table (25).
Hallucination Number Of Cases % Of Total
Auditory Voices 11 9 %
VoicesUnknowr 7 5 %
Voices
Understood 7 5 %
Visual People 15 12 %
PeopleUn knowr 11 9 %
People Known 9 7 %
Animal 6 5 %
Table (26). For the different DSM3R groups:










Apart from the psychotic and affective symptomatology
enquired into, other aspects of the non-cognitive changes in
dementia was also documented from the behavioural
questionnaire. Selected data from the MOUSEPAD is summarised







On Feet 44 35 %
Following
Another
Around 48 38 %









Verbal 47 37 %
Eating behaviour
Eating more =22 (17%)
Eating more quickly = 31 (25%)
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Emotional lability
Outbursts of crying = 26 (21%)
Outbursts of laughing = 21 (17%)
Some of these items are also described by DSM3R
grouping:
Table (28).
Behaviour Alzheimer Multi- Alcohol Mixed
(n=60) Infarct (n=14) (n=25)
(n=13)
Walking
More active 25 (42%) 6 (46%) 1 (7%) 12 (48%)
Walking
Following 29 (48%) 3 (23%) 1 (7%) 14 (56%)
Eating
Quicker 16 (27%) 3 (23%) 3 (21%) 8 (32%)
Eating
More 13 (22%) 3 (23%) 1 (7%) 4 (16%)
Aggression,
all forms. 32 (53%) 5 (38%) 4 (28%) 12 (48%)
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Neurological Examination Results.
Some selected items, for the group of 126, are shown
below:
Table (29). Primitive reflexes:








This can also be described for the different DSM3R
groups:
Table (30).




Hoffman 5 (8%) 0 0 1 (4%)
Grasp 14 (23%) 4 (31%) 0 5 (20%)
Palmo-
Mental
0 1 (8%) 1 (7%) 0
Jaw 5 (8%) 1 (8%) 1 (7%) 3 (12%)
Snout 6 (10%) 1 (8%) 0 1 (4%)
Glabellar 8 (13%) 5 (38%) 3 (21%) 2 (8%)
Sucking 2 (3%) 1 (8%) 0 1 (4%)
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Alzheimer 2 (3%) 2 (3%) 9 (15%) 14 (23%)
(n=60)
Multi- 1 (8%) 1(8%) 2 (15%) 3 (23%)
infarct
(n=13)
Alcohol 0 0 2 (14%) 1 (7%)
(n=14)
Mixed 2 (8%) 0 2 (8%) 5 (20%)
(n=25)
And the results for tone; myoclonus; abnormal
movements, for the DSM3R groups:
Table (32).






27 (45%) 6 (46%) 2 (14%) 8 (32%)
Myoclonus 6 (10%) 1 (8%) 0 1 (4%)
Abnormal
Movements. 12 (20%) 2 (15%) 0 2 (8%)
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The mean Webster scores were, for the: Alzheimer's
group = 4; Multi-infarct group = 4; Alcohol group = 2 and the
Mixed group = 2.
One-way Analysis of Variance.
As described in the Method: Statistics, one-way analysis
of variance for the CAPE-BRS and CAMCOG, for the first
assessment, was used to compare the group means in the four
diagnostic categories.
At the end of this chapter, an Appendix gives the
descriptive statistics for the CAPE and CAMCOG totals and
subscores, for the first and the second assessments .
A summary of the findings from the first assessment
(phase I), is given in table (33). Significance is at the 0.05 level.
From this table, the statistically significant differences in
group mean scores occur between the Alcohol group, and at least
one other group. This is true for the CAPE subscores of: Physical
disability; Communication difficulty and Social disruption. In each
case the Alcohol group is scoring significantly lower in the CAPE
assessment compared to the other diagnostic groups.
Similarly for the CAMCOG statistically significant
differences in group mean scores occur between the Alcohol
group, and at least one other group for all subscores. However,
the Alcohol group is scoring significantly higher than all other
diagnostic groups.
The Alcohol group can therefore be distinguished in its
profile from the other three groups.
Summary of Results, Phase I.
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Table (33).





























Ale & Comb. 0.85 vs 2.5
































































Calculation 2.44 >0.05 .
Abstract
thinking






(0.04) Ale & Comb.
4.69 vs 1.67







Results From The Second Assessment.
The descriptive analysis done for the first assessment
was not repeated in full again after the second. The description
from the 2nd assessment data uses new information, particularly
about service needs. Whereas the CAMDEX H questionnaire was
found not relevant at the 2nd assessment, the data sheet, CAPE,
CAMCOG, MOUSEPAD and neurological examination were.
Meeting DSM3R Criteria.
Following the second assessment, two of the cases
previously not meeting the DSM3R criteria for dementia, did so.
Total no. of cases =126.
No. DSM3R+ve =114.
12 cases remained in the possible group.
DSM3R Dementia Diagnosis.
One new case was in the Alzheimer's / Alcohol group,
the other in the Alcohol group.
The DSM3R diagnosis for the 114 cases is shown below.
As before, 2 cases (1%), were 'other' dementia types and 4 cases
(4%) were in the group overlapping all three.
Table (34),
DSM3R TvDe. Alzheimer's. Multi-Infarct. Alcohol.
Alzheimer's 60 (53%) 17 (15%) 3 (3%)
Multi-Infarct 13 (12%) 1 (1%)
Alcohol 14 (12%)
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This is also shown as a Venn Diagram:
Table (35). DSM3R Severity Rating at the First and
Second Assessments.
DSM3R Severity Cases and % at 1st Cases and % at 2nd








* (One case not known, as not re - assessed).
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Looking at the different DSM3R groups, the distribution
of the severity ratings at the second assessments, compared with
those quoted for the first was as follows, (n=114).
Table (36).









































* The Moderate/Severe group described an intermediate
category of cases in the moderate rating at the severe end of the
spectrum, who were often still at home (see Discussion).
The next graph shows the severity ratings for the
different DSM3R groups at the 2nd assessment, which can be
compared with the first assessment. For this graph, the
Moderate/Severe cases are included in the Moderate category:
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Figure (7).






Alz MID Ale Mixed
DSM3R Dementia Type.
In total 16 cases changed severity rating:
Table (37).
Change No. of Cases
To mild 2
Mild to Moderate 2
Mild to Severe 1
Moderate to Severe 6
Moderate to Mod/Sev. 5
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The distribution of these changes amongst the various
DSM3R groups is as follows:
Table (38).









The McKhann criteria for Alzheimer's Type Dementia
were fulfilled as at the first assessment.
Table (39). Attrition after 2nd Assessments.
Reason No. of Cases %
Deceased 18 14
Refusal 2 2
Only two neuropathological post-mortem examinations
were done. The results of these can be found in the individual
case histories given in the appendix. The cases are ma2 and
ihlOl. The findings were not used to retrospectively alter the
individual's DSM3R grouping.
The time intervals for the second visits was between 12
and 15.4 months after the first.
185
Table (40). Profile of Services Used, bv 126 cases at the
second assessment.
N.B. These are not exclusive categories; those not in long-
term care (LTC), may be receiving more than one service. Of the
50 not in LTC, 15 were receiving no services (30%). The data
includes those who deceased in the follow-up.
Service Used. No. of Cases % of 126.







Respite Care 12 1 0


















(home help / meals
on wheels).
9 7







Table (41). Supports used bv Relatives at 2nd Assessment.




Carer Group 22 17
Other 3 2
Unknown in 3 cases (2 %).
Where the 126 Cases Were at 1st and 2nd Assessment.
The majority of the group of 126 cases were in LTC but a
substantial number were cared for by a spouse (or other family)
at home:
Table (42),
Where Assessment 1 Assessment 2
Alone 8 (6%) 6 (5%)
Spouse or other 50 (40%) 37 (30%)
Long Term Care 64 (51%) 61* (48%)




4 (3%) 4 (3%)
Total 126 126
* Of the people in LTC at the second assessment, the 15
who died are not included but the 12 new cases admitted, are.
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This is displayed graphically in Figure (8).
Figure (8).















S = spouse or other
L = long term care
D = deceased
0 = other
At the second assessment, 30 people with dementia,
were currently at home, living with relatives. Of these, the
severity distribution was: mild = 4; moderate = 24; severe = 1;
(one case not reassessed). The carers were as follows: wife, 13;
husband, 11; son, 3; daughter, 1; other combination of relatives, 2.
The ages of the spouses was also collected as part of the initial
data, but is not presented here.
Admission to Long-Term Care (LTC).
Of the 18 cases who deceased during the follow-up
period, 15 died in LTC, two shortly after entry and 12 new cases
had been admitted into LTC in the follow-up period.
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Table (43). Time in Long-Term Care, since admission.
(figures include those deceased.) It is striking that about 50% of
these subjects had been in LTC for more than 3 years .
Time in months no = %














95 relatives completed the questionnaire. The score
distribution is shown here:
Table (44).









The section on Measures of Change in the Method :
Statistics, describes the comparison of the means of the
differences between the two phases, using one-way analysis of
variance.
The Phase II - Phase I results are given here:
Table (45).






0.72 (0.5) _ _
Apathy
Subscore
















(0.03) Ale and Alz. 6 vs -7.10
Orientation 1.88 (0.14)
Language 0.95 (0.42)






Learning 3.23 <0.05 (0.03) Ale and MID. 1.30 vs -1.0





thinking 2.86 <0.05 (0.04) Ale and Alz.
0.70 vs -0.52
Perception 3.06 <0.05 (0.03) Ale and Alz. 1.1 vs -0.67
MSE 2.11 (0.10)
*
= No statistically significant results, after adjusting for multiple
testing.
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The only significant difference shown, in the change of
the mean scores between the phases, was that of the Alcohol
group and
1) the Alzheimer's group, for the CAMCOG total and subscores of:
memory; attention; abstract thinking; and perception.
2) the MID group, for the CAMCOG subscores of memory and
learning.
The Results Appendix already mentioned, has details of
the descriptive statistics for the CAPE and CAMCOG subscores, for
the first and second assessments. The following figures (9-26)
display the mean scores, for phase I and phase II, by diagnostic
group, and show the Alcohol group to be improving by the second
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In addition, the Neurological examination and Webster
scale data, were analysed, to detect changes from the first
assessment to the second, for the four groups. It became apparent
when inspecting individual questions that when changes did
occur their direction were similar over diagnostic groups and no
clear pattern emerged.
The following tables summarise both the Neurological
and Webster scale data to display where changes occur. These
combine all sections of the questionnaire. The X 2 test was used
to determine whether the diagnostic group was independent of
whether a change occurred between assessments.
Table (46). Numbers of patients changing in at least one subgroup
between the first neurological assessment and the second.
No change. Change. Total.
Alzheimer 29 31 60
MID 4 9 13
Alcohol 9 4 13
Combination 8 16 24
Total 50 60 110
X2 ,3 = 5.72, p = 0.13.
203
Table (47). Numbers of patients changing in at least one subgroup
between the first Webster scale assessment and the second.
No change. Change. Total.
Alzheimer 29 31 60
MID 4 9 13
Alcohol 10 3 13
Combination 11 13 24
Total 54 56 110
X2 ,3 = 5.89, p = 0.12.
In both examinations, the X 2 statistic shows that when
a change occurs it is independent of diagnostic group.
From the Kruskal-Wallis one-way analysis of variance
for the total neurological change score, aX2 ,3 = 9.65, (p = 0.02)
indicates a statistically significant difference in the change score
between the four groups. (MID mean rank 30.29, Combination
mean rank 56.23.)
From the Kruskal-Wallis one-way analysis of variance
for the total Webster scale change score, a X2 ,3 = 4.83, (p = 0.18)
indicates no evidence of differences in changes between the four
groups.
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Results of Multiple Linear Regression Analysis.
Table (48) shows the model which best descibes the
data. Included are the regression coefficients, standard error in
parenthesis and the significance level of the independent
variables.
For the CAMCOG total and the Neurological total (N
score), statistically significant differences were observed between
diagnostic groups. In each case the group means, F-value and
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The table shows for the CAPE subscores of physical
disability, communication and the CAPE total, that age at
diagnosis is a statistically significant factor in explaining the
change score between phases. Since the sign of the regression
coefficient is positive in all cases, this indicates an increase in the
change score, i.e. a deterioration as age at diagnosis increases.
However, the opposite effect is seen for the physical disability
subscore and duration of illness. As duration of illness increases,
the CAPE subscore reduces and hence an improvement is
detected. These findings, and others from this table, are discussed
in the next chapter.
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Genetic Results.
Analysis Of Genotype Frequencies At The APOE,
VDRL-R and ACT Loci In Dementia Patients.
Description of data.
Genotype data on the three loci were received on 119
dementia patients and 152 non-demented controls. For the
dementia patients, additional data were recorded on: DSM3R
diagnosis; sex; age at referral; whether familial or not; duration of
illness; severity rating at first and second assessments. Of the 119
dementia patients, 59 were classified by the DSM3R diagnosis as
'Pure' Alzheimer's, 22 as 'Mixed' Alzheimer's (Alzheimer's
together with Alcohol-related or Multi-infarct dementia), and 38
as non-Alzheimer's. The mean ages at referral of these three
groups of dementia patients were very similar, both to each other
- respectively 58.4, 59.6 and 55.9 - and to the mean age of the
controls - 58.0. The corresponding proportions of males were
respectively 40.7%, 45.5%, 39.5% and 62.5%. There was therfore a
marked difference in sex ratio between patients and controls, but
not between the three patient groups.
Tables G1-G13, give the genetics results and are in the
Results: Appendix.
Analysis of APQE locus.
(In this part of the text, APOEc4, is symbolised by E4.)
Genotype frequencies.
Table (Gl) gives the breakdown according to diagnostic
grouping and genotype. Because the frequency of E2 was low, and
because of the strong prior hypothesis concerning the role of E4,
the genotypes were grouped (for the purposes of statistical
testing) as homozygous E4, heterozygous E4 or non-E4 carrier (i.e.
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having 2, l,or 0, E4 alleles respectively). Also, in the initial
analysis all 81 patients with an Alzheimer's diagnosis, whether
'Pure' or 'Mixed', were grouped together. They are specifically
referred to in the genetics results as the 'Combined' Alzheimer's
group. The overall chi-squared comparing the three groups
(Alzheimer's, non-Alzheimer's and controls) was highly
statistically significant (X ^ = 19.1, 4 d.f., P= 0.00074). However,
of the pairwise comparisons, only that between the Alzheimer's
and controls was significant
(X ^ = 19.5, 2d.f., P= 0.000059), with an excess of E4 carriers in
the patient group. The non-Alzheimer's group did not differ
significantly (at the P=0.05 level) from either of the other two.
The analysis was repeated with the four groupings:
'Pure' Alzheimer's, 'Mixed' Alzheimer's, non-Alzheimer's and
controls. Here the overall chi-squared was again significant (X =
20.5, 6 d.f., P =0.0022). Pairwise comparisons showed that there
were highly significant differences between the 'Pure'
Alzheimer's and controls (X^ =13.9, 2 d.f., P =0.00095), and
between the 'Mixed' Alzheimer's and controls (X ^ =17.9, 2 d.f, P
=0.00013), but not between the non-Alzheimer's and controls
(X^ = 4.90, 2 d.f., P =0.086), nor between the 'Pure' and 'Mixed'
Alzheimer's (X 2 = 0.88, 2 d.f., P =0.65). (N.B. Some P-values
quoted in this paragraph are unreliable, because of small
numbers in some categories; however, the general conclusions are
unaffected).
Analysis of allele frequencies.
Table (G2) is a breakdown of allele frequencies by
patient grouping. Statistical tests gave broadly similar results to
those comparing genotype frequencies. Thus, the overall chi-
squared comparing the three groups ('Combined' Alzheimer's,
non-Alzheimer's and controls) was highly significant (X ^ = 21.2,
4 d.f., P = 0.00029). However, of the pairwise comparisons only
that between the Alzheimer's and controls was significant (X ^ =
20.6, 2 d.f., P = 0.000033), with an excess frequency of E4 in the
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patient group. The non-Alzheimer's group did not differ
significantly (at the P = 0.05 level) from either of the other two.
As in the case of the genotype frequencies, the analysis
was repeated with the four patient groupings. Here the overall
chi-squared was again significant (A 2 = 23.4, 6 d.f., P = 0.00066).
Pairwise comparisons showed that there were highly significant
differences between the 'Pure' Alzheimer's and controls (X 2 =
14.4, 2 d.f., P= 0.00074), and between the 'Mixed' Alzheimer's and
controls (A2 = 14.7, 2 d.f., P = 0.00065), but not between the non-
Alzheimer's and controls (A2 =3.27, 2 d.f., P = 0.19), nor between
the 'Pure' and 'Mixed' Alzheimer's (A2 = 2.35, 2 d.f., P = 0.31). (As
above, some P-values quoted in this paragraph are unreliable).
Hardv-Weinberg equilibrium.
Using the observed allele frequencies in the control
group, the expected numbers of each genotype can be calculated,
under the assumption that the population from which the
controls were drawn is in Hardy-Weinberg equilibrium. The
expected numbers of genotypes 2/2, 2/3, 2/4, 3/3, 3/4, 4/4 were
respectively 1.0, 18.8, 4.1, 86.3, 37.7 and 4.1 (compare with
observed numbers in Table Gl). Small expected numbers for
some genotypes make it unwise to apply standard tests of
significance. However, since the observed and expected numbers
differed by no more than 1, the fit appears to be very close. The
main practical use of this result is that it justifies using expected
rather than observed values in calculations of risk (see below),
leading to estimates with lower standard errors.
Relative and attributable risks.
Table (G3) gives relative risk estimates for 'Combined'
Alzheimer's, for various comparison groups and using both
observed and Hardy-Weinberg expected numbers in the control
categories. Table (G4) gives corresponding values for 'Pure'
Alzheimer's. It can be seen that the estimates are all slightly
higher for the 'Combined' than the 'Pure' group, and that the
effect of using Hardy-Weinberg expected values was to reduce
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the widths of the 95% confidence intervals (though by a rather
small amount in most cases).
It is also possible to calculate the so-called 'population
attributable risk'. This is an attempt to answer the question: if the
risk in E4 carriers were reduced to the same level as in non-
carriers, by how much would the population incidence of the
disease be reduced? It is therefore a some-what hypothetical
concept, but nonetheless gives a measure of the impact of the E4
allele as a cause of Alzheimer's. The answers from the present
data are 31.0% (95% C.L.: 11.4% -46.2%) for 'Combined '
Alzheimer's and 29.5% (95% C.L.: 6.8% - 46.7%) for 'Pure'
Alzheimer's (these figures were derived using observed numbers
in the controls; using Hardy-Weinberg expectations made little
difference).
Characteristics of Alzheimer patients.
Analysis of the recorded characteristics of the Alzheimer
patients, led to the following conclusions (unless otherwise stated
the conclusions apply to both the 'Combined' and 'Pure' groups):
(1) the sex ratio did not differ significantly between genotype
groups (i.e. non-E4 carriers, E4 heterozygotes and E4
homozygotes);
(2) there was a trend towards a higher proportion of familial
cases with increasing numbers of E4 allele; the significance levels
for the regression were 0.038 and 0.049 for the 'Combined' and
'Pure' groups respectively;
(3) there were no significant differences between genotype
groups in the severity at first or second assessment, or in the
change between them;
(4) there were no significant differences between genotype
groups in the duration of illness (N.B. the standard deviations
were extremely large);
(5) there was a significant regression of age at referral on the
number of E4 alleles; for the 'Combined' and 'Pure' groups the
estimates were respectively +1.83 (SE 0.73) years and +2.03 (SE
0.88) for each additional E4 allele;
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(6) the mean age at referral was lower for familial cases than for
non-familial ones in each genotype group, but after adjusting for
genotype, the multiple regressions including familiality as a
predictor, were not significant (at the P = 0.05 level); over all
genotype groups combined, the mean difference was less than 1
year.
Analysis of VDRL-R locus.
Genotype frequencies.
More than 97% of alleles were identified at one of three
loci (97, 106, 109). The remainder were at 115 (2.0%), 112 (0.4%)
and 103 (0.2%). Since none of these 'minor' loci showed any
interesting associations, they were pooled together with 109 for
purposes of statistical analysis (Table G5). No significant
differences were found between any of the groups ('Pure',
'Mixed', 'Combined', Non-Alzheimers and Controls). Because of the
reported association with the 97-allele (Okuizumi et al 1995), the
data were also analysed in terms of individuals with 0, 1 or 2,
97-alleles. Again, no significant differences were found. Table
(G7) summarises the results.
Allele Frequencies.
No significant differences in allele frequencies were
found between any of the groups (Table G6). When all alleles
except for 97 were pooled, there was a single significant
7
difference between the non-Alzheimer patients and controls (X -
= 4.93, 1 d.f., P = 0.026). Table (G8) summarises the results.
Hardy-Weinberg equilibrium.
The espected distribution of control genotypes under the
assumption of Hardy-Weinberg equilibrium was (in the order
shown in Table G5): 14.8, 24.4, 40.9, 10.0, 33.6, 28.2. The
7
observed distribution did not differ significantly from this (X ~ =
1.94, 3 d.f., P = 0.58).
Relative and attributable risk.
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There seemed little point in calculating these for the
VLDL-R locus, since no significant associations were found.
Characteristics of Alzheimer patients.
Similar analyses were carried out for the VLDL-R locus
as for APOE. The only significant results were an increased level
of recorded familiality in patients with at least one 106-allele
(68% vs. 31%, A2 = 7.42, 1 d.f., P = 0.0065), and an increased
proportion of the highest severity rating at first assessment in
patients lacking a 97-allele (76% vs. 57%, A2 = 7.92, 1 d.f., P =
0.0049). There was a similar, though less marked, effect in the
severity rating at second assessment.
Analysis of ACT locus.
Genotype frequencies.
No significant differences in ACT genotype frequencies
were found between any of the groups ('Pure', 'Mixed',
'Combined', Non-Alzheimers and Controls). See Tables (G9) and
(Gil).
Allele frequencies.
No significant differences in ACT allele frequencies were
found between any of the groups. See Tables (G10) and (G12).
Hardv-Weinberg equilibrium.
The expected distribution of control genotypes under the
assumption of Hardy-Weinberg equilibrium was: 35.54 (TP),
75.92 (AT), 40.54 (AA). The observed distribution differed
significantly from this (A2 = 5.87, 1 d.f., P = 0.015).
Relative and attributable risks.
As with the VDRL-R locus, there seemed little point in
calculating these, since no significant associations were found.
212
Charateristics of Alzheimer patients.
Similar analyses were carried out as for VDRL-R and
APOE. No significant results were found.
Further Comments.
In these analyses, each locus has been analysed
independently. Also, the influence of covariates, such as sex, has
been ignored. This may be unwise, since there was a gross
disparity between the sex ratios of cases and controls. The best
way to deal with these problems is to use logistic regression
methods, which allow one to model the risk as a simultaneous
funtion of all potentially predictive variables - in this case
genotypes at all loci and sex.
Further Analysis Of Genotype Frequencies At The
APOE, VDRL-R And ACT Loci In Dementia Patients:
Results Of Logistic Regression.
Background and methods.
In the previous analysis, each locus was examined
independently of all others as a possible risk factor for
Alzheimer's disease. Also no account was taken of the large
discrepancy in the sex ratio between cases and controls, which
resulted largely from the method of sampling the latter. In order
simultaneously to investigate the effects of all loci, and to allow
for the biased sex ratio in the controls, logistic regression
analysis can be used. This is a multiple regression procedure
which models the logarithm of the odds ratio as a linear function
of whatever predictor variables required. The model is:
log [ P ] = B0+ BjXj + B2X2+
f-P
P denotes the probability of being affected.
X]X2 represent predictor variables
B0BjB2 are coefficients reflecting the influence of each predictor
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The coefficients themselves are estimated, together with
standard errors and correlations, using maximum likelihood.
Furthermore, standard methods exist for judging whether the
influence of any particular predictor is statistically significant (at
say the p=0.05 level), either alone or in conjunction with other
variables. By starting from a basic model with no predictor
variables at all, then adding them one at a time according to their
statistical significance and stopping when no more can be found,
there is the possibility of building a model that explains the data
with the smallest number of predictors. This is known as the
'forward selection' approach and, although it is not guaranteed to
give an identical result to that obtained by other methods, it
usually does.
The predictor variables used in the analysis are listed
and defined in Table (G13). Note that two variables are defined
for each allele. In each case, the first variable represents a
contrast between non-carriers and carriers, while the second
represents one between homozygous carriers and the rest
(heterozygous carriers plus non-carriers). Although there are
many different ways of defining contrasts, a maximum of only
two can be included in any analysis, and any set of two will lead
to the same final result.
Results.
As a check that the procedure was correctly
implemented, a model was fitted with predictors APOE. f and
APOE.2 only. The relative risks were calculated from the
estimated B-values and, as expected, were found to be identical
to those obtained from the previous analysis. The confidence
intervals were also identical.
All variables and their interactions were put into a
'forward selection' analysis with p=0.05 as the criterion for
including predictors. For the pure Alzheimer data, only SEX
(p=0.0056), APOE.2 (p=0.0011) and VDRL.f06.1 (p=0.0176) were
selected, while for the combined Alzheimer data, SEX (p=0.0040),
APOE.f (p=0.051), APOE.2 (p=0.0036) and VDRL.106.1 (p=0.0f85)
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were selected. The effect of AP0Ee4 was therefore highly
significant, as previously, and the estimates of relative risk
associated with them were very similar. In interpreting these
results however, it must be bourne in mind that the SEX variable
in itself is uninformative - it simply adjusts for the bias in
sampling the controls. In effect, it allows us to estimate a pooled
risk for the two sexes from data on each sex separately. What is
important is that there were no significant interactions between
SEX and any other variable i.e. there was no evidence that any of
the risks differed significantly between the sexes. The coefficient
of VLDLR. 106.1 was positive, indicating a protective effect in
those carrying at least one copy of this allele. Interestingly, the
effect was not significant, or only marginally so, when this
variable was considered on its own. This explains why it was not
detected by the previous analysis, and illustrates the usefulness
of the logistic regression approach. However, the effect was
considerably smaller than that in APOEe4 homozygotes; the
relative risk for 106-non-carriers to carriers was estimated as
2.33 (95% C.I. 1.16-4.67) for pure Alzheimer's and 2.11 (95% C.I.
1.13-3.92) for the combined Alzheimer group.
Results: Appendix.
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(all tables in this section numbered independently from the rest of the
chapter)
Descriptive Statistics for CAPE and CAMCQG bv group.
I. CAPE-BRS:
An increase in these scores indicates a deterioration.
i) Physical Disabiltv,
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 6.40 3.68 0 12 59* 8.14 4.60 0 31
MID 13 7.69 2.90 2 11 13 8.77 2.80 3 11
Ale 13 4.00 2.97 0 8 13 4.85 3.63 0 11
Comb 24 7.33 3.16 2 12 24 8.46 2.47 3 12
* One Alzheimer case was not reassessed as the family refused
the second visit.
The analysis was done using those cases who were DSM3R +ve at
the first assessment, i.e. excluding the 2 cases who became so at
the second assessment.
These points apply to all the following tables.
ii). Apathy.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 6.80 3.37 0 10 59 7.75 3.00 0 10
MID 13 7.85 2.27 2 10 13 8.15 1.95 3 10
Ale 13 5.23 3.22 0 10 13 5.38 3.33 0 10
Comb 24 7.92 2.47 2 10 24 8.83 1.74 4 10
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iii). Communication.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 2.05 1.47 0 4 59 2.75 3.01 0 23
MID 13 1.85 1.52 0 4 13 2.15 1.63 0 4
Ale 13 0.31 0.48 0 1 13 0.31 0.63 0 2
Comb 24 2.33 1.27 0 4 24 2.75 1.26 0 4
iv). Social Disruption.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 1.67 1.69 0 6 59 1.86 1.81 0 6
MID 13 2.15 1.99 0 5 13 1.62 1.61 0 4
Ale 13 0.85 1.28 0 4 13 1.62 1.71 0 4
Comb 24 2.50 1.56 1 5 24 2.04 1.49 1 5
v). Total score.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 16.92 8.58 0 30 59 20.49 8.82 0 43
MID 13 19.54 7.09 4 28 13 20.69 6.25 6 28
Ale 13 10.38 6.78 1 18 13 12.15 7.57 0 24
Comb 24 20.08 6.88 5 29 24 22.08 4.69 9 29
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II. CAMCOG.
A decrease in these scores indicates a deterioration.
i). Total.
Assessment I. Assessment II.
n mean SD Min Max n* mean SD Min Max
Alz 60 22.62 30.90 0 94 48 19.35 31.14 0 98
MID 13 18.15 19.92 0 48 11 15.64 16.19 3 44
Ale 13 57.00 21.84 19 85 10 64.40 25.11 4 90
Comb 24 15.54 27.33 0 96 22 12.82 27.13 0 97
* The second assessment of the CAMCOG was not done in 19 cases,
18 who died and 1 who was refused. This applies to all the
following tables.
ii). Orientation.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 2.33 3.41 0 10 48 1.73 3.06 0 10
MID 13 1.62 2.10 0 5 11 1.45 1.57 0 4
Ale 13 5.00 2.48 2 9 10 5.60 3.24 0 10
Comb 24 1.63 2.83 0 10 22 1.09 2.54 0 10
iii). Language.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 7.63 10.09 0 29 48 6.33 9.73 0 28
MID 13 7.23 7.82 0 18 11 6.00 6.10 0 18
Ale 13 21.77 6.80 7 29 10 22.00 6.85 4 27
Comb 24 5.88 9.19 0 29 22 4.36 8.81 0 27
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iv). Memory.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 4.23 6.30 0 21 48 4.17 6.97 0 26
MID 13 3.38 3.69 0 8 11 2.55 2.70 0 7
Ale 13 10.31 4.53 3 17 10 12.20 5.38 0 18
Comb 24 2.58 5.39 0 21 22 2.41 5.70 0 24
v). Remote.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 1.15 1.82 0 5 48 0.96 1.65 0 6
MID 13 1.23 1.42 0 3 11 1.00 1.10 0 3
Ale 13 3.00 1.63 1 6 10 3.10 2.02 0 6
Comb 24 0.79 1.74 0 6 22 0.73 1.78 0 6
vi). Recent.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 0.70 1.29 0 4 48 0.65 1.19 0 4
MID 13 0.38 0.51 0 1 11 0.45 0.52 0 _j 1
Ale 13 1.69 1.11 0 3 10 1.90 1.10 0 4
Comb 24 0.50 1.06 0 4 22 0.36 0.95 0 4
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vii). Learning.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 2.38 3.89 0 14 48 2.56 4.54 0 17
MID 13 1.77 1.88 0 4 11 1.09 1.38 0 4
Ale 13 5.62 2.81 1 9 10 7.20 3.68 0 12
Comb 24 1.29 2.90 0 11 22 1.32 3.21 0 14
viii). Attention.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 1.00 2.03 0 7 48 0.92 2.08 0 7
MID 13 0.08 0.28 0 1 11 0.18 0.60 0 2
Ale 13 3.62 2.66 0 7 10 4.60 2.50 0 7
Comb 24 0.67 1.99 0 7 22 0.59 1.56 0 5
ix). Praxis.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 2.95 4.03 0 12 48 2.33 3.84 0 12
MID 13 2.08 2.53 0 7 11 2.09 2.21 0 6
Ale 13 7.00 3.96 0 12 10 8.20 3.43 0 12
Comb 24 1.75 3.57 0 12 22 1.68 3.47 0 12
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x). Calculation.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 0.38 0.72 0 2 48 0.29 0.62 0 2
MID 13 0.31 0.48 0 1 11 0.18 0.40 0 1
Ale 13 0.92 0.76 0 2 10 1.20 1.03 0 2
Comb 24 0.38 0.71 0 2 22 0.27 0.70 0 2
xi). Abstract thinking.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 1.42 2.47 0 8 48 1.21 2.42 0 8
MID 13 1.38 2.14 0 6 11 1.27 2.00 0 5
Ale 13 3.69 2.66 0 8 10 4.80 2.82 0 8
Comb 24 1.00 2.23 0 7 22 1.09 2.60 0 8
xii). Perception.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 2.67 3.41 0 10 48 2.38 3.59 0 10
MID 13 2.08 2.50 0 6 11 1.91 2.07 0 5
Ale 13 4.69 2.21 0 7 10 5.80 2.97 0 10
Comb 24 1.67 2.91 0 9 22 1.32 2.70 0 9
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xiii). MSE.
Assessment I. Assessment II.
n mean SD Min Max n mean SD Min Max
Alz 60 6.62 8.70 0 29 48 5.08 7.63 0 27
MID 13 5.08 5.36 0 13 11 5.18 5.06 0 14
Ale 13 16.69 6.38 5 25 10 17.90 7.43 2 27




Numbers of cases bv DSM3R patient grouping and APOEe4
genotype.
2/2 2/3 2/4 3/3 3/4 4/4 Total
'Pure' 0 3 1 27 19 9 5 9
A 1 z
'Mixed' 0 3 0 6 8 5 22
A 1 z
Non-Al? 2 3 0 1 8 1 1 4* 38
Control 1 18 5 87 37 4 152
Total 3 27 6 138 75 22 271
* One MID, 2 Alcohol and one 'other', case cf82.
For the McKhann grouping, 75% of the McKhann +ve
group, have the 4/4 allele combination.
Table (G2).
APOEe4 allele frequencies bv patient grouping.
E2 E3 E4 Total
•Pure' 4 76 3 8 118
A 1 z
' Mixed' 3 23 1 8 44
A 1 z
Non-Alz 7 5 0 19 76
Controls 2 5 229 50 304
Total 39 378 125 542
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Table (G3)
Relative risk estimates for 'Combined' Alzheimer's.
using observed numbers using H-W expectation
95% limits. 95% limits.
R.risk lower upper R.risk lower upper
E4 homo/
non-E4
9.51. 2.95 30.66 9.27 3.92 21.92
E4 hetero/
non-E4
1.81 0.99 3.31 1.82 1.03 3.23
E4 carr/
non-E4 ca
2.48 1.42 4.33 2.49 1.44 4.30
E4 homo/
rest
7.73 2.45 24.37 7.52 3.46 16.34
E4 homo/non-E4 = E4 homozygotes/non-E4 carriers.
E4 hetero/non-E4 = E4 heterozygotes/non-E4 carriers.
E4 carr/non-E4 ca = E4 carriers/non-E4 carriers.
E4 homo/rest = E4 homozygotes/rest.
Table (G4)
Relative risk estimates for 'Pure' Alzheimer's.
using observed numbers using H-W expectation
95% limits. 95% limits.
R.risk lower upper R.risk lower upper
E4 homo/
non-E4
7.95 2.29 27.63 7.74 2.96 20.24
E4 hetero/
non-E4
1.68 0.86 3.28 1.69 0.89 3.22
E4 carr/
non-E4 ca
2.23 1.20 4.13 2.24 1.22 4.11
E4 homo/
rest
6.66 1.96 22.57 6.48 2.69 15.62
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Table (G5).
Numbers of cases by patient grouping and VLDL-R genotype.





8 4 22 3 10 12 59
'Mixed'
A 1 z
5 2 6 1 6 2 22
Non-Al2 9 5 11 2 9 2 38
Control 17 21 40 9 39 26 152
Total 39 32 79 15 64 42 271
X includes alleles 103, 109, 112 and 115.
Table (G6). VLDL-R allele frequencies bv patient grouping.
97 106 X Total
'Pure'Alz 42 20 56 118
'Mixed' Alz 18 10 16 44
Non-Alz 34 18 24 76
Controls 95 78 131 304
Total 189 126 227 542
X includes alleles 103, 109, 112 and 115.
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Table (G7). Tests of significance for differences in VLDL-R
genotype frequencies between groups.
6 classes 3 classes
Comparing X**2 DF P X**2 DF P
A 1 1 14.13 15 0.52 6.64 6 0.36
groups
'Pure'vs 3.47 5 0.63 1.07 2 0.58
'Mixed'
'Pure'vs 5.41 5 0.37 0.72 2 0.70
Controls
'Mixed'v 3.21 5 0.67 2.34 2 0.31
Controls
Non-Alz 6.52 5 0.26 4.89 2 0.087
vs.
Controls
'Comb'.v 4.95 5 0.42 1.5 3 2 0.47
Controls
Notes: For the 6-class analysis, alleles 103, 109, 112 and 115
were pooled. For the 3-class analysis, all alleles except 97 were
pooled. Many of the P-values are approximate because of small
numbers in some categories.
226
Table (G8). Tests of significance for differences in VDRL-R allele
frequencies between groups.
3 c asses 2 classes
Comparing X**2 DF P X**2 DF P
A 1 1 9.76 6 0.14 5.75 3 0.12
groups
' Pure'vs 1.71 2 0.43 0.39 1 0.5 3
'Mixed'
'Pure'vs 3.64 2 0.16 0.73 1 0.39
Controls
'Mixed'v 1.65 2 0.44 1.64 1 0.20
Controls
N o n - A1 z 5.33 2 0.070 4.93 1 0.026
vs.
Controls
'Comb'.v 3.43 2 0.18 1.59 1 0.21
Controls
Notes: For the 3-class analysis, alleles 103, 109, 112 and 115
were pooled. For the 2-class analysis, all alleles except 97 were
pooled.
Table (G9). Numbers of cases by patient grouping and ACT
genotype.
TT AT A A Total
' Pure'Alz 15 30 14 59
'Mixed'Alz 8 9 5 22
Non-Alz 15 14 9 38
Controls 43 61 48 152
T otal 81 114 76 271
X includes alleles 103, 109, 112 and 115.
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Table (G10). ACT allele frequencies by patient grouping.
T A Total
' Pure'Alz 60 58 118
' M i xed' A lz 25 19 44
Non-Alz 44 32 76
Controls 147 157 304
Total 276 266 542
X includes alleles 103, 109, 112 and 115.
Table (Gil). Tests of significance for differences in ACT genotype
frequncies between groups.
Comparison X**2 DF P
All groups 5.02 6 0.54
'Pure* vs 1.01 2 0.31
'Mixed'
'Pure' vs 2.15 2 0.34
Controls
'Mixed' vs 0.93 2 0.63
Controls
Non-Alz vs 1.96 2 0.38
Controls
'Comb'.vs 2.00 2 0.37
Controls
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Table (G12). Tests of significance for differences in ACT allele
frequencies between groups.
Comparison X**2 DF P
All groups 2.89 3 0.41
'Pure' vs 0.25 1 0.62
'Mixed'
'Pure' vs 0.12 1 0.73
Controls
'Mixed' vs 0.79 1 0.3 7
Controls
Non-Alz vs 1.85 1 0.17
Controls




Definition of variables used in logistic regression analysis.
Variable Definition
SEX = -1 if m
= +1 if f
AP0E.1. = 1 if #of p4-alleles is 0
= 0 if #of e4-alleles is 1
= 0 if #of e4-alleles is 2
APOE.2 = 0 if #of e4-alleles is 0
= 0 if #of e4-alleles is 1
= 1 if #of e4-alleles is 2
VLDLR.0.97.1 = 1 if #of 97-alleles is 0
= 0 if #of 97-alleles is 1
= 0 if #of 97-alleles is 2
VLDLR.0.97.2 = 0 if #of 97-alleles is 0
= 0 if #of 97-alleles is 1
= 1 if #of 97-alleles is 2
VLDLR. 106.1 = 1 if #of 106-alleles is 0
= 0 if #of 106-alleles is 1
= 0 if #of 106-alleles is 2
VLDLR. 106.2 = 0 if #of 106-alleles is 0
= 0 if #of 106-alleles is 1
= 1 if #of 106-alleles is 2
VLDLR. 109.1 = 1 if #of 103+109+11 2+1 15-alleles is 0
= 0 if #of 103+109+112+11 5-alleles is 1
= 0 if #of 103 + 109+112+115-alleles is 2
VLDLR. 109.2 = 0 if #of 103+109+112+1 15-alleles is 0
= 0 if #of 103+109+112+115-alleles is 1
- 1 if #of 103+109+112+115-alleles is 2
ACT.E.1 = 1 if #of T-alleles is 0
= 0 if #of T-alleles is 1
= 0 if #of T-alleles is 2
ACT.E.2 = 0 if #of T-alleles is 0
= 0 if #of T-alleles is 1




From such a wide-ranging set of data and possible
analysis, what are the useful points to raise and discuss in this
section? The results have included the identification, and clinical
and genetic description, of the study group. Measurement of
change, and the identification of associations with it, have also
been attempted.
There are various aspects of the design of this study,
both good and bad, which can be commented upon. It is also
possible to compare the results in the context of other studies,
but much of the work stands alone, without the possibility of
comparison.
Arising from the discussion will be indications of data
analysis and research ideas that can be persued in the future,
based on this piece of work.
Discussion of the Study Ascertainment.
Where the cases were from.
During the course of the study, planning for a service to
provide for the population of people with younger-onset
dementia has become of interest locally. For such planning,
epidemiological data is required, to provide a guide as to the
number of expected cases in the region. Can the data obtained in
this study help in this? The answer is yes, but only with a clear
awareness of the biases introduced in the study. These biases will
be discussed here. The Introduction: Epidemiological Issues
introduced some of these points but not specifically with respect
to the study. An approach to provide epidemiological data is
discussed, at the end of this section on the ascertainment.
The aim of the study, was to identify and describe a
population of live cases of presenile dementia in the Lothian area.
The use of the Lothian Psychiatric Case Register (LPCR), enabled
an efficient starting point for the identification of cases, but only
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included those people who had been referred to the service. For
this reason, the neurology case records were also investigated.
However, it is likely that this case finding method was not
entirely comprehensive, although these would have been the
most likely referral specialities. In order to ascertain all cases, all
individual general practitioners and residential units would also
have had to have been approached.
Cases of Down's Syndrome-related dementia were not
included in the study. They would not have been recorded in the
LPCR, unless requiring a separate psychiatric referral. No cases of
AIDS-related dementia were identified for the study, and this
was in part due to the separate service for the AIDS-related
cases, based at the City Hospital. Only 15 cases of Huntington's
Disease were found from the search, whereas it is likely that a far
greater number of cases exist, but are not found by the
ascertainment method used.
Another group of cases who would be hard to identify,
would be people with chronic psychiatric illness, in long-term
care, who go on to develop dementia. Cases of Alcohol-related
dementia would be a difficult group to trace, unless they were
severely affected and under the care of the National Health
Service.
Issues about the accuracy and completeness of the
Scottish Mental Health inpatient data, are discussed by McGonigal
et al (1992a). They review the limitations of the data obtained
from this computerised record of patients admitted and
discharged from, or who died in Scottish Mental Hospitals. 93% of
cases were identified under a variety of different diagnostic
codes, 17% of the cases were not identified and 23% were
wrongly classified. Methods of retrospective study, using death
certification, have been found to under-report the cases of
dementia, see Morgan and Clarke (1995), and Newens et al,
(1993b).
When looking at Neurology Records, the cases included
for the study clearly stated dementia. However, in the cases of
Parkinson's Disease, where a dementing process could have been
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a part of, but not necessarily the overriding feature of the illness,
cases may not have been identified. It would be necessary to
review all such cases for more precise epidemiological figures.
This study only included the cases with an established diagnosis
of dementia.
Inclusion of Alcohol-related Cases.
The inclusion of cases of Alcohol-related diagnoses will
be discussed here. The identification of heavy alcohol
consumption as a risk factor, will often preclude the inclusion of
an individual to a sample of more purely defined cases of, for
example, Alzheimer's Disease. However, it would appear that of
all individuals who drink heavily, only some go on to develop a
definite and irreversible cognitive impairment, possibly of a
declining nature. The pathology of alcohol-related damage and
other aetiologies, may often co-exist and even act to aggravate
each other. Also, the overlap between Korsakoff s Psychosis and
Alcohol-related dementia is unclear, see Lishman (1986). The
criteria for Korsakoff s Psychosis have been described by Deary et
al (1991), but the data available on the investigations done on
this group, was often incomplete, and the diagnosis had been
assumed.
The analysis has revealed this group to have a distinct
pattern of symptoms and pattern of decline. Whether the
condition would continue to improve, remain the same, or
deteriorate over time and the effect of continued drinking, would
require a longer period of follow-up. As discussed, the accurate
documentation of the amounts of alcohol previously consumed is
difficult.
Saunders et al (1991), looked at the relationship
between drinking history and current psychiatric morbidity.
Explaining the relationship between alcohol and dementia,
presents problems. Investigation to examine the risk factors for
SDAT, have failed to identify alcohol as a significant risk factor.
But as already stated, in general, these studies select and
investigate what is presumed to be a single diagnostic entity.
233
They therefore employ inclusion criteria specifying the absence
of indicators of past or present alcohol abuse. Here, they found
heavy drinking as a risk factor for depression and dementia in
elderly men. They suggest that maybe a higher proportion of
cases of dementia are alcoholic than was previously suspected.
This however does not account for the delay in onset of
detectable cognitive deficit following cessation of heavy alcohol
intake. It may be that chronic alcohol intake may cause
premature ageing of the brain.
Case Note Diagnosis.
Series such as that of Tomlinson et al (1970), have
provided percentages of the different dementia types found at
post-mortem in their series. It is of interest to look at the case
note diagnoses of the sample. The most interesting feature of this,
is the 25% of cases who have a case note diagnosis of atypical,
mixed or uncertain type dementia. This appears to be a more
commonly used category than for an elderly population. It may
reflect the greater degree of uncertainty in diagnosis, at
presentation of these conditions.
It may be hypothesized that the Lothian study would
show a greater percentage of alcohol-related cases than would a
more rural area, and perhaps geographically reveal a higher
incidence than other parts of the U.K. with correspondingly lower
drinking rates.
Case Non-Inclusion.
Cases found to have deceased on inspection of the notes,
were excluded. Another bias which the study has, is that the
cases of younger-onset dementia seen, are likely to be less
rapidly declining than cases which would have declined more
quickly and died. Taking the sampling period further back than
1988 found that most cases were deceased, so the sampling
frame of 1988 to the end of 1993 was kept.
Further biases introduced into the sample, were at the
stage of exclusion of cases of Huntington's Chorea, Down's
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Syndrome, and major head injury, before the cases were
contacted. Examples of head trauma were following: a road traffic
accident; subarachnoid haemorrhage; or hypoxia as a result of
overdosage. In these situations there was a defined and
recognisable insult precipitating the disorder. In Huntington's
Chorea, the underlying genetic mechanism has already been
discovered, see Introduction: Genetics. This group of subjects was
also felt to be sufficiently different in presentation to be less
suitable for the study. Cognitive decline is not a primary element,
and the neurological and physical problems would not have been
adequately assessed by the test battery chosen. In the pilot
study, one case of Huntington's was included but was later
excluded from the study.
Down's Syndrome cases likewise had a clear
chromosomal cause for their dementia, and furthermore, there
would be difficulties in testing this group of people using the
instruments chosen for this study. It is difficult to establish the
evidence for cognitive decline in the situation where there is
premorbid impairment, see Royston et al (1994). The need to
plan a service for younger people with cognitive impairment,
including such groups, is discussed in the Introduction:
Epidemiological Issues.
It would also be of interest to know more about the
cases inwhich permission was not granted to participate in the
study, either by the General Practitioner or the family. It could be
that the families most under stress, felt unable to cooperate, so
that some severely disturbed cases were not included. This would
introduce a bias, by not including the more disturbed cases. The
proportion of cases at home, or in long-term care, who were
refused for the study, would also be of interest.
The cases found to be unsuitable, are commented upon
in the Results. The majority of these were found to be cases of
non-progressive cognitive decline, but only a longer-term
follow-up of such cases would effectively exclude them. The other
main group was of non-progressive damage due to head injury.
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Can the figures be used to estimate the number of cases
of presenile dementia in Lothian?
The nature of a case finding study such as this, is that it
has led to a large number of exclusions (431 out of 557 potential
cases). A total of 123 cases were found to have deceased, which
does not include an estimate from the missing cases. When
looking at the other 299 exclusions, a large proportion have been
excluded for reasons pertinent only to the study itself (e.g. cases
refused, 40; untraceables, 23; Down's Syndrome and Huntington's
Chorea, 19; Unsuitables, 21). A large number of these, could be
legitimate cases, and should be included (or account taken of
them) for the purpose of calculating prevalence rates. The other
major source of exclusions can be generally classified under false
positives (e.g. wrong diagnosis, 116; wrong age, 16; out of area,
14). This study has not however been able to detect false
negatives - those who had the right diagnosis but were wrongly
coded, those who were in the right age group but wrongly
recorded etc. The study is therefore biased toward excluding false
positives but not including false negatives.
As has already been mentioned, a hospital study, by its
nature, is biased towards identification of the more severe end of
the spectrum of any disease. People with mild or moderate
symptoms, who do not go to their CPs or are not referred by their
GPs to the specialist services, or who are misdiagnosed, are not
included. Furthermore, certain types of dementia have not been
included: cases of related to head injury, Aids, Huntington's and
Down's are either positively excluded or underestimated.
Although the criteria used for inclusion and exclusion of
cases in this study are directed toward achieving the aims of this
particular study, its findings have to be modified to reach an
estimate of all cases of presenile dementia in Lothian.
Calculating the Incidence Rate.
To compare the Lothian incidence rate with those found
elsewhere, the people who were 65 years old at the time of
diagnosis would have to be excluded.
An estimate of the number of cases that were not
included but were likely to have been cases is needed. One way
to do this would be calculate the percentage of the definite
dementia group from the total seen, and apply this percentage to
the group of cases who had died, refused and were untraced. This
could be done for the categories in the DSM3R groupings and the
McKhann groupings. The incidence rates could be calculated using
the Census data for the Lothian Region (1991). Annual incidence
would be estimated by dividing by 6, since the years 1988 -
1993 provide 6 years of data.
Calculating the Prevalence Rate,
To compare the Lothian point prevalence figure with
those found elsewhere, the people who had reached the age of 65
would have to be excluded. For these figures, none of the deaths
of included individuals should have occurred before the end of
the ascertainment period (31/12/93).
After the First Assessment.
The data set for this study is extremely large, and
selected areas are discussed here.
Diagnosis Application.
This has already been discussed in the chapter on
Method: Contact. The issue as to the subjective nature of clinically
defined criteria, has been raised. It is interesting to see how well
the APOE allele typing corresponds to the Alzheimer's group, as
defined by the DSM3R criteria.
For the most clear distinction between the various
aetiologies seen for the study, the DSM3R groupings have been
used. As mentioned previously, the inclusion of overlap groups
allowed for cases inwhich the known risk factors were
sufficiently strong to weigh equally in the final diagnosis. By the
second assessment there were 24 cases who overlapped between
Alzheimer's and other DSM3R diagnostic groups. As stated, only
one case overlapped between groups not involving Alzheimer's
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(the Alcohol/Multi-infarct group). As alcohol represents a risk
factor for cerebrovascular disease, and possibly also for Multi-
infarct dementia, it would not have been surprising to find more
overlap between these two groups, see Fisman et al (1996).
As described in the Results, the DSM3R and McKhann
groups are equated. The McKhann criteria state that the diagnosis
of Alzheimer's Disease can only be made: "in the presence ofa
second systemic or brain disorder not considered to be the
primary cause", but this requires some subjective judgement as
to the primary cause. For this reason, three cases met the DSM3R
Alzheimer's criteria, but not the McKhann probable criteria, and
three cases were in the DSM3R Alzheimer's plus other group, but
not the McKhann group. The McKhann criteria are stricter than
the DSM3R criteria. It should however be noted, that some
individuals classified in this way, had not had complete
investigations recorded.
It is likely that the majority of the case note diagnoses
of uncertain, atypical or mixed aetiology, infact become classified
in the DSM3R Alzheimer group. Application of the DSM3R criteria
for Alzheimer's Disease is likely to include several other forms of
presenile dementia. For example, if Lewy Body type dementia in
the elderly does represent the second commonest cause of
dementia, it will be likely to be represented here by DSM3R
Alzheimer's Disease. Frontal type dementias have also been said
to be commoner amongst the presenile dementia population, and
only specific criteria could distinguish these from the umbrella
heading of Alzheimer's Disease as used here. The application of
these other criteria to the data set would be of future interest.
The accurate application of the diagnostic criteria was a
difficult part of the study process, and of crucial importance. It
also provides a base-line, so that cases of cognitive impairment,
not fulfilling the dementia criteria, are excluded. Investigating
who of this possible group go on to develop dementia, would
require a study with longer follow-up.
It is interesting to note that the cases which did not
meet the criteria for dementia when seen for the study, had been
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clinically diagnosed as having the condition at some stage
previously. Hence the change is not only in the direction of
becoming demented.
Severity Rating.
The DSM3R severity criteria are based on rather general
description, depending on the level of independence of the
individual. This means that the severity rating will not only
depend on the individual's level of functioning, but also on the
physical setting of their care. There is a subjective element to the
application of such criteria.
The changes in severity over the year between
assessments provides a crude measure of the decline. It was
necessary to consider a group intermediate to the moderate and
severe categories, that of moderate-severe. This was for the
individuals who although still at home and perhaps not receiving
the same level of nursing care as in hospital, were never the less
extremely impaired and significantly declined from the first visit.
Risk Factors.
The study is not a true epidemiological one, comparing a
group of early-onset dementia cases with a non-demented cohort.
However, it is possible to comment in a descriptive way, on a
range of risk factors looked at.
Sex Differences.
McGonigal et al (1993), suggest that female sex is
associated with presenile Alzheimer's Disease. This finding was
challenged as an artefact in letters following the publication.
The results in the study show that there are more
females than males in all categories but the DSM3R Alcohol-
related group.
Age of Onset.
The difficulty in the objective measurement of this has
been discussed in the Introduction: Epidemiological Issues. The
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age at referral for diagnosis provides a standard which is used as
an alternative to the age of onset, in some parts of the analysis.
In the genetic studies by Mullan et al (1993), it was
found that age of onset demarcated aetiological subtypes of
familial Alzheimer's Disease. The early-onset forms they found,
conformed to autosomal dominant patterns of inheritance,
whereas later-onset forms appeared more complex. They
suggested that early-onset Alzheimer's Disease could be
subdivided by genetic aetiology, with which the age of onset
correlated. This is also shown in figure (6) of the Introduction:
Genetics.
The average age at referral, in years, in this study for
cases of Alzheimer's was 58; Mixed Alzheimer's, 59; MID, 62; and
Alcohol-related, 55.
In the analysis of the APOE results, there was a
significant regression of age at referral on the number of APOEe4
alleles, in the Alzheimer group. It is also an important variable to
consider in looking for heterogeneity, and was investigated as a
predictor of decline. It has been demonstrated to be statistically
significant in explaining the change of scores in some assessments
between the phases. Deterioration (in the CAPE-BRS total and
physical disability and communication difficulty subscores, and
the Webster score), was associated with an older age at referral.
But this may be due to the fact that cases of Alcohol-related
dementia (with the pattern of less deterioration) had a younger
average age at referral.
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Socio-Economic Group (Class).
The distribution of socio-economic group (class I-V)
within the group, compared with that of the population, is of
interest because of the possible link between deprivation, and the
subsequent development of dementia.
in the study by Whalley etal(1995a&b), looking at the
epidemiology of presenile Alzheimer's dementia in Scotland, the
group reported that socio-economic deprivation was related to
vascular dementia. This would predict that people in the lower
socio-economic groups (classes IV and V) would be more prone to
vascular problems and secondary dementia associated with this.
There were no marked differences apparent in the study
group, but there was a higher percentage of individuals in socio¬
economic group class IV, in the MID and Alcohol-related DSM3R
groups.
Education and Premorbid Intelligence.
The possible protective effect of education and
premorbid intelligence on the subsequent development of
dementia, is a debated issue. It is reviewed by Katzman (1993).
Work done with older subjects, has found no association
between early educational achievement and a protective effect
with respect to Alzheimer's Disease, see Katzman et al (1989).
Fratiglioni et al (1991), revealed differences between educational
levels in total prevalence ratios for dementia, but not with
respect to the diagnosis of Alzheimer's Disease. Ott et al (1995),
looked at the association between education in Alzheimer's
Disease and vascular dementia, and found an inverse dose-
response relationship between education and dementia, in
particular for Alzheimer's Disease. This association was not
explained by cardiovascular disease co-morbidity.
Extending the theme further, the beneficial effect of
continued mental stimulation is possibly able to act as a
protective factor. Orrell and Sahakian (1995), concluded that
although more research is needed in this area, there may be truth
in the statement "use it or lose it".
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The IQ.distribution, in subjects in this study, when
calculated from the small number of subjects able to do the
NART, showed a normal distribution. There was not a significant
difference between the mean IQof the DSM3R groups.
Down's Syndrome
Heston and Mastri (1977), initially reported an increased
occurrence of Down's Syndrome (DS), among the relatives of
individuals with Alzheimer's Disease. Sadovnick et al (1994),
studied the rate of Down's Syndrome among 578 offspring of 206
women with Alzheimer's Disease. The data did not suggest that
women who subsequently developed Alzheimer's Disease had a
higher (or lower) rate of Down's Syndrome offspring than
expected. However, Schupf et al (1994), showed familial
aggregation of dementia among mothers of adults with Down's
Syndrome, supporting the hypothesis of a shared genetic
susceptibility to DS and AD.
Tanzi (1996b), reviews the presence of a specific
amyloid p-protein in the brains of Down's syndrome patients,
suggesting a common aetiological pathway for the development of
Alzheimer Disease-related neuropathology. Molecular aspects of
the links between AD and DS are given in the chapter
Introduction: Genetics.
The study enquired in the CAMDEX H interview with the
informant, into the presence of relatives with Down's Syndrome
or mental handicap. There was no significant difference between
the DSM3R groups for this.
Stress.
Orrell and O'Dwyer (1995), explore if stress, or an
abnormal stress control system is involved in the genesis or
exacerbation of Alzheimer's Disease. There is insufficient
evidence to make a case for this yet. Several families wondered
about this as a potential aetiological factor for their relatives with
dementia. No objective measure was available from the study
data to test this hypothesis.
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Head Injury.
Head injury has been demonstrated to be a risk factor
for the development of Alzheimer's Disease. Mortimer et al
(1985), conducted a case controlled study to look at the
frequency of prior head injury assessed in 78 patients with DAT
and 124 matched controls. They found head injury to be a
possible aetiological factor in the development of Alzheimer's
Disease. Mayeux et al (1993), investigated head injury as a risk
factor for Alzheimer's Disease among community dwelling elderly
persons and found severe head injury to be associated with the
disease. Roberts et al (1994), discuss the implications for the
pathogenesis of Alzheimer's Disease, of p-amyloid protein
deposition in the brain after severe head injury. The area is
reviewed by Roses and Saunders (1995). The influence of the
APO&4 genotype on the outcome following head injury, has been
discussed in the Introduction: Genetics.
By DSM3R group, the percentages of the Alzheimer,
Multi-infarct, Alcohol-related and Mixed groups, with a history of
head injury, were respectively 8%, 15%, 28% and 24%.
Blood Pressure.
Although hypertension is a risk factor for
cerebrovascular disease, no definite link has been established
between hypertension and impaired cognitive function.
Hypotension has even been claimed to be a risk factor for the
development of dementia. How the process of hypertension could
cause dementia, is still unconfirmed. White matter lesions
prevalent in late-onset Alzheimer's Disease may represent
vascular lesions which act by disconnecting subcortical from
cortical association pathways. The deposition of p-amyloid has
been shown in animal models to interact with endothelial cells
causing vascular constriction. Superoxide-mediated endothelial
damage may also be related to this process. See Martyn (1996).
Skoog et al (1996), found that hypertension predicted
both Alzheimer's Disease and Multi-infarct dementia.
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The terms of exclusion from the McKhann Criteria are
that "no other condition that could account for the progressive
deficits in memory and cognition should be present". This
necessarily excludes vascular lesions as a cause, but this may
seriously prejudice thinking about aetiology, at a time when
vascular mechanisms are found to possibly contribute to the
development of Alzheimer's Disease.
The percentages of the DSM3R groups, Alzheimer's,
Multi-infarct, Alcohol-related and Mixed, with a history of, or
current hypertension, were respectively 12%, 61%, 14% and 56%.
Family History.
In the chapter Introduction: Genetics, the familial
occurrence of Alzheimer's Disease has been discussed, and the
presence of a family history noted to be found in about 30-50 %
of cases, in series studied.
In a study by Hofman et al (1989), of 198 people with
Alzheimer's Disease, diagnosed before the age of 70 years, 48%
had at least one first-degree relative with dementia, as compared
with 19% of controls. They found familial aggregation of
Alzheimer's Disease and also evidence for familial aggregation of
Alzheimer's Disease with Parkinson's Disease. This latter point
was especially the case for men with earlier-onset of Alzheimer's
Disease. It was suggested that this may point to a joint aetiology
of these diseases.
Van Duijn et al (1993), studied the age at onset and
transmission patterns of Alzheimer's Disease, in the families of
the subjects described by Hofman et al (1989). These subjects
had onset of symptoms before the age of 65 years and were
diagnosed before the age of 70 years. Although the study
confirmed that a dominant major gene is implicated in
early-onset Alzheimer's Disease, the results suggest that other
genetic or perhaps non-genetic factors may account for the
disease in a considerable number of patients.
Korten et al (1993), assessed the risk of Alzheimer's
Disease in first-degree relatives of cases with Alzheimer's Disease.
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No evidence was found that a familial form of Alzheimer's Disease
is more common in those with earlier-onset Alzheimer's Disease
(before the age of 75 years), nor in those who display early,
prominent features of aphasia or apraxia, nor that an Alzheimer's
Disease gene maybe sex linked.
However, in another study by Li et al (1995), with 200
clinically diagnosed Alzheimer Disease cases, and 179 controls,
the finding was different. They investigated the relationship
between probands age at onset of Alzheimer's Disease, with the
risk of primary progressive dementia in the probands' first-
degree relatives. They found patients with an earlier age at onset
of Alzheimer's Disease were more likely to have relatives with
Alzheimer's Disease, than patients with a later age at onset of the
disease. The study of Heston et al (1981), found a similar effect.
Silverman et al (1994), examined the possible age-
related characteristics associated with a more familial variety of
Alzheimer's Disease. They found that for relatives of probands
with Alzheimer's Disease, while the lifetime risk of progressive
dementia is greater than in the relatives of controls, the familial
contribution to the risk, decreases with increasing age.
In this study, the report of a close relative, (in the
majority of cases a first degree relative), having had a dementing
illness, was given in 31% of the sample. No verification of such
reports was possible, but it would be of interest as a further
study to look in more detail at these cases and their families. Of
those with a family history of dementia, for DSM3R Alzheimer's,
this was 37% of the total, Mixed Alzheimers 36%, MID 31% and
less for the Alcohol-related group. There were no statistically
significant differences between the DSM3R groups for any of the
family history features.
The variable of having a family history of dementia, was
of interest in the genetic analysis, and was also investigated as a
possible predictor of decline. No evidence was found that this is a
predictor of change, but from the genetic results, there was a
trend towards a higher proportion of familial cases with
increasing numbers of APOEe4 alleles in Alzheimer cases.
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Duration of Symptoms and Survival.
Linked to the patterns of decline, is the consideration of
the overall duration of symptoms and survival time. The
difficulty here, as with the estimation of illness onset, is having
an objective starting point. Survival is not of particular relevance
to this study as it did not aim to follow up cases to death, but will
be briefly considered. Van Dijk et al (1991), reviewed the
evidence on survival in dementia, and this is discussed by
McGonigal et al (1992b), and Newens et al (1993a), for presenile
dementia.
Another potential area of study, would be to investigate
the study cases who died, and to see if the rates were as
expected. The place and cause of death of individuals, identified
at the stage of: case note assessment; contacting individuals; and
during the follow-up period, could be investigated.
Duration of Illness.
In this sample, there are a group of subjects who appear
to have a long-lasting illness. As mentioned, it may be that the
sample selection has favoured the inclusion of these cases. Of
those who were in long-term care, over 50% had been there for
over 3 years.
The association of genetic type and illness duration was
analysed, but no significant differences found between the
DSM3R groups. Illness duration was also investigated as a
predictor of decline. The data indicates (for cognitive testing) that
a detectable deterioration is associated with a longer duration of
illness. This is rather surprising, as clinically the subjects with
long-standing illnesses were very impaired at both asssessments.
However, the opposite effect was seen for the CAPE-physical
disability subscore, where there is a trend to improvement as the
duration of the illness increases. Clearly, this also, does not fit
clinically. No explanation is apparent for these findings, which
may be the result of artefact.
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Non-Cognitive Symptoms.
The literature in this area refers to Alzheimer's Disease,
and in general does not specifically study a presenile group. In
the following section, psychopathological, affective, behavioural
and neurological symptoms will be discussed. A review of the
findings in other studies will be given, and those of this study
mentioned. The background to the testing in these areas is given
in the Method: Battery, which provides an introduction to the
following discussion.
Psvchopathological Symptoms.
Ballard and Oyebode (1995c), have reviewed the area of
psychotic symptoms in patients with dementia. The majority of
studies have found a prevalence of psychotic symptoms in excess
of 60%, and those with dementia of moderate severity having the
highest prevalence.
In a study by Ballard et al (1995a), 124 patients
referred to an old age psychiatry service and memory clinic with
dementia were studied. 66.9.% were found to have at least one
psychotic symptom. 35% had at least one visual hallucination,
12.9% had at least one auditory hallucination, 48.4% had at least
one delusional belief and 29% had at least one delusional
misinterpretation.
Patterson et al (1990), studied a series of 34 patients
with Alzheimer's Disease, and 21 spousal control subjects and
enquired into noncognitive behavioural symptoms in the week
previously. In the dementia group, delusional or paranoid
features were present in 38%, and hallucinations in 18%.
Jabeen et al (1992), studied the case notes of 37 patients
neuropathologically confirmed with Alzheimer's Disease, for non-
cognitive features during the illness. 11% had exhibited delusions,
6% misidentification syndrome, 14% non-delusional but paranoid
thinking, 14% visual hallucinations, and 3% auditory
hallucinations. Possible explanations for the wide variation in
reported rates of psychotic symptoms in Alzheimer's Disease in
the literature, are discussed.
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Migliorelli et al (1995), studied 103 patients with
probable Alzheimer's disease and found a rate of 20% DSM3R
delusional disorder, the most frequent being paranoid, 71%;
hypochondriacal, 67%; Capgras syndrome, 29%; house
misidentification, 29%; grandiose, 29%. Of these subjects, 76% had
three or more delusions simultaneously. They found no
significant association with age, education and age of onset. The
type and severity of other impairments, such as myoclonus, were
similar for AD patients with and without delusions. However, the
AD patients with delusions had higher mania and anosognosia
scores, (that is, the patient was less aware of their cognitive and
emotional deficits).
Associations have been reported for psychotic
phenomena with a number of other variables, such as older age
of onset, race, a longer course of illness, lower levels of education,
and gender. Ballard et al (1995 b), demonstrated differences in
associations for visual hallucinations and delusions, and found
sensory impairments were associated with both. Delusions were
associated with deafness. Visual impairments were associated
with visual hallucination. Older age was associated with delusions
and later age of onset was associated with visual hallucinations.
The authors suggest that grouping the psychotic symptoms as one
entity may mask important differences.
Work on the psychotic symptomatology found in Lewy
Body Dementia by McKeith et al (1992), found 47.6% of patients
to have visual hallucinations, 19% to have auditory hallucinations
and 57% to have delusions. However, the sample size was small
and the instruments used to detect the phenomena not
structured.
In the series of papers by Burns et al (1990b), disorders
of thought content (delusions and persecutory ideation),
perception, mood and behaviour, were described in 178 patients
with Alzheimer's Disease. In studying disorders of thought
content, they found delusions had occurred in 16% of the sample
since the onset of the illness. Simple delusions of theft and
suspicion were the most common types. Cognitive function at the
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entry to the study, and cognitive deterioration over the next 12
months, was not influenced by the presence of disorders of
thought content. Their finding was of a lower rate of disorder of
thought content that previously published - presumably because
of the methodology and sample used. The rates of disorders of
perception are also reviewed. The reported range of frequency
for hallucinations is from 3 - 49%. Such differences may be due to
variations in the populations studied, the method of case
ascertainment, the presence or absence of symptoms, and the
periods of time to which the rates refer. The authors found
disorders of perception occurred commonly in Alzheimer's
Disease. The study found visual hallucinations in 13% and
auditory hallucinations in 10%. Misidentification syndromes were
found in 30% - these were associated with a younger age and
younger age at onset of the illness, and proportionally more men
than women were affected. There was a reduced 30-month
mortality in this group. Subjects with hallucinations had a greater
deterioration in cognitive function at the 12-month follow-up.
Rubin (1992), reviews delusions as part of Alzheimer's
Disease, and the relationship of them to the stage and progression
of the illness. Methodological issues, involving research design
and assessment tools are addressed, and the advantages of
studying delusions at several levels are discussed, ranging from
psychological to neuroanatomical.
The results using the method described for this study,
found for the DSM3R Alzheimer's Disease group, at some stage of
the illness, 43% had delusions; 15% visual hallucinations and 13%
auditory hallucinations. The study provides data on DSM3R MID
and Alcohol-related group, so far unreported on.
Affective Symptoms.
As mentioned, the data obtained from the Cornell Scale
for Depression in Dementia in this study, was not felt to be
reliable. The assessment of mood will not be a detailed area for
discussion, but will be briefly covered.
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Sunderland et al (1988), states that depressive
symptoms frequently accompany dementia and states that the
estimates have ranged as high as between 30 - 50%. Ballard et al
(1996), described a one year follow-up study of depression in
dementia sufferers and indicated that the annual incidence rate
for major depression was 10.6% and for minor depression was
29.8%. Some subjects had a mild persistent form akin to
dysthymia, and depression in vascular dementia appeared to be
persistent. Whereas most cases of depression in dementia
resolved in 3 months, 20% experienced symptoms for 6 months
or longer.
In the study by Cummings et al (1995), no relation was
found between the patient's depression and dementia severity,
self awareness of cognitive deficits (memory self-rating scale) or
mood of carer. Delusional patients had higher scores on mood
rating scales than non-delusional patients. The study by Weiner
et al (1994), confirmed the low prevalence and incidence of major
depression in Alzheimer's Disease, as found by other
investigators. They suggested that Alzheimer's Disease does not
predispose to major depression as diagnosed according to the
DSM3 R criteria.
At the second assessment for the study, the subjects on
antidepressant treatment in the DSM3R groups, Alzheimer's,
Multi-infarct, Alcohol-related and Mixed, were respectively 12%,
15%, 7% and 20%.
Behavioural Symptoms.
In the study of Burns et al (1990b), in the group of 178
patients with Alzheimer's Disease, aggression was present in 20%,
wandering in 19%, binge-eating in 10%, hyperorality in 6%,
urinary incontinence in 48% and sexual disinhibition in 7%.
Behavioural abnormalities were greater in those with more
severe dementia. Features of the Kluver-Bucy syndrome were
commonly seen.
In the study by Patterson et al (1990), mentioned above,
activity disturbance was recorded for 44% of the group. Ryden
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(1988), studied the aggressive behaviour of people with dementia
in the community, using an aggression scale. The results of a pilot
survey of caregivers revealed aggressive behaviour in 65% of 183
subjects, weekly or more in 31% and daily in 16%. Verbal and
physical aggression were the most prevalent, at 50% and 46%
respectively and sexual aggression less frequently at 18%.
Aggression was significantly related to the degree of cognitive
impairment and past history of aggression, not to diagnosis nor
drugs.
The distressing aspects of these symptoms to the carers
can only be imagined. The high levels of morbidity in these areas
are reported in the Results, and are also illustrated in the
Appendix: Case Studies and Appendix: Carers. The data collected,
illustrates that whereas most attention has been directed to
Alzheimer's Disease, these symptoms are also occurring in other
dementia types too.
For comparison, in this study, some of the behavioural
problems displayed at some stage of the illness, by the Alzheimer
group are given here: overativity, 42%; following behaviour, 48%;
and all forms of aggression, 53%.
Neurological Signs.
Involvement of the extrapyramidal system is a common
finding in Alzheimer's Disease, Funkenstein et al (1993). The
work found a strong association between a diagnosis of
Alzheimer's Disease and changes in the neurologic examination,
especially those suggesting extrapyramidal dysfunction, frontal
release signs and impaired alternating motor sequences.
Pearce (1974), examined 65 patients referred to a
neurology unit with organic dementia, 86% of whom were
presenile cases. He found extrapyramidal features in 40 cases,
mainly of akinesia, and mild dyspraxia of the arms and gait, and
also primitive reflexes.
The relationship between extrapyramidal signs and
cognitive function, in patients with moderate to severe AD, was
investigated by Richards et al (1995). They studied 137 patients
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and found the presence of extrapyramidal signs (EPS) in AD was
associated with a distinct neuropsychological profile, suggestive
of the additive effect of frontostriatal degeneration. There was no
significant difference in the functional capacity between patients
with and without EPS. These findings support the hypothesis that
EPS represent a parallel independent pathology superimposed
over the classical features of AD, rather than providing a marker
for global AD severity.
Molsa et al (1984), studied 143 patients with AD. Only
8% were free of EPS. The commonest signs were: rigidity and
hypokinesia. Resting tremor was rare, and 17% had dyskinesia,
mostly orofacial.
In the paper by Burns et al (1991b), on neurological
signs in Alzheimer's Disease, the reported frequencies of various
neurological signs from previous studies is given. The frequency
of: the snout reflex occurring in about 20%; grasp reflex, 10-17%;
palmomental reflex, 10-47%; myoclonus, 8%; and extrapyramidal
signs, 60%. For their study of the group of 178 AD patients, the
neurological assessment revealed a snout reflex in 41%,
extrapyramidal features in 12%, drug induced extrapyramidal
signs in 3%, myoclonus in 5% and a history of epileptic fits in 3%.
A grasp reflex and extrapyramidal symptoms and signs were
associated with severe cognitive impairment, and extrapyramidal
signs and primitive reflexes were associated with a higher
mortality.
The Results section describes some of the neurological
findings. To compare with some of the studies mentioned, for the
Alzheimer group, the frequency at the first assessment of: the
snout reflex was 10%; grasp reflex, 23%; and myoclonus, 10%.
From the analysis of change, for the total neurological change
score, there was a statistically significant difference between the
four DSM3R groups. This does not distinguish the Alcohol-related
cases from the others, and indicates that the Multi-infarct group
tends to improve. This does not fit clinically with the findings,
and may be an artefact of the analysis.
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After the Second Assessment.
Information on the services provided for and used by
the subjects and their carers, was collected. Some of these
findings are discussed more fully in the Appendix: Carers. The
data from the second assessment was also used to measure
change. From the statistical comparison between the DSM3R
groups after the first and second assessments, using the CAPE-
BRS and CAMCOG, the Alcohol group appears to be distinct from
the others.
Measuring Deterioration.
Prospective longitudinal studies have assessed the rate
of cognitive decline in Alzheimer's Disease, and have attempted to
identify variables that affect the rate or pattern of deterioration.
Reliable prediction of the rate of deterioration in AD is important
for the patient, the family, and the treating physician aswell as
for health-planning authorities. To demonstrate that subgroups of
AD patients have different rates of deterioration, also has
implications for neuropathological and aetiological heterogeneity.
However, Stern et al (1990), have commented that functional loss
in AD is difficult to measure or predict.
Teri et al (1990), studied cognitive deterioration in AD,
and found the rate of decline quite variable on an individual
basis, according to various health and behavioural factors. Alcohol
abuse, additional neurological disease and agitation, were
significantly related to the rate of decline. Van Belie et al (1990),
commented on the reliability of estimates of changes in mental
status test performance in SDAT and found it depended primarily
on the length of time of observation, not the number of
observations made. Green et al (1993), studied the functional
decline in AD in a longitudinal study, with evaluations every six
months. 104 patients with McKhann probable AD were followed
up over an average of 31 months, using a physical self-
maintainance scale, and an instrumental activities of daily living
scale. Rogosa et al (1982), consider the statistical and
psychometric properties of measures of individual change, in the
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sphere of the behavioural sciences. They examine the measures
of change for data with more than two observations on each
individual.
Other considerations of assessing change over time in the study.
It is worth considering the meaning of the score totals,
for example, with the CAPE, the higher the score, the greater the
overall behavioural disturbance. In the case of a person who is
declining rapidly, the behavioural problems may be actually
decreasing as the docility and inability to respond increase. The
change that is best reflected is of increasing disturbance rather
than increasing disability and this may not therefore be a good
reflection of overall decline.
Describing the changes in various symptoms with time is
also possible from a more detailed analysis of the information
from the MOUSEPAD. In a cruder way, the CAMDEX H interview,
asks the carer to describe the pattern of decline since the onset of
the illness.
Questions to ask of the data include, does the description
of a step-wise decline, presumed to be a feature of MID, hold true
for the group studied here? Difficulties with this are that if the
steps are very steep the slope of decline may appear smooth.
Infections and other accidents can precipitate steps, rather than
them being intrinsic to the illness itself. Another area enquired
into was the fluctuating nature of the symptoms. Fluctuations
which occur as part of the clinical picture, for example in Lewy
Body Dementia, are difficult to substantiate, see McKeith et al
(1994). This becomes especially hard to distinguish later on in the
course of the illness, when the level of confusion is greater.
The individuals at base-line at the first assessment will
have already undergone their deterioration, whether rapid or
slow. Therefore the rates of decline measured, will depend in
part, on the stage of the illness of the individuals. The only way
to really examine the different decline patterns would be to begin
a study, where the individuals were at the same point of the
illness (the start), and measure the changes from there.
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The most suitable way to measure the changes that had
occurred between the two assessments was considered. This
could very crudely be seen by looking at who of the group had
had a severity change during the follow-up period, and
describing the characteristics of this group. But a more sensitive
measure was also required. As described, the most objective
parts of the assessment battery were the CAPE-BRS, CAMCOG and
neurological examination. These could provide a profile for the
individuals assessed on both occasions, of the behavioural,
cognitive and neurological features. The statistical methods used
to measure change, have already been described.
Does Heterogeneity exist?
There are different dementia types, based on
aetiological risk factors (such as Alcohol-related and vascular),
and on distinct clinical presentations (such as for Pick's Disease or
Lewy Body dementia). Within Alzheimer's Disease, do further
subtypes exist? Do these have distinct patterns of decline? if so,
can predictors be identified?
Subtypes could be based on certain clinical features or
clusters of these such as: neuropsychological profile; neurological
profile; psychotic features; and behavioural disturbances. Risk
factors, such as family history, have also been examined as
subtype indicators.
Heterogeneity Based on Age of Onset.
Are these potential subtypes based on age of onset?
Overall, it is unclear from the evidence whether clinically
separable subgroups of patients exist, and the relation of age to
disease subtypes is poorly defined.
Rossor et al (1984), reviewed the neurochemical
characteristics of early and late onset types of AD, and found that
the older type had relatively pure Ach deficiency in the temporal
lobe and hippocampus. The younger type had more widespread
and severe changes.
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Rubin et al (1993), found a similar pattern of
psychopathology in younger and more elderly persons with AD,
supporting the suggestion that these changes are the direct
effects of the illness on the central nervous system.
Stern et al (1992), studied 111 subjects with probable
AD, and the deterioration on the Blessed Test. They found that
age of onset had no significant effect on the rate of decline.
Evidence for the existence of subgroups within
Alzheimer's in terms of neurocognitive profile, is shown by the
work of: Jorm (1985); Filley et al (1986); and Seltzer and Sherwin
(1983). This last paper, indicates that younger Alzheimer patients
have greater levels of language disorder. Becker (1988),
demonstrated that early-onset cases had greater syntactic
problems. Other reports are of early-onset dementia having: a
more pronounced aphasia (Seltzer and Sherwin 1983); and a
more severe non-dominant hemisphere dysfunction (Loring and
Largen 1985).
Even differences in fingerprint pattern have been
reported between early- and late-onset cases, see Seltzer and
Sherwin (1986). But such reports of differences between the two
types, are not consistently found. There is also a hypothesis that
the early-onset form of dementia is more aggressive, or rapidly
declining, with shorter survival time, than the older-onset form.
Barclay et al (1985), investigated factors associated with
duration of survival in Alzheimer's Disease. Factors associated
with decreased duration of survival in Alzheimer's Disease
include: male sex, presenile onset and an increased severity of
behavioural disturbance.
Loring and Larger (1985), found that patients who
developed a degenerative dementia in their presenium, were
more impaired that their senile counterparts, on age-adjusted
measures of sustained concentration and mental tracking. The
data supports the relative worsening of behavioural performance
in presenile dementia of the Alzheimer type and is consistent
with the literature describing a more rapid clinical course for this
group of people.
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Heyman et al (1987), looked at the clinical predictors of
institutionalisation and death, in their study of 92 early-onset
cases. They found language ability and cognitive function were
predictors. The age of the patients had a significant modifying
effect on these predictive factors, resulting in a greater risk of
institutionalisation and death in younger patients with severe
cognitive impairment as compared with older individuals with
the same degree of dysfunction.
There is therefore some evidence that different
subgroups of Alzheimer's Disease exist, based on symptoms or
age of onset, with a faster decline in younger patients. This is not
supported by the work of Grady et al (1987), where cerebral
metabolism and cognitive performance in early- and late-onset
Alzheimer Disease patients with the equivalent duration and
severity of illness were studied.
In the study by Newens et al (1993a), the area is
reviewed and it is concluded that recent data does not suggest
that patients with presenile Alzheimer's Disease suffer a
malignant course with short survival, compared with older
patients, and do not support the view that there is an age related
heterogeneity in Alzheimer's Disease.
As already mentioned, the data from this study suggests
that deterioration within the presenile group, was associated with
older age at original referral.
Heterogeneity Based on Other Clinical Features.
Myoclonus has been discussed as a potential predictor
of rapid decline associated with Alzheimer's Disease. Chui et al
(1985), in their study of 146 individuals with Alzheimer's
Disease, found that independently of the duration of the illness,
myoclonus and non-iatrogenic extrapyramidal disorder, were
associated with greater severity of dementia. They also evaluated
the possibility of other clinical subtypes, and found that early-
onset dementia was significantly associated with more prevalent
and severe language disorder. However, the familial risk could
not be differentiated on the basis of age of onset or aphasia.
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Folstein and Breitner (1981), and Breitner and Folstein (1984),
have indicated from their studies, that familial cases have more
apraxia and language disorder.
Mayeux et al (1985), studied 121 Alzheimer Disease
cases and found those with myoclonus or extrapyramidal signs,
had greater intellectual decline and functional impairment in
their daily activities. The heterogeneity demonstrated that
certain clinical manifestations may be useful in predicting
outcome. Work by Stern et al (1990), indicated that
extrapyramidal signs and psychosis, are powerful predictors of
the rate of decline in basic self-care activities and cognition.
In the work by Heyman et al (1987), the significance of
epileptic phenomena in Alzheimer's Disease, was felt to need the
consideration of the severity of the dementia process. Chen et al
(1991), looked at the development of extrapyramidal symptoms,
myoclonus and psychosis in the course of Alzheimer's Disease and
concluded that these features mark progression rather than
indicate subtypes.
Forstl et al (1996), indicate that neuroimaging,
neurophysiology and genetic risk markers maybe more important
for early differential diagnosis, than prediction of the course of
the illness. Cognitive performance may represent a better
predictor of further course of intellectual and morphological
changes in Alzheimer's Disease, than EEG alterations and brain
atrophy.
The results from this study do not allow a comparison of
older- and younger-onset forms of dementia, but may identify
subgroups based on various features. The results have indicated
the distinctions that can be made between the DSM3R groups.
From the one-way analysis of variance of the CAPE and
CAMCOG data, the Alcohol group can be clearly distinguished
from the other DSM3R groups, by its profile. In general, the
subjects with Alcohol-related dementia in this study, had a less
profound dementia. However, there were a higher proportion of
mild severity cases in this group at the first assessment.
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From the CAMCOG data, the Alcohol group can also be
distinguished in its pattern of change, with some areas of
assessment showing a trend to improvement over the follow-up
period. Clearly, the nature and definition of Alcohol-related
dementia needs scrutiny in order to make sense of the results.
The analysis of the changes in the neurological data has
revealed differences betwen the four DSM3R groups, but not in a
meaningful way.
From the multiple logistic regression analysis, family
history and gender are not found to have any significant
association with change. The findings with regard to diagnostic
group, age at referral and illness duration have been discussed.
Genetic Results.
The results from the analysis for the three alleles, APOE,
a-1 antichymotrypsin, and VLDL-R, and their interaction, have
been summarised in the Results. Whereas the APOE allele has
been well established as a genetic risk factor for Alzheimer's
Disease, the other two loci have not.
APOE.
This confirms that the APOEe4/APOEe4 allele type is
represented to a greater extent in the cases clinically defined as
having Alzheimer's type dementia. The results confirm that there
is a trend towards a higher proportion of familial cases with an
increasing number of APOEe4 alleles, and demonstrates a
significant regression of the age at referral, on the number of
AP0Ee4 alleles. This is in keeping with reports from other work,
see Introduction: Genetics.
VLDL-R.
There were a couple of findings of significance in the
Alzheimer's group, which would need further investigation. There
were increased levels of familiality in subjects with at least one
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106-allele, and an increased proportion of the highest severity
ratings in those without a 97 allele.
ACT.
There was nil significant in the Alzheimer's group for
this gene.
Interaction.
The logistic regression analysis suggests the possibility
of a protective effect associated with the possession of the VLDL-
R 106-allele. No substantiation was made of the report of Kamboh
et al (1995), that the ACT genotype modifies the risk from
APOEe4.
Future Directions For The Study.
As mentioned, not all the data analysis possible has been
presented in this thesis, and other questions have arisen from it
as a process of evolution. Some could be answered using the
collected data and others would require additional studies,
possibly using cases from the identified group.
Some of these points have been mentioned already, and
are summarised here:
1. Using the data to make epidemiological estimates of the
incidence and prevalence of early-onset dementia in the Lothian
area.
2. Identification of distinct subgroup profiles
- using the DSM3R defined groups.
- within the Alzheimer or mixed Alzheimer group






Risk factors ( e.g. family history; sex; premorbid IQ;
history of or current hypertension, depression etc).
Rate of decline, in different variables, to identify
possible predictors.
Genetic markers.
Symptoms: possibility of clusters, and associations of
patterns and with other risk factors:
Neurocognitive features.
Psychotic phenomena e.g. delusions
hallucinations
Behavioural disturbances e.g. aggression
CAPE subscores
MOUSEPAD data
(The MOUSEPAD could be more extensively analysed).
Neurological problems e.g. Webster score
Primitive reflexes
3. Explore the Alcohol-related cases and look for differences
between those still drinking and the patterns of previous
consumption (likely not enough data).
4. Investigate the cases who deceased.
those who refused to participate.
5. Investigate cases of Parkinson's dementia, not formally
diagnosed with dementia.
6. Apply other
- diagnostic criteria, e.g. for Lewy Body and Frontal Dementia.
- dementia scales, e.g. of Blessed et al (1968).
7. More detailed analysis (possibly with an additional interview)
to find out the reasons for admission to LTC.
8. Another study could find out more details of those with a
family history, and follow-up of other family members.
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9. A more detailed analysis of the presentations, and onset
symptoms, (possibly with an additional interview), would be of
interest. Comparing the presentation of an age- and sex-matched
group with cases presenting with the new CJD-BSE variant, may
be valuable.
10. Look at the details of the individuals from the control group
who were APOEe4/APOEe4.
11. The possibility of scanning with MRI would provide
extremely valuable information in study of early-onset dementia.
12. Comparison with a group of age- and sex-matched Down's
cases with dementia.
13. Genetic testing
- looking at new candidate genes (perhaps even PrP analysis).
Conclusion.
This study provides a detailed and careful clinical
description of a group of subjects with early-onset dementia. It is
the first study of its kind, to look at dementias of various
aetiologies, and attempt to compare them. There is no other
literature to compare directly with it. The feature of having a
second assessment, after a year, has meant that change can also
be monitored.
The DSM3R Alcohol-related dementia group, appears to
have a distinct profile from the CAPE-BRS and CAMCOG scores. In
general, the dementia in this group seems to be less severe. The
pattern of change in some cognitive assessments over the year,
also appeared to have a distinct profile in this group. Over the
follow-up period, the deterioration was minimal in the Alcohol-
related group and there was even evidence of improvement in
scores, compared with the other groups.
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Other predictors of decline have been looked for, but no
relevant themes have emerged.
The data collected has been analysed only in part, and
will provide the basis of future work as outlined in the
Discussion.
The genetic analysis confirmed the effect of the APOEe4
allele previously reported in Alzheimer's Disease. No substantial
findings were apparent for the other two loci tested, but there
was a suggestion of a possible protective effect associated with
the possession of the VLDL-R 106-allele. As molecular advances
are made, it remains an exciting prospect that the clinical
differences in presentation, rate and pattern of progression, and
demographic characteristics, may be explicable at the molecular
level.
Some data concerning the services provided for, and
used by this specific group of patients and their carers, in
Lothian, had also been collected. This information can be shared
with organisations, working to find funding for presenile
dementia in the health service. The data will give a greater
chance to plan appropriately for those involved in caring , and
managing these illnesses.
End of Volume I,
